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PREFACE 
The neonatal respiratory distress syndrome (RDS) is characterized by immaturity of the 
lung, resulting in relative or absolute absence of pulmonary surfactant. Worldwide, 
neonates suffering from RDS have been treated successfully with exogenous surfactant 
preparations. Currently, exogenous surfactant administration has been accepted as a 
valuable treatment for this syndrome. Nevertheless, many questions on exogenous 
surfactant treatment remain unanswered. 
It has been observed that some infants did not respond to, or had only transient 
improvement after, a single dose of exogenous surfactant. In other studies it was 
observed that better clinical outcome was seen in infants treated with either a higher 
dose of surfactant, or after repeated surfactant substitution. It was argued that exogenous 
surfactant, after intratracheal substitution, was gradually inhibited by surfactant inhibitors 
present in the terminal lung units. By giving more exogenous surfactant this inhibition 
was abolished, resulting in improved lung function. 
The adult respiratory distress syndrome (ARDS) is characterized by acute 
respiratory failure (ARF), and high-permeability edema fluid accumulating in the 
alveolar spaces. From experimental and clinical studies it is known that the pulmonary 
surfactant system is also disturbed in this syndrome. Recently, a few patients suffering 
from ARDS have been treated with exogenous surfactant. Although these case reports 
are poorly documented, the best results were observed in patients treated with high doses 
of exogenous surfactant. 
The work presented in this thesis focuses on the mechanisms of inhibition of 
surfactant function in different animal models of acute respiratory failure. To overcome 
this inhibition, different treatment modalities with an exogenous surfactant preparation 
will be presented. 
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OVERVIEW OF THE STUDY 
Chapter 1 addresses the pulmonary surfactant system. The composition of pulmonary 
surfactant and its functions are explained. Special attention is given to exogenous 
surfactant therapy in neonates suffering from respiratory distress syndrome (RDS); 
clinical studies on exogenous surfactant therapy in neonatal RDS are summarized (see 
Appendix A). 
In Chapter 2 involvement of the pulmonary surfactant system in acute respiratory 
failure (ARF) in the adult respiratory distress syndrome (ARDS) is described. Animal 
models on ARF are presented. with special reference to models used in our laboratory 
and the effect of exogenous surfactant therapy in these models. Also. the first case 
reports on exogenous surfactant therapy in patients suffering from ARDS are discussed 
(see Appendix B). 
lt has been proposed that in patients suffering from ARF / ARDS, the surfactant 
function is inhibited by plasma-derived proteins present in the intra-alveolar space. It has 
also been suggested that in patients not responding to a single dose of exogenous 
surfactant (so-called "non-responders"), this surfactant was inhibited by these proteins. 
Chapter 3 presents a study in which the inhibitory capacity of both high-permeability 
edema fluid and homologous plasma is investigated both in vivo and in vitro. 
In Chapter 4 we investigate the amount of exogenous surfactant needed to 
overcome the inhibitory capacity of heterologous (human) plasma in rats suffering from 
ARF after whole lung lavage. 
It is known that aspiration of gastric contents leads to protein-rich pulmonary 
edema fluid, containing inhibitors of surfactant function. In clinical practice it is known 
that ARF caused by massive aspiration of gastric contents is difficult to treat. In Chapter 
5, in a model for massive aspiration of hydrochloric acid (HCl), the influence of 
exogenous surfactant instillation at different time intervals post-HCl aspiration on lung 
function is investigated. It is demonstrated that respiratory failure can be prevented when 
exogenous surfactant is given before deterioration of lung function (i.e. within 10 min 
after HCl aspiration), whereas after development of ARF exogenous surfactant cannot 
restore gas exchange. For this reason, the study in Chapter 6 is designed to investigate 
the optimal way to treat rats suffering for a longer period from ARF due to HCl 
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aspiration with exogenous surfactant. Exogenous surfactant is given 1) as a bolus, 2) after 
removal of pulmonary edema fluid with bronchoalveolar lavage (BAL), or 3) BAL with 
a diluted surfactant suspension. It is demonstrated that lung function can be restored 
after edema fluid is removed prior to exogenous surfactant instillation. Also, gas 
exchange can be restored after BAL with the diluted surfactant suspension, probably due 
to simultaneous removal of surfactant inhibitors and surfactant treatment. 
In the acute phase of pneumonia, protein-rich edema fluid accumulates in the 
alveolar space. Recently we have demonstrated that exogenous surfactant could restore 
lung function in rats and mice suffering from pneumonia due to Sendai virus and 
influenza A virus infection, respectively. In pneumocystis carinii pneumonia (PCP) the 
pulmonary surfactant system is also involved. In the study discussed in Chapter 7, rats 
suffering from ARF due to PCP are successfully treated with a bolus of exogenous 
surfactant. 
As natural exogenous surfactants contain proteins foreign to the patient, it seems 
likely that formation of antibodies to these proteins can be observed. In the study 
presented in Chapter 8 a monoclonal antibody is raised against a hydrophobic surfactant-
associated protein (11 kDa). It is demonstrated that a mixture of this monoclonal 
antibody and exogenous surfactant is not able to restore lung function in rats suffering 
from ARF after whole lung lavage. Although surfactant-antisurfactant immune complexes 
have been detected in neonates with RDS, no effect on exogenous surfactant therapy has 
been reported. These results also indicate the importance of the 11 kDa surfactant-
associated protein for exogenous surfactant function. 
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CHAPTER 1 
PULMONARY SURFACTANT: BASIC PHYSIOLOGY AND ITS USE FOR 
REPLACEMENT THERAPY 
B. Lachmann and E.P. Eijking 
In: Drug targeting and delivery. Concepts in dosage fonn design. HE. Junginger ( ed. ). Ellis 
Horwood Limited. New York, 1992, pp 129-154 
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HISTORY 
In 1929, von Neergaard wrote '1t may be possible that the surface tension of the alveoli is 
diminished by concentration of surface-active substances against other physiologic solutions" 
(77). He was referring to the existence of a surface film in the alveoli and his assumption 
was based on the following observations. Neergaard measured pressure-volume diagrams 
from human and animal lungs, first filling them with air and then with liquid. The 
surprising result was that the pressure necessary for filling the lung with liquid was only 
half the pressure necessary for filling the lung with air. His explanation of this 
remarkable difference was based on the assumption that in each alveolus there must be 
a barrier between air and fluid (such as the wall of a soap-bubble) with a tendency to 
diminish its size according to the law of Laplace (P=2y /r, in which P = pressure to 
stabilize a bubble/alveolus; y = surface tension at air-liquid interface; and r = radius 
of the bubble/alveolus). The amount of retraction pressure for the lung is larger than the 
retraction force of the elastic fibres. By filling the alveoli with liquid, the air-liquid 
barrier is replaced by a liquid-to-liquid barrier without any surface tension. The 
retraction pressure, measurable in the fluid-filled lung is, therefore, equal to the 
retraction force of the elastic fibres. The same procedure for determining the influence 
of surface tension on the overall retraction of the lung was later reported by other 
scientists, and is now a well-established method. 
In 1955 Pattie (60) showed that bubbles resulting from lung edema, as well as 
bubbles squeezed from lung cut, are very stable. Pattle assumed that the walls of these 
bubbles consist of surface-active materials and that their stability depends on the quantity 
and quality of surfactant phospholipids. In 1957 Clements ( 6) was the first to investigate 
lung extracts in a Wilhelmy-balance and demonstrated that these extracts had, in contrast 
to detergents or plasma, genuine hysteresis properties. 
Avery and Mead (1) were the first, in 1959, to draw attention to the possibility 
that lungs of infants with respiratory distress syndrome (RDS) may have abnormal 
surface tension properties, due to a deficiency in lung surfactant. 
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BIOCHEMICAL COMPOSITION 
Biochemical characterization has shown that surface-active phospholipids, proteins and 
mucopolysaccharides are the main constituents of the surfactant system of the lung. 
Generally, between 80% and 90% of surfactant is phospholipid. The major representative 
(70% to 80%) of surfactant phospholipids is phosphatidylcholine (PC) and about 60% 
of the PC molecules contain two saturated acyl chains. This disaturated PC (DSPC) is 
largely dipalmitoylphosphatidylcholine (DPPC). In most adult manunalian species, 
phosphatidylglycerol (PG) is the second most abundant phospholipid class, accounting 
for up to 10% of total surfactant lipid. Surfactant contains, in addition, small proportions 
ofphosphatidylinositol (Pl), phosphatidylserine (PS), phosphatidylethanolantine (PE) and 
sphingomyelin (for review see [76]). 
Phospholipids are synthetized in the type !I alveolar cells. They are stored in these 
cells as so-called lamellar bodies, before being released to the surface of the alveoli. The 
surfactant lipids spread as a monolayer at the air-liquid boundary. They reduce the net 
contractile force of the alveolar surface, thus preventing the airspaces from collapsing at 
low lung volumes. 
Besides phospholipids, surfactant also contains specific surfactant-associated 
proteins. At least four surfactant-associated proteins (SP-A, B, C and D) are produced 
by type II cells. These proteins have, apart from functions such as the regulation of 
phospholipid metabolism, an important function in the formation of the surfactant 
monolayer (76). It has been demonstrated that for optimal function of the lipids the 
presence of a few small proteins is a prerequisite for optimal in vivo function of artificial 
surfactant and surfactant extracted from manunalian lungs (76). 
FUNCTION OF THE SURFACTANT SYSTEM 
Mechanical stabilization of the lung 
The integriry of the surfactant system of the lung is a prerequisite for normal breathing 
with the least possible effort. The surfactant system acts by decreasing surface tension 
of the interface between alveoli and air. This provides an explanation as to why we have 
to generate a "negative" pressure of only 5-10 cmH20 during each inspiration; in the 
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absence of surfactant the surface tension at the air-liquid interface would be that of 
plasma and the pressure needed to maintain lung aeration would be 25-30 cmH20 
(depending on the radius of the alveoli). This is a well-known problem in patients with 
respiratory failure. 
In alveoli with different radii an equal lowering of surface tension would not, 
however, produce stabilization of the alveolar system. It would instead, according to the 
law of Laplace, lead to the collapse of the smaller bubbles or alveoli, and to their 
emptying into the larger bubbles/alveoli. Since alveoli in vivo do not exhibit such 
behavior, one can conclude that the second quality of the alveolar lining layer is that it 
can change the surface tension in a manner related to the size of the alveoli. 
SCHEMATIC DIAGRAM OF WATER BALANCE IN THE LUNG 
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Figure 1. Simplified schematic diagram representing the factors influencing the fluid balance in the lung. 
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Swfactant as anti-edema factor 
Another function of the pulmonary surfactant system is stabilization of the fluid balance 
in the lung, and protection against edema. The normal plasma oncotic pressure of 37 
cmH20 is opposed by the oncotic pressure of interstitial proteins of 18 cmH20, the 
capillary hydrostatic pressure of 15 cmHzO, and by the surface tension conditioned 
suction of 4 cmH20 (Fig. 1). 
In general, alveolar flooding will not occur as long as the suction force in the 
pulmonary interstitium exceeds the pressure gradient generated by the surface tension 
in the alveolar air-liquid interface. Since this pressure gradient is inversely related to the 
radius of the alveolar curvature there is, for each combination of interstitial resorptive 
force and average surface tension, a critical value for surface tension and for alveolar 
radius, below which alveolar flooding occurs (20). 
Swfactant and local defence mechanisms 
It has been suggested that the surfactant system is involved in the local defence 
mechanisms of the lung. In the past it has been demonstrated that alveolar macrophages 
ingest bacteria (and destroy them intracellularly) only in the presence of sufficient 
surface-active material (29,30). In this context surfactant seems to reduce the surface 
forces of bacterial membranes and it is also an energy-rich substrate which supports the 
macrophages' high rate of metabolism. 
Recently we have demonstrated that the pulmonary surfactant system may also 
be involved in protecting the lung against its own mediators (e.g. angiotensin ll) and in 
protecting the cardiocirculatory system against mediators produced by the lung. 
Surfactant and ain-vays stabilization 
As early as 1970, Macklem eta! (46) called attention to the significance of bronchial 
surfactant for the stabilization of the peripheral airways and hinted that lack of 
stabilization may cause airway obstruction or collapse of the small bronchi with air 
trapping. This has been proved in our laboratory in an animal model where the bronchial 
surfactant was selectively destroyed (39). It was demonstrated that the pressure to open 
up the collapsed bronchi is about 20 cmHzO. 
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Besides its role in mechanical stabilization, bronchial surfactant also has a 
transporting function for mucus and inhaled particles. This has been proven, in vitro, in 
a study showing that particles on a surface film move in one direction only if the surface 
film is compressed and dilated, comparable to the compression and eJ.-pansion during 
expiration and inspiration (39). Furthermore, bronchial surfactant also acts as an antiglue 
factor preventing the development of large adhesive forces between mucus particles, as 
well as between mucus and the bronchial wall (Fig. 2) ( 63). 
FREE CELL SURFACE (ADHESIVE) 
~~~ ~ @ip 
~ @ ® 
CELL SURFACE COVERED BY SURFACTANT 
(NON ADHESIVE) 
Figure 2. Schematic diagram demonstrating the interaction between mucus and airway. Note that there will 
be non-adhesive forces only if the mucus particle and the airways are covered with surfactant (thick solid 
line). 
A further possible function of bronchial surfactant, which to date has scarcely been 
discussed, is its masking of receptors on smooth muscle with respect to substances which 
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induce contraction and could lead to airway obstruction. We have recently demonstrated 
that lining the airway with surfactant in ovalbuntin-sensitized gninea pigs prevented 
significant bronchial obstruction during antigen challenge in these animals. This means 
that the bronchial surfactant could also be involved in asthma ( 40). This is further 
supported by the fact that drugs used in the treatment of asthma (corticosteroids and 
betantimetics) lead to a release of surfactant. 
FUNCTIONAL CHANGES DUE TO A "DISTURBED" SURFACTANT SYSTEM 
When considering the main physiologic functions of the alveo-bronchial surfactant system 
it can easily be understood that alteration in its functional integrity will lead to: 
decreased lung distensibility (decreased lung compliance) and thus increased work 
of breathing and increased oxygen demand by the respiratory muscles 
atelectasis and decreased functional residual capacity (FRC) 
transudation of plasma into the interstitium and into the alveoli with decreased 
diffusion for oxygen and C02 
inactivation of the surfactant system by plasma proteins and specific surfactant 
inhibitors 
hypoxentia and respiratory acidosis 
metabolic acidosis secondary to increased production of organic acids under 
anaerobic conditions 
enlargement of functional right-to-left shunt due to perfusion of non-ventilated 
alveoli 
decreased production of surfactant as a result of hypoxemia, acidosis and 
hypoperfusion. 
This will finally lead to a vicious circle and the lung will fail as a gas exchange organ 
(Fig. 3) (44). 
19 
I AL VEOLOTOXIC INSULT I 
I 
!VIA AIRWAYS! !VIA BLOOD! 
l II DISTURBANCE OF THE BARRIER FUNCTION OF .1: I 
CAPILLARY ENDOTHELIUM AND ALVEOLAR EPITHELIUM 
DAMAGE TO 
GRANULAR -!PROTEIN-RICH EDEM~ 
PNEUMOCYTES ......----
(TYPE 2 CELLS) INACTIVATION OF LOSS OF SURFACTANT DEPLETION BY 
SURF ACT ANT BY INTO INTERSTITIUM FOAMING AND 
SPECIFIC INHIBITORS AND BLOOD ART. VENTILATION 
AND PLASMA WITH LARGE 
COMPONENTS TIDAL VOLUMES 
+ t 
DECREASE OF Al VEOLAA AND BRONCHIAL SURF ACT ANT 14----
SURF ACT ANT J COMPENSATION FOR THE 
REPLACEMENT HIGH RETRACTIVE FORCES BY 
A PRESSURE HIGHER THAN 
THE ATMOSPHERIC PRESSURE 
~I RES? IRA TORY INSUFFICIENCY rll INHIBITION OF 
FRCI, Crs/FRC!, PaO•!. PaCo;i. oH SURFACTANT 
METABOLISM 
Figure 3. Pathogenesis of ARDS with special reference to the surfactant system, including suggestions to 
compensate for a damaged surfactant system. 
SURFACTANT REPLACEMENT THERAPY 
Three decades of active research have resulted in the probability that surfactant 
treatment of surfactant deficiency states will soon be generally possible. 
Exogenous surfactant therapy offers great promise for reducing the severity, 
morbidity and early mortality attributable to RDS. The RDS remains a major cause of 
neonatal mortality; it is responsible for approximately one neonatal death per 1000 live 
births and it contributes to the number of infants with chronic pulmonary sequelae and 
neurodevelopmental handicaps, emphasizing the need to make efficacious therapies 
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available. 
Soon after the identification of DPPC as the principal surface-active component 
of surfactant and the recognition in 1959 that saline extracts from lungs of infants who 
died of RDS had abnormal surface properties (1), aerosols of DPPC were used to treat 
RDS, but with little beneficial effect (5,66) (Tables 1 and 2: see Appendix A). However, 
during the 1970s, Enhorning and Robertson (10) developed a reliable experimental basis 
for the concept that RDS could be treated with exogenously administered surfactant. The 
idea was first successfully tested in infants by Fujiwara and coworkers in 1980 (13) and, 
subsequently, the number of clinical studies have increased exponentially. Clinical trials 
have been designed either as rescue or as prophylactic studies (Tables 1 and 2: see 
Appendix A). 
The terminology used to describe various surfactants in the experimental and 
clinical literature is inconsistent. There are four general categories of surfactants that are 
being evaluated for clinical use: 
Natural suifactant. The surfactant that can be removed from fresh alveolar washes or 
from amniotic fluid by simple centrifugation and/or filtration procedures designed to 
recover the large surface-active aggregates of surfactant (23,31). Such natural surfactant 
contains more protein (and all categories of surfactant-associated proteins) than the more 
highly purified surfactant, but it can be recovered in the large amounts necessary for 
treatment protocols. Surfactant prepared after lipid extraction procedures are specifically 
excluded from this category since the native surfactant aggregates are disrupted. 
Modified natural suifactants are made from species homologous or heterologous lungs, 
or alveolar lavage. Such surfactants are prepared by extraction of lipids followed by 
selective addition and/ or removal of compounds, sterilization and suspension procedures 
designed to restore the desired surface properties (8,15,75). The final surfactant may 
contain as much as 1% hydrophobic surfactant-associated proteins (SP-B and SP-C) (78). 
Modified natural surfactants are designed to reproduce or improve upon the 
characteristics of natural surfactant, to decrease protein contamination and to assure 
sterility. 
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Anificial surfactan.ts are those surfactans made from a mixture of synthetic compounds 
that may or may not be normal components of natural surfactant. The most studied 
artificial surfactant is a mixture of 70% DPPC and 30% PG (54). While both 
phospholipids are present in natural surfactant, the proportions differ and the acyl groups 
of PG are different from those found in the PG of natural surfactant. Another artificial 
surfactant contains compounds foreign to natural surfactant, such as hexadecanol and 
tyloxapol. There are no surfactant-associated proteins present in these artificial 
surfactants. 
Synthetic natural swfactants are just beginning to be a possibility. With the recent 
isolation and characterization of the surfactant-associated proteins, synthetic natural 
surfactants are being tested. In the near future, such surfactants will be reconstructed in 
vitro from surfactant-associated proteins synthesized using molecular biology techniques, 
and from mixtures of lipids and phospholipids. 
CONCLUSIONS 
Initial reports suggest that surfactant treatments will simplify care sufficiently that 
hospital stay and thus cost of care may be decreased (11). Many practical aspects of the 
treatment of infants with surfactant have not been evaluated. The dose, the most 
effective method of administration and the benefits from repetitive doses are not well 
defined. While a number of surfactants have been evaluated clinically, some were "home-
made" and not well standardized. Different surfactants have not been compared directly 
in clinical trials. The surfactant with the best clinical response may not be a surfactant 
that can be easily standardized and prepared in bulk as a pharmaceutical. Practical 
considerations of formulation and licensure will, in part, dictate which surfactant will 
ultimately be available for clinical use. 
Surfactant therapy should not only be beneficial to those infants in need of 
supplemental surfactant, but also indirectly to infants who suffer secondary to surfactant 
deficiency. Other uses of surfactant are now being considered. Experimental models of 
lung injury in adult animals such as saline lavage (2,33), oxygen injury (47), viral and 
bacterial pneumonia, oxygen free radicals, anti-lung serum and pulmonary edema 
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(38,41,42,43) (see Chapter 2), together with first clinical trials (44) suggest that there is 
a role for surfactant in the treatment of the adult respiratory distress syndrome (ARDS). 
Surfactant treatments will become a major advance in the care of preterm infants with 
severe RDS, and may ultimately prove useful in other lung diseases. 
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CHAPTER2 
PULMONARY SURFACTANT FUNCTION IN ACUTE 
RESPIRATORY FAILURE 
E.P. Eijking 
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INTRODUCTION 
The adult respiratory distress syndrome (ARDS) was first described in 1967 by Ashbaugh 
and colleagues (1). Hopewell and Murray described a large number of disorders, 
including shock of any etiology, sepsis, pneumonia, aspiration of gastric contents, trauma, 
acute pancreatitis, drug overdose and many others which can lead to this pathological 
entity (41). ARDS is characterized by acute respiratory failure (ARF). An operational 
definition of ARDS includes at least the following features: an appropriate risk factor; 
tachypnea; dyspnea; severe hypoxemia refractory to increased inspiratory oxygen 
concentrations (Pa02/Fi02 < 150 mmHg); decreased lung compliance (total compliance 
of the respiratory system < 0.7 ml/ cmH,O /kg); bilateral diffuse infiltration on the chest 
radiograph, severe pulmonary edema and absence of left ventricular failure (pulmonary 
wedge pressure < 12 - 18 mmHg) (22,23). 
Despite increased sophistication in methods of respiratory and metabolic support, 
since its description in 1967, mortality associated with ARDS currently is still around 50-
70% (21) whatever the criteria of diagnosis (76,102). 
PATHOPHYSIOLOGY OF ACUTE RESPIRATORY FAILURE 
Humoral and cellular mechanisms 
In the pathogenesis of ARF j ARDS numerous cellular and humeral mechanisms are 
involved, including neutrophils, macrophages, platelets, complement-, kallikrein-kinin, 
coagulation and fibrinolytic systems. These mechanisms are functionally linked to each 
other, so that the activation of one system leads to the activation of the others. This 
results in synthesis of arachidonic acid metabolites in lung tissue, and generation and 
liberation of mediators from target cells. These mediators, such as pro teases, arachidonic 
acid metabolites, m,ygen radicals and others, directly damage cellular and tissue structure 
and attract more mediator-generating cells (82). As a result of damage to the alveolar-
capillary membrane, high-permeability pulmonary edema, containing plasma-derived 
proteins, accumulates in the alveolar space. 
Besides these complex mechanisms causing damage to the alveolar-capillary 
membrane, direct damage to lung tissue can be a result of noxes entering the airways, 
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such as aspiration of gastric contents, inhalation of toxic gases, micro-organisms entering 
the airways, and in near-drowning. 
Role of swfactant 
Bronchoalveolar lavage (BAL) material of ARDS patients demonstrates impaired 
surfactant function. Ashbaugh and colleagues found decreased lung compliance and 
increased minimal surface tension in lung extracts from two ARDS patients (1). Petty 
and coworkers examined the lungs from five patients who died from ARDS and found 
reduced lung compliance compared to normal lungs and the BAL fluid was found to 
have increased surface film compressibility (87). Von Wichert and Kohl found increased 
total phospholipid content and decreased dipalmitoyllecithin in lung homogenates from 
ARDS patients (113). Earlier, Lachmann and colleagues demonstrated a significant 
correlation between the duration of artificial ventilation and surfactant activity in lung 
homogenates from 16 ARDS patients (62). In BAL fluid from ARDS patients, Hallman 
and colleagues found a normal total phospholipid content, but a low 
lecithin/sphingomyelin (L/S) ratio, low concentrations ofphosphatidylglycerol (PG) and 
disaturated lecithin, whereas concentrations of sphingomyelin and phospbatidylserine 
(PS) were high (31). Pison and colleagues found normal total phospholipid content in 
BAL fluid from ARDS patients, but a relative decrease in phosphatidylcholine (PC) and 
PG, and an increase in phosphatidylinositol (PI), phosphatidylethanolamine (PE) and 
sphingomyelin (88). Gregory and colleagues observed a decrease in total phospholipids 
and minimal surface tension in BAL fluid from ARDS patients and patients at-risk to 
develop ARDS (29). Also, in this study, in BAL fluid from ARDS patients decreased 
levels of PC, PG and increased levels of PI, PE and sphyngomyelin were observed; 
concentrations of surfactant-associated proteins SP-A and SP-B were also decreased. In 
BAL fluid from patients at-risk to develop ARDS, similar phospolipid profiles as in BAL 
fluid from ARDS patients were observed; also, there was a significant decrease in 
lavagable concentration of SP-A in BAL fluid of at-risk patients (29). 
Due to increased permeability of the alveolar-capillary membrane in ARDS 
plasma proteins enter the alveolar space from the pulmonary circulation. Plasma proteins 
(such as fibrin(ogen), albumin, globulin and transferrin), hemoglobin and cell membrane 
lipids are known to inhibit pulmonary surfactant function in a dose-dependent way 
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(10,19,24,31,36-38,40,44-47,56,95,100,101). The existence of a specific plasma-derived 
surfactant inhibitor (MW = 110.000 Da, unreduced) has been proposed ( 46). 
Furthermore, due to damage to the lung, especially damage to surfactant-
producing type II cells in ARDS, surfactant synthesis is decreased ( 4,34,39,94,107). This 
leads to a further decrease of surfactant concentration at the air-liquid interface. Due to 
dintinished surfactant function, surface tension on the alveolar walls increases, leading 
to increased suction force across the alveolar-capillary membrane, with further 
accumulation of edema fluid in the alveolar spaces. Altogether, this leads to a vicious 
circle (73). 
SURFACTANT TREATMENT IN ARF 
A simple and rational hypothesis for treatment of ARF in which the surfactant system 
appears to be involved has been developed (72): 
If surfactant is necessary for keeping retractive forces as low as possible and for 
optimal gas exchange, any disturbance in the surfactant system will result in 
abnormalities in lung distensibility and gas exchange. 
If this is correct, surfactant replacement will restore lung distensibility and gas 
exchange to normaL 
This hypothesis has been investigated in the last 10 years in different animal models of 
ARF and in a few patients with ARDS. The following section discusses selected animal 
models of ARF, with special reference to the models used in our laboratories to 
investigate disrurbances of the surfactant system and/ or surfactant replacement therapy. 
ANIMAL MODELS 
l-In vivo lung lavage: Experiments on postmortem lung specimens have revealed that a 
considerable portion of the alveolar phospholipids can be recovered by repeated washing 
of the airspaces (25). With this knowledge a model for ARF was developed by Lachmann 
and colleagues for use in different animals, in which pulmonary surfactant is removed 
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by repeated bi-lateral whole lung lavage with warm saline (64,67,96). 
In these lavage models, severe respiratory insufficiency is defined as a decrease 
in Pa02 to below 80 mmHg during artificial ventilation with 100% oxygen. The first 
lavage already results in significant reduction of thorax-lung compliance and repeated 
lavage results in a derangement of lung function persisting for at least 8 h. These 
disturbances, which include a 35% decrease in functional residual capacity (FRC), are 
almost certainly secondary to increased surface tension in the alveolar lining 
( 42,48,64,67), especially as lung lavage with saline does not alter the elastic properties 
of the pulmonary parenchyma ( 42). However, removal of alveolar surfactant by in vivo 
lung lavage significantly increases permeability of the alveolo-capillary membrane, as 
demonstrated by Wollmer and coworkers in their studies on 99mTc-DTPA clearance (20). 
Histologic exantination of lungs from animals 5 min after the last lavage shows 
atelectasis, desquamation of bronchial and bronchiolar epithelium, and incipient 
formation of hyaline membranes (64). Electron microscopic studies of the same lungs 
revealed necrosis and desquamation of alveolar type I cells. Some type II cells were also 
necrotic, but the majority of these cells seemed to be intact and should thus be available 
for synthesis and discharge of surfactant phospholipids ( 64 ). 
Intratracheal instillation of exogenous surfactant in lavaged lungs results in 
dramatic improvement of gas exchange, even when the treatment is given 2 h after the 
lavage procedure (5,53,64,68). Improved blood gases are stable for at least 5 h (68), 
whereas in lavaged animals receiving no surfactant Pa02 remains low despite ventilation 
with positive end-expiratory pressure (PEEP) and pure oxygen. Histologic sections from 
surfactant-treated animals showed a uniform pattern of well-aerated alveoli with only 
minimal intra~alveolar edema and hyaline membranes, whereas lavaged animals receiving 
no surfactant, ventilated with the same ventilator settings, had extensive atelectasis and 
prontinent hyaline membranes (5,68). 
The lung lavage models are useful for a variety of experimental purposes, 
including testing of different surfactant preparations (5,53,96), evaluation of 
pharmacologic agents stimulating discharge of alveolar phospholipids (63), and studies 
on the significance of different ventilator settings (7,67). 
Recently the lavage model was used to investigate the influence of anti-surfactant 
monoclonal antibodies on the ability of exogenous surfactant to restore gas exchange (17) 
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(see Chapter 8). Also, the influence of plasma and edema fluid on exogenous surfactant 
function was tested using this model (see Chapters 3 and 4). 
11-Pulmonary infection: Pneumonia continues to be a leading cause of death and ARDS 
is often associated with or complicated by pneumonia of different microbial etiology. 
Puhnonary infection causes direct injury to the alveolar membrane with destruction of 
both type I and type II cells (107). This results in permeability edema with decreased 
pulmonary compliance, decreased FRC, impaired gas exchange and decreased surfactant 
activity (33,79,105, 110). Acute pneumonia-associated decrease of pulmonary function can 
be explained by decreased production of surfactant due to damage to type II cells, 
impairment of surfactant function by inhibitors present in edema fluid, increased 
breakdown of surfactant phospholipids and proteins during the inflammatory reaction to 
puhnonary infection, and increased loss of surfactant into the blood or into the airways. 
We investigated the possibility of surfactant replacement therapy during 
respiratory failure due to pulmonary infection in three animal models with pneumonia 
of different microbial etiology. 
Ila-Pneumocystis carinii: Pneumocystis carinii pneumonia (PCP) frequently occurs in 
immunocompromised patients and is currently the most frequent cause of pneumonia in 
patients suffering from the acquired immunodeficiency syndrome (AIDS) (90). 
Pneumocystis carinii infection leads to degenerative changes in type I pneumocytes with 
resulting increased permeability of the alveolar-capillary membrane and pulmonary 
edema (115). Furthermore. it was demonstrated in a PCP rat model with decreased 
pulmonary compliance, that pulmonary phospholipid content of BAL fluid was 
significantly decreased, whereas phospholipase A2 was significantly increased (51,103). 
BAL fluid from patients suffering from PCP showed a decrease in total phospholipid 
content, a decrease in PC and PG, an increase in sphingomyelin, and an increase in total 
proteins (89). 
We demonstrated in rats with PCP, suffering from severe respiratory failure, that 
instillation of a natural surfactant could significantly improve gas exchange (16) (see 
Chapter 7). Histologic examination clearly showed that lungs of untreated animals were 
filled with characteristic foamy edema, whereas lungs of surfactant treated animals were 
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clearly more aerated compared with saline-treated animals. Lung homogenates of all 
PCP animals showed large amounts of cysts, confirming the presence of PCP in all 
animals, whereas bacterial pneumonia was excluded in all animals. 
llb-lnfluenza A virus: Earlier, we reported the positive therapeutic effect of surfactant 
replacement on lung mechanics in mice with influenza A pneumonia (70). In this model, 
mice are exposed to a live nebulized influenza A virus and subsequently develop a severe 
pneumonia with lethal outcome within six days. 
Recently (13) we showed that during the development of lethal influenza A 
pneumonia in mice, thorax-lung compliance (C/kg) and lung volume at PEEP=5 cmH20 
(V5/kg) significantly decreased, whereas lung water content significantly increased. 
Furthermore, surface tension of BAL fluid significantly increased in infected animals, 
indicating loss of surfactant function. Surfactant replacement therapy (200 mg/kg BW) 
during the endstage of pneumonia increased C/kg and V5/kg. Instillation of the vehicle 
for surfactant (1:2 mixture of H20 and saline) in control animals did not significantly 
affect pulmonary compliance but significantly decreased V5/kg. 
Ilc-Sendai virus: To study the effects of surfactant replacement therapy on gas exchange 
we developed a model of viral pneumonia, caused by Sendai virus infection of rats, 
closely resembling ARDS ( 14 ). In this model, rats are exposed to nebulized concentrated 
live Sendai virus. Subsequently, the animals develop a severe pneumonia with lethal 
outcome within four days. During this period gas exchange and pulmonary compliance 
significantly deteriorate whereas total protein content ofBAL fluid significantly increases. 
In another study using the same model (12), animals showed severely impaired 
gas exchange and acidosis 48 h after infection. Arterial oxygenation could not be 
sufficiently improved by artificial ventilation with high peak airway pressures and PEEP. 
At this time, at the same ventilator settings, surfactant replacement dramatically 
increased arterial oxygenation within 5 min and resulted in a fourfold increase in Pa02 
within 2 h (Fig. 1). Histological examination of surfactant-treated lungs showed clearly 
improved alveolar aeration compared to saline-treated controls. 
Results from the influenza A virus pneumonia model in mice and those from the 
Sendai virus pneumonia model in rats lead us to conclude that intratracheal 
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administration of surfactant is a promising approach in the treatment of severe 
respiratory failure associated with viral pneumonia. 
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Figure 1. Pa02 values (mean :!: SD) 4S h after infection with a lethal dose of Scndai virus, during pressure-
controlled artificial ventilation with pure m.:ygen, and after treatment with surfactant (solid line, n=9), saline 
(broken line, D""-7) or respiratory support only (dotted line, n=6); *p<0.05, surfactant-treated animals vs. 
saline-treated controls; #p<O.OS, vs. pre-treatment values at the same ventilator settings; 15/0 =peak airway 
pressure (P ,.,.J = 15 cmH20; 20/0 = P peak= 20 cmH20; 25/4 = P prn. = 25 cmH 20 with PEEP = 4 cmH20 
(from Van Daal et al [12]). 
III-Hydrochloric acid instillation: The pulmonary effects of acid aspiration have been 
extensively documented in animal models (2,28,111). Data from these studies show that 
in the pH range below 2.5, the degree of lung injury is proportional to the hydrogen ion 
concentration of the aspirated material (for review see [26]). Hydrochloric acid (HCI) 
aspiration leads to damage to the alveolar-capillary membrane with subsequent increased 
permeability to and accumulation of plasma-derived proteins. It is also likely that 
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surfactant is directly damaged by HCL Shortly after acid instillation, type II pneumocytes 
show cytoplasmic swelling (28) and the surface properties of alveolar lavage fluid and 
lung extractS are characterized by increased minimal surface tension and decreased 
hysteresis (3,8), 
Several studies have been performed on animals suffering from respiratory failure 
due to HCI aspiration and treated with surfactant. Kobayashi and colleagues 
demonstrated that surfactant instillation could only partly restore gas exchange in rabbits 
suffering from respiratory failure due to HCI aspiration after intra-alveolar lung edema 
was removed by BAL; surfactant, when given without prior lung lavage, only prevented 
further deterioration of blood gases (54). Larnm and coworkers showed improved lung 
distensibility in rabbits receiving surfactant 5 min after HCI aspiration, but no effect was 
seen on blood gases (74). Recently we showed that intratracheal surfactant instillation 
witbin 10 min after HCI aspiration could prevent development of respiratory failure, 
whereas surfactant, given after deterioration of gas exchange, had no effect on pulmonary 
gas exchange (18) (see Chapter 5). In another study we demonstrated that lung function 
could be restored in rats suffering from respiratory failure due to HCl aspiration after 
lavaging the lungs with a diluted surfactant suspension, or by lavaging the lungs with 
saline, followed by surfactant treatment (104) (see Chapter 6). 
Because surfactant treatment alone does not suffice to improve pulmonary 
function it is speculated that BAL with saline (followed by surfactant treatment), or with 
a diluted surfactant suspension, removes the inhibitory proteins present in the alveolar 
edema fluid, resulting in improved efficacy of surfactant treatment. 
IVa-Immunological mechanisms: Monoclonal antibodies: Inactivation of the small (:5 
15kDa) hydrophobic surfactant proteins decreases surfactant function with subsequent 
loss of pulmonary function, resulting in ARDS. Suzuki and coworkers (109) 
intraperitoneally inoculated mice with hybridoma cells, producing a monoclonal antibody 
against the 15 kDa surfactant protein. Subsequently, animals developed respiratory 
failure within 9 days with markedly reduced thorax-lung compliance, lung congestion, 
alveolar collapse, hemorrhagic pulmonary edema and hyaline membranes, minticking 
ARDS. Recently, we also demonstrated the importance of this surfactant-associated 
protein for surfactant function in a surfactant replacement smdy using the lavage model 
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in rats. It was shown that inhibition of an 11 kDa surfactant protein caused loss of 
effectiveness of tbe used surfactant preparation (17) (see Chapter 8). Kobayashi and 
coworkers demonstrated that as a result of inactivation of surfactant by a monoclonal 
anti-surfactant antibody directed against SP-B, this preparation was not able to improve 
lung compliance in immature rabbit fetuses (55). In another study Robertson and 
colleagues demonstrated tbat intratracheal instillation of a monoclonal antibody against 
SP-B in near-term newborn rabbits caused a decrease in thorax-lung compliance, when 
compared to rabbits which received nonspecific lgG (97). These studies demonstrate tbat 
SP-B is important for surfactant function and inhibition of this protein in a surfactant 
preparation makes the preparation inactive. 
IVb-Immunological mechanisms: Anti-lung serum: The structural and functional 
pulmonary abnormalities due to capillary leakage in ARDS can be imitated in 
experimental animals by administration of anti-lung serum (59-61). This serum contains 
antibodies against surfactant-associated proteins and against the basement membrane of 
alveolar capillaries. 
Earlier, Lachmann and colleagues demonstrated in artificially ventilated guinea 
pigs, that intravenous injection of anti-lung serum leads to respiratory failure with 
decrease of lung compliance, hypoxemia, and respiratory and metabolic acidosis. 
Morphologic lesions include interstitial and intra-alveolar edema, hemorrhage, and 
desquamation of alveolar epithelium. These structural abnormalities are associated with 
a marked reduction in the phospholipid content of the lungs (71). The decrease in lung 
compliance reflects accumulation of fluids in the air spaces and inactivation of surfactant 
components by plasma proteins. Instillation of a single dose of exogenous natural 
surfactant (280-350 mgjkg BW) after deterioration of blood gases improved gas 
exchange. 
V-Other models for ARF and surfactant treatment have been published (Table 1). These 
will not be discussed in tbis chapter. Table 1 does not contain all literature references; 
for more detailed information, see Robertson and Lachmann (96). 
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Table 1: Animal models 
Model Animals Source 
Immature newborn Rabbits B. Lachmann (65,66) 
animals R. N'~sson (84) 
B. Robertson (96) 
Lambs M. lkegami ( 43,44) 
Neurogenic ARDS Head injury Cats DJ. Crittenden (11) 
Vagotomy Rats V.E. Goldenberg (27) 
D. Berry (6) 
Oxygen toxicity Different J. Klein (52) 
species C.G. Cochrane (9) 
JJ. Ennema (19) 
Oxydant producing Xanthine oxidase Guinea pigs O.D. Saugstadt (99) 
enzymes B. Lachmann ( 69) 
Septicemia E. coli(E. coli Rats K.T. Oldham (86) 
endotoxin J.E. Rinaldo (92) 
Pseudomonas Pigs RA. Mustard (81) 
aeruginosa Dogs P. Hanly (33) 
N-nitroso-N- Rats J.D. Harris (34) 
methylurethrane Rabbits J.F. Lewis (75) 
(NNNMU) Dogs S.F. Ryan (98) 
Oleic acid Rabbits S.B. Hall (30) 
Sheep M. Zeiter (116) 
Paraquat Mice B.W. Manktelow (77) 
Rats B. Robertson (93) 
Hemorrhagic shock Dogs J.N. Henry (35) 
Baboons G.S. Moss (80) 
Tumor necrosis factor Guinea pigs K.E. Stephens (106) 
(TNF) 
BAL with plasma Dogs G.F. Nieman (83) 
Bile acid aspiration Rabbits T. Kaneko (50) 
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CASE REPORTS 
A few reports on ARDS patients with different etiologies treated with surfactant have 
been published (Table 2: see Appendix B). The surfactant preparations used varied from 
synthetic to natural surfactants. Dosage used to treat this syndrome varied from very low 
( <20 mgjkg body weight) to high (300 mgjkg body weight); the method of 
administration varied from single intratracheal instillation to continuous nebulization 
during 5 days. Although these patients treated with surfactant are "worst scenario cases" 
and most case reports are poorly documented, (transient or incomplete) restoration of 
respiratory failure was observed; no adverse immunological reactions were reported 
(Table 2: see Appendix B). Also, case studies have been reported during international 
congresses. For example, during a congress in Tok-yo (organized by the Japanese Society 
for Anesthesia and Intensive Care, and Tok-yo Tanabe, July 1992) a few reports on 
surfactant treatment in adults suffering from ARF were presented. In these patients a 
natural surfactant at a dosage of240-480 mg in total was selectively instilled in atelectatic 
lung parts by means of a bronchofiberscope. Atelectasis in these patients was a result of, 
e.g. pneumothorax after cardiopulmonary resuscitation (CPR), postoperative 
intrapulmonary hemorrhage, postoperative pneumonia, or postoperative atelectasis. The 
results were not consistent, although some improvements in gas exchange, lung 
mechanics and chest X-rays were reported after one or more days. From these results 
it could be concluded that, due to the small amounts used, exogenous surfactant had no 
clear effect on lung function. 
Since 1980 reports on surfactant replacement trials for treatment of neonatal RDS 
have been published (see Chapter 1, Appendix A), and surfactant treatment has become 
accepted in the neonatal intensive care unit. However, discussions still continue 
concerning the time of treatment (e.g. rescue vs. prophylactic), dosage of surfactant and 
type of mechanical ventilation to be used. Concerning the dosage of surfactant in RDS, 
it has been reported that some neonates did not respond to, or had an only transient 
improvement after a single treatment of low-dose surfactant (32,57). It has been 
suggested that in these patients surfactant was gradually inhibited by proteins present in 
the pulmonary edema fluid. This hypothesis was confirmed in other clinical studies in 
which better clinical outcome was seen in neonates treated with either a higher dose of 
40 
surfactant (57) or with multiple doses (15). 
For treatment of ARDS many questions remain unanswered: for example, what 
type and what dosage of surfactant should be used, when should surfactant treatment 
start, how should it be administered, etc. To address these questions controlled clinical 
trials need to be performed. 
CONCLUDING REMARKS 
All the experimental and clinical findings summarized above support the contention that 
ARF / ARDS is caused by multiple factors, leading to increased permeability of the 
alveolar-capillary membrane and disturbance of the pulmonary surfactant system. The 
wide variations of clinical ARDS are presented in case reports and simulated in the 
e>:perimental models of ARF described above, which all differ with respect to etiology, 
severity of respiratory distress, and time course. In all experimental models in which 
surfactant replacement therapy has been evaluated, a significant beneficial effect of 
surfactant instillation was observed. Although much still remains unclear and much 
experimental work still has to be done, these findings provide additional indication of the 
potential therapeutic significance of surfactant replacement therapy in ARDS. In order 
to get a clear view on the therapeutic effects in patients with ARDS, controlled clinical 
trials should be performed, addressing questions such as which patient should be treated 
(e.g. in extended pulmonary fibrosis little or no effect can be expected after surfactant 
administration), the dosage and type of surfactant to be used, the method of 
administration, the type of ventilatory support, and many others. 
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SUMMARY 
Both ARDS and neonatal RDS are characterized by intraalveolar protein-rich edema 
fluid, capable of inhibiting surfactant function. This study investigated the influence of 
pulmonary edema fluid raised in rat lungs after hydrochloric acid aspiration and 
homologous plasma on surfactant function. The first part of the study demonstrated that 
both edema fluid and plasma, intratracheally instilled in healthy rats, led to respiratory 
failure as evidenced by decrease of Pa02 and increase of PaC02, and to high minimal 
surface tension of bronchoalveolar lavage material. The second part showed that 
exogenous surfactant (100 mgjkg), which normally restores gas exchange in surfactant-
depleted lungs, failed to do so when mixed with either edema fluid or plasma; these 
mixtures showed high minimal surface tensions compared to exogenous surfactant alone. 
In contrast to rats which received plasma, bronchoalveolar lavage fluid of rats which 
received edema fluid showed a high percentage of neutrophils, suggesting the presence 
of chemotactic factors in the edema fluid. lt is concluded that both edema fluid and 
plasma have the same inhibitory capacity on surfactant function. However, in these 
studies the origin of the chemotactic factors present in the edema fluid and the role of 
the neutrophils have not yet been established. 
INTRODUCTION 
Both the adult respiratory distress syndrome (ARDS) and the neonatal respiratory 
distress syndrome (RDS) are characterized by high-permeability pulmonary edema 
containing plasma-derived proteins. From in vitro studies it is known that these proteins 
inhibit pulmonary surfactant function in a dose-dependent way (1-8). Also, 
bronchoalveolar lavage fluid (BAL) and lung homogenates of ARDS and RDS patients 
demonstrate both quantitative and qualitative changes in phospholipid composition of 
surfactant and decreased surfactant activity (5,9-12). These findings have led to the 
rationale for exogenous surfactant therapy in clinical trials. 
In neonates exogenous surfactant has been generally accepted for treatment of 
RDS (for review see [13]). To improve gas exchange in these infants, a single dose of 
surfactant (approximately 100 mg/kg, depending on the surfactant preparation used) has 
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proven sufficient (13). However, some infants did not respond to a single dose and 
required either a higher dose (14), or multiple doses (15) of exogenous surfactant. A few 
case reports on exogenous surfactant treatment for ARDS have been published; the best 
results were seen in patients treated with higher surfactant concentrations (approximately 
300 mgjkg) (16-18). In both ARDS and RDS lack of response, or only transient 
response, after a single (low) dose of surfactant could probably be attributed to the 
alveolar space being filled with protein-rich edema fluid. 
In a recent study (19) we reported that in rats suffering from respiratory failure 
due to hydrochloric acid (HCl) aspiration, exogenous surfactant could not restore gas 
exchange when given after 90 min. However, when surfactant was given before 
deterioration of lung function (i.e. within 10 min after HCl aspiration), almost normal 
gas exchange could be preserved. It was discussed whether failure of exogenous 
surfactant treatment to restore gas exchange after deterioration of lung function was due 
to edema fluid forming a mechanical barrier, preventing exogenous surfactant from 
entering the alveolar space, or surfactant being directly inhibited by plasma proteins. 
Another possibility could be that edema fluid contains specific mediators capable of 
inhibiting exogenous surfactant function. For this reason, the present study is designed 
to investigate the influence of pulmonary edema fluid and homologous plasma on lung 
function of healthy adult rats after intratracheal instillation. Also, the question is raised 
whether there is any difference in inhibitory capacity between edema fluid and plasma. 
MATERIALS AND METHODS 
Exogenous surfactant 
The surfactant used in these experiments is a freeze-dried natural surfactant isolated 
from bovine lungs in basically the same manner as previously described (20). It consists 
of approximately 90% phospholipids, 1% hydrophobic proteins (SP-B and SP-C), the 
remainder being other lipids such as cholesterol, glyceride and free fatty acids. There is 
no SP-A (the largest surfactant-associated protein: molecular weight 26-38 kDa) in this 
surfactant preparation. In this study surfactant was suspended in saline. The surfactant 
preparation used has proven to be highly effective in improving gas exchange and lung 
mechanics in various animal models of respiratory failure of differing etiologies (19,21-
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23) and in newborn babies suffering from respiratory failure due to congenital 
diaphragmatic hernia (24 ). 
Pulmonary edema fluid 
This protocol was approved by the Animal Care and Use Committee of the Erasmus 
University Rotterdam, The Netherlands. 
Pulmonary edema was raised in male adult Sprague-Dawley rats (body weight: 
300-350 g) after the following procedures (19). In brief: after induction of anesthesia with 
nitrous oxide, oxygen and halothane (65/33/2%) the animals were tracheotomized and 
a catheter was inserted into the carotid artery. Anesthesia was maintained with 
pentobarbital sodium (60 mg/kg, i.p.) and muscle relaxation was attained with 
pancuronium bromide (0.5 mg/kg, i.m.). The animals were ventilated at the following 
ventilator settings: pressure-controlled ventilation, Fi02 = 1.0, peak airway pressure 
(P ""'') = 14 cmH20, positive end-expiratory pressure (PEEP) =2 cmH20, ventilation 
frequency=30/min and inspiratory/expiratory ratio = 1:2.; a Servo Ventilator 900 C 
(Siemens-Elema, Solna, Sweden) was used. After reaching steady state (Pa02 > 500 
mmHg) the animals received HCl intratracheally (0.1 N, 3 mljkg); P ""''was increased 
to 26 cmH20 and PEEP to 6 cmH20 and these ventilator settings were maintained 
throughout the observation period. Blood samples were taken at regular intervals for 
measurement of Pa02 and PaC02 (ABL 330; Radiometer, Copenhagen, Denmark). After 
1-2 hours Pa02 decreased below 100 mmHg at the used ventilator settings and an 
amount of 1.5-2.0 ml (4.5-6.0 ml/kg body weight) hemorrhagic edema fluid could be 
aspirated from the lungs by gentle suction via the trachea cannula. The animals were 
then sacrificed with an overdose of intra-arterially administered pentobarbital sodium. 
Before instillation of HCl, 2 ml of citrated blood was taken from all rats and replaced 
by saline. Both edema fluid and blood were centrifugated at 2000 g for 15 min to remove 
all cellular material. The supernatant of all edema samples and plasma were pooled and 
stored at -20 • C until used for experimental purposes. Before storage, pH of edema flnid 
and plasma was measured (7.6 and 7.4, respectively). Also, protein concentrations of 
edema fluid and plasma were measured using a modified Lowry method (25), with 
bovine serum albumin as standard. 
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In the edema fluid, clot formation was observed after 30 min at room 
temperature; this clot was removed from the edema fluid. Because of this observation 
a quantitative measurement of fibrinogen concentration was performed. Wells of an 
agarose-plate containing goat antiserum against rat fibrinogen (Nordic Immunological 
Labs, Tilhurg, The Netherlands) were filled with (a) rat plasma at different dilutions, (b) 
rat serum at different dilutions and (c) rat edema fluid at different dilutions. The 
proteins were allowed to migrate overnight in an electric field. After precipitation the 
agarose-plate was stained. The height of the precipitation peak is related to the protein 
concentration ("rocket immunoelectrophoresis"). 
Animal studies 
Experiment I: To study the effect of intratracheal instillation of edema fluid and 
homologous plasma on lung function, 24 male Spragne-Dawley rats were used (body 
weight: 300-350 g). These animals underwent the same anesthesia procedure as described 
above and the same ventilator settings were used. After reaching steady state (Pa02 > 
500 mmHg) the rats were randomly divided into three groups: Group IA (n=8) received 
edema fluid intratracheally (4 ml/kg); Group IE (n=6) received plasma (4 ml/kg) and 
Group IC (n = 10) received saline ( 4 ml/kg). P pak was increased to 26 cmH20 and PEEP 
to 6 cmH20. These ventilator settings were maintained throughout the observation 
period. Blood samples for measurement of Pa02 and PaC02 were taken from the carotid 
artery of each rat before intratracheal instillation and at 5, 30, 60, 90 120, 150 and 180 
min post-instillation. At the end of the experiment (180 min) all rat lungs were lavaged 
with saline (37 • C; 30 ml/kg) and the animals were then sacrificed as described above. 
Experiment II: To study the effect of edema fluid and homologous plasma on an 
exogenous surfactant preparation 18 male Spragne-Dawley rats were used (body weight 
300-350 g). These animals underwent the same anesthesia procedure as described above 
and the same ventilator settings were used. After reaching steady state (Pa02 > 500 
mmHg) respiratory failure was induced by bronchoalveolar lavage (BAL) as described 
by l.achmann and colleagues (26). In brief: lungs were lavaged 6-7 times with warm 
saline (37•C; 30 ml/kg) to produce aPa02 <80 mmHg atPp~k=26 cmHzO and PEEP=6 
cmH20. In all animals the first lavage was collected and prepared as described below 
("Control" lavage). The ventilator settings were unchanged throughout the entire 
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observation period. Approximately 5 min after Pa02 < 80 mmHg animals were randomly 
divided into three groups: Group IIA (n=6) received surfactant mixed with undiluted 
edema fluid intratracheally; Group liB (n = 6) received surfactant mixed with undiluted 
plasma. and Group !IC (n=6) received surfactant mixed with saline. All rats were treated 
with a surfactant dose of 100 mg/kg; the surfactant preparation used in all groups was 
suspended in saline at a concentration of 30 mg/ml. Mixtures (v:v= 1 ml:1 ml) used in 
all rats were incubated together for 30 min at 37 • C. Blood samples for measurement of 
Pa02 and PaC02 were taken from the carotid artery before BAL and 5 min after the last 
lavage (directly followed by treatment) and at 5, 30, 60, 90, 120, 150 and 180 min post-
treatment. At the end of the experiment rat lungs were lavaged •Jith saline (37 ° C; 30 
ml/kg) and the animals were sacrificed, as described before. 
Inhibitory activity of edema fluid 
lnfluence of the edema fluid on the surface tension properties of the exogenous 
surfactant preparation was investigated using a modified Wilhelmy balance (E. Biegler 
GmbH, Mauerbach, Austria). In brief: a tight-fitting teflon barrier reduces the surface 
area of a teflon trougb from 100-20% at a cycle speed of 0.33/min. Saline is used as 
subphase and is kept at 37 ° C. The force on a platinum slide (lx1 ern), dipped into the 
subphase, is measured by a force transducer and expressed as surface tension. Further, 
maximal surface tension is measured at 100% surface area and minimal surface tension 
at 80% surface-compresion and are expressed as milli Newton/meter (mNjm). Surface 
tension characteristics of a sample are measured after application on the surface of the 
saline-filled trough. 
In this study the surfactant suspension was used at the same concentration as used 
in the animal study (30 mg/ml). There were 5 groups of samples for surface activity 
measurements; each group consisting of 4 samples. In the first group 25 ILl of the 
surfactant suspension is applied to the surface of the saline-filled trougb. In the second 
group 25 ILl of the undiluted edema fluid and in the third group 25 ILl of undiluted 
plasma. is applied to the surface. In the fourth group 25 ILl of surfactant suspension is 
mixed with edema fluid (v:v= 1:1); in the fifth group 25 ILl of surfactant suspension is 
mixed with plasma (v:v= 1:1), and applied to the surface. Maximal and minimal surface 
tensions are measured after 3 cycles. 
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Bronchoalveolar lavage fluid 
The bronchoalveolar lavage (BAL) samples of all rats (Groups IA-IC, Groups IIA-IIC 
and the "Control" lavages) were prepared as follows: All BALsamples were centrifugated 
for 5 min at 400 g. After removal of the erythrocytes by washing with cold H20 and 
centrifugation, the cellular sediment was prepared for total cell count and cell 
differentiation according to standard techniques. The supernatant was centrifugated for 
15 ntin at 2000 g to remove the remaining cell material. 
Total protein concentration was measured in all BAL samples using a modified 
Lowry method (25), with bovine serum albumin as standard. 
Surface activity in BAL fluid was measured with the Wilhelmy balance by applying 
500 ILl of BAL fluid to the surface of the saline-filled trough. Maximal and ntinimal 
surface tensions were measured after 3 cycles. 
Statistical analysis 
All data are ex"j)ressed as mean :!: standard deviation (SD). For Pa02 and PaC02 values 
statistical analysis was performed using repeated measurements ANOV As, with time as 
the repeat variable. For analysis ofBAL parameters, standard AN OVA procedures were 
performed. When significant differences between and/ or within groups occurred, these 
differences were further analyzed with a test that compensated for multiple comparison 
(Student-Newman-Keuls test). Statistical significance was accepted at p,;O.OS. 
RESULTS 
In vitro studies 
The total protein concentration in pooled edema fluid and plasma were 44.5 and 56.6 
mg/ml, respectively; pooled edema fluid and rat serum did not contain any fibrinogen. 
Both edema fluid and plasma led to inhibition of exogenous surfactant, as 
demonstrated by an increase of both maximal and minimal surface tensions of the 
exogenous surfactant preparation (Table 1). 
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Table 1: Effect of edema fluid and plasma on surface properties of exogenous surfactant. 
Sample n Surface tension 
[mN/m] 
maximal minimal 
Surfactant 4 23.9* 11.6* 
±: 3.44 ±: 133 
Edema 4 61.7 33.4# 
±: 1.45 ±: 1.60 
Plasma 4 63.4 40.0 
±: 2.25 ±: 2.45 
Swf +Edema§ 4 33.0@ 22.8 
± 2.05 :!:. 1.40 
Surf + Plasma§ 4 39.9 21.9 
± 3.83 ± 1.66 
All data are mean ± SD; "'p<O.OS between Surfactant and other groups; #p<O.OS between Edema and 
Plasma; @p<O.OS between Surf + Edema and Surf + Plasma; §p<O.OS between Surf + Edema/Surf + 
Plasma and Edema/Plasma. 
Animal studies 
Experiment I: Figure 1 shows Pa02 values from healthy animals which received either 
edema fluid, plasma, or saline. Before instillation Pa02 values were above 500 mmHg 
in all groups. After receiving edema fluid or plasma Pa02 values decreased, whereas 
Pa02 values of rats receiving saline remained above 500 mmHg. After receiving edema 
fluid there was a slight increase in PaC02 values, whereas PaC02 values did not change 
in rats receiving plasma; in rats which had received saline there was a slight decrease of 
PaC02 values (Fig. 2). For statistically significant differences, see Figures 1 and 2. 
Experiment II: The intergroup differences in Pa02 values both before and after lavage 
were not statistically different (Fig. 3). After treatment, the Pa02 values of the rats 
receiving surfactant mixed with saline increased to pre-lavage values and were 
significantly higher compared to rats receiving surfactant mixed with edema or plasma. 
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PaC02 values of rats receiving surfactant mixed with saline were significantly lower 
compared to rats receiving surfactant mixed with edema fluid or plasma (Fig. 4). 
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Figure 1. PaOz values (mean :t SD) of different groups: healthy rats received edema fluid, plasma or saline 
intratracheally at 4 ml/kg; *""" significant difference between rats which received edema fluid and saline; # = 
significant difference between rats which received plasma and saline; Pa02 = arterial oxygen tension. 
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Figure 2. PaC02 values (mean :t: SD) of different groups; for explanation of groups, see Figure 1; * = 
significant difference between rats which received edema fluid and saline; PaC02 = arterial carbon dioxide 
tension. 
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Figure 3. Pa02 values (mean± SD) of different groups: after BAL (=grey bar) rats received surfactant (100 
mg/kg) mixed with edema fluid, plasma or saline; Control = Pa02 values before BAL; t=O indicates Pa02 
values 5 min after BAL, immediately followed by treatment; "'= significant difference between rats which 
received surfactant mixed with saline and other groups; # = significant difference between rats which received 
surfactant mixed with edema fluid and plasma; Pa02 = arterial o:...-ygen tension. 
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Figure 4. PaC02 values (mean ± SD) of different groups; for explanation of groups, see Figure 3; "'= 
significant difference between rats which received surfactant mixed with saline and other groups; PaC02 = 
arterial carbon dioxide tension. 
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Bronchoa/veolar lavage fluid 
Experiment I: BAL fluid of rats receiving edema fluid showed high minimal surface 
tension compared to lavage fluid from healthy rats (Control) (Table 2). Significantly 
higher total cell count/ml was seen in BAL fluid from rats which received edema fluid, 
compared to all other rats; also, significantly low macrophage percentage and high 
granulocyte percentage was seen in rats which received edema fluid, compared to the 
other rats (Table 3). 
Table 2: BAL parameters from Experiment I. 
Group n Recovery Protein Surface tension 
[%] [mg/ml] [mN/m] 
maximal minimal 
Edema 8 96.7 6.79" 59.1 28.9@ 
± 2.36 ::!: 0.78 ± 3.00 ± 3.36 
Plasma 6 95.0 6.01# 573 26.2 
± 4.47 ± 0.55 ± 334 ± 2.93 
Saline 10 96.3 0.48 61.8 25.8 
± 4.33 ::!:: 0.51 = 3.40 ± 3.12 
Control 8 95.6 0.23 61.2 23.3 
± 6.43 ± 0.07 ± 6.72 ± 3.63 
All data are mean ± SD; Control = BAL fluid of healthy control rats; "'p < 0.05 between rats receiving 
edema fluid and saline/Control; #p<0.05 between rats receiving plasma and saline/Control; @p<0.05 
between rats receiving edema fluid and ControL 
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Table 3: Cellular parameters in BAL from Experiment I. 
Group Cell count Macrophages# Granulocytes@ Lymphocytes v;abi!ity 
[xlO'/ml] [%] [%] [%] [%] 
Edema 17:2* 11.7 87.7 0.70 98.6 
± 4.44 ± 4.50 ± 450 ± 0.47 ± 0.83 
Plasma 5.64 42.0 565 1.53 98.9 
± 2.77 ± 9.86 ± 10.5 ± 154 ± 0.79 
Saline 2.68 61.0 36.5 2.50 95.0 
± 1.57 ± 7.18 ± 5.94 ± 2.06 ± 1.73 
Control 2.54 962 251 131 94.6 
± 1.46 ± 3.16 ± 2.09 ± 1.15 ± 3.75 
All data are mean ± SD; *p<0.05 between rats receiving edema fluid and other groups; #,@p<0.05 between 
all groups; viability "" percentage of living leucocytes. 
Table 4: BAL parameters from Experiment II. 
Group n Recovery Protein Surface tension 
[%] [mg/ml] [mN/m] 
maximal minimal 
Surfactant + edema 5 100 5.35 60.1 21.4 
"0 ± 033 ± 1.98 ± 2.08 
Surfactant + plasma 5 100 5.09 57.1 21.1 
" 0 ± 0.74 ± 1.44 ± 1.24 
Surfactant + saline 6 100 1.86* 55.1 19.6 
" 0 ± 1.11 ± 3.97 ± 2.27 
All data are mean ± SD; *p<0.05 between rats which receiving surfactant + saline and other groups. 
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Table 5: Cellular parameters in BAL from Experiment II. 
Group Cell count Macrophages Granulocytes Lymphocytes Viability 
[xlO' /ml] [%] [%] [%] [%] 
Surfactant + 12.4"' 20.5# 79.0# 0.50 99.9 
edema ± 4.89 ::!:: 9.50 ± 9.67 ::!:: 0.50 ± 0.13 
Surfactant + 3.88 433 52.3 1.00 85.1 
plasma ::!:: 1.44 ::!:: 5.44 ::!:: 5.44 ::!:: 0.82 ± 8.80 
Surfactant + 4.00 65.0 34.0 1.10 89.7 
saline ± 131 ::!:: 21.6 ::!:: 2.02 ± 1.44 ± 6.95 
All data are mean ::!:: SD; *p<0.05 between rats receiving surfactant + edema and other groups; #p<0.05 
between rats receiving surfactant + edema and surfactant + saline; viability = percentage of living 
leucocytes. 
Experiment II: There was no difference in surface tension properties between all groups 
(Table 4). Total cell count/ml was significantly higher in BAL fluid from rats which 
received surfactant mixed with edema fluid, compared to all other groups; BAL fluid 
from rats which received surfactant mixed with edema fluid demonstrated a significantly 
low macrophage percentage and significantly high granulocyte percentage, compared to 
BAL fluid from rats which received surfactant mixed with saline (Table 5). 
DISCUSSION 
The first part of this study (Experiment I) demonstrated that intratracheal instillation of 
both protein-rich edema fluid and homologous plasma in healthy rats were capable of 
disturbing gas exchange across the alveolar-capillary membrane at the used ventilator 
settings. BAL fluid of rats receiving edema fluid showed high minimal surface tension 
compared to lavage fluid from healthy controls. These results suggest interference of 
both edema fluid and plasma with the surfactant layer of the lungs. 
The BAL fluid of healthy rats receiving edema fluid contained a significantly 
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higher percentage of (neutrophilic) granulocytes compared to BAL fluid of other groups. 
These findings suggest attraction of neutrophils into the alveoli, probably due to 
chemotactic factors present in the edema fluid, as is also described in animal lungs after 
HCI aspiration (27,28). These neutrophils are capable of producing toxic oxygen radicals 
and specific proteases (29,30), leading to further destruction of the alveolar-capillary 
membrane and, perhaps, also to direct damage of the surfactant system (31). This not 
only suggests that certain factors in edema fluid in ARDS are capable of interfering with 
the surfactant layer, it also appears that high-permeability edema fluid itself can induce 
and maintain an ARDS-Iike situation in healthy animals. This observation could explain 
why it is difficult to treat the respiratory insufficiency when the cause of the ARDS has 
been treated successfully: the ARDS may support itself. 
The second part of this study (E>.-periment II) was designed to investigate whether 
edema fluid and homologous plasma are capable of inhibiting the ability of a 
therapeutical dosage of an exogenous surfactant preparation to restore gas exchange in 
animals suffering from acute respiratory failure. For this purpose the lung lavage model 
was used. This model has proven useful for a variety of experimental purposes, including 
e.g. testing of different surfactant preparations and demonstrating that exogenous 
surfactant restores blood gases to normal (26,32,33). The dose of surfactant (100 mg/kg) 
used in this study has proven to be sufficiently high to restore lung function in rats 
suffering from respiratory failure after bilateral whole lung lavage (33). However, 
surfactant at this concentration mixed with edema fluid or plasma was not able to restore 
lung function. This observation could not be explained by a fluid effect, per se: surfactant 
ntixed with saline was capable to restore gas exchange to normal values. Surface tension 
measurements of these ntixtures showed that both maximal and minimal surface tensions 
of surfactant ntixed with edema fluid or plasma were significantly higher compared to 
surfactant alone. BAL fluid of rats receiving surfactant mixed with edema fluid again had 
a significantly higher percentage of neutrophils compared to BAL fluid of other groups. 
It is known that surfactant function can be inhibited in a dose-dependent way by 
whole blood, plasma, serum and different plasma proteins such as fibrinogen, fibrin 
monomers, albumin, globulin, hemoglobin and cell membrane lipids (1-4,7,8). Also, it has 
been demonstrated that phospholipases can inhibit surfactant function (34). A specific 
plasma-derived surfactant inhibitor (MW = 110.000 Da, unreduced) has been isolated 
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from the alveolar washes of prematurely delivered and ventilated lambs, and in alveolar 
washes of infants suffering from RDS (5,6). 
The mechanism by which plasma-derived proteins inhibit surfactant function is not 
clear. Balis and colleagues have postulated two different types of surfactant inhibition 
(1). They demonstrated that inhibition of surfactant by serum could be reversed by 
centrifugating the surfactant-serum mixture: the sediment revealed normal surfactant 
function. Mixing surfactant with plasma allowed clot formation to occur; this "coagulative 
type" of inhibition, could not be reversed by centrifugation. The existence of this type of 
inhibition seems plausible, because of the fact that alveoli of infants with RDS are 
covered with hyaline membranes, containing fibrin and cellular debris (35). Also, as 
already mentioned, fibrinogen and fibrin monomers are potent surfactant inhibitors 
(2,7,8). As mentioned in the section "Materials and Methods" clot formation was 
observed in the edema fluid. One explanation could be that the edema fluid resembles 
(non-citrated) plasma, resulting in clot formation. Another explanation could be that the 
(endogenous) surfactant reveals thromboplastic activity (8). In the present study it 
appears that fibrinogen is not essential for inhibition of surfactant function, since the 
edema fluid did not contain any fibrinogen. However, no measurements on fibrin-
breakdown products were performed. 
Other investigators have hypothesized that inhibition of surfactant by plasma 
derived proteins is due to competition for space at the air-liquid interphase. Holm and 
colleagues reported that, at high surfactant concentrations the inhibitory effect of high 
concentrations of plasma protein or membrane lipids was abolished (3,4). Other studies 
confirm the probable existence of a competition mechanism: after centrifugation of 
surfactant-inhibitor mixtures derived from BAL fluid of animals treated with surfactant, 
or after centrifugation of surfactant-protein mixtures, the sediments containing surfactant 
revealed normal surface tension characteristics compared with pre-centrifugation (1,4,5). 
Also, when these BAL fluids or the surfactant-protein mixtures were investigated for 
surface tension properties, it could be demonstrated that after a certain number of cycles 
the ntinimal surface tension decreased from initial high levels to low levels (2,6,7). 
If the inhibition of surfactant function is dose-dependent, this would be of great 
importance for treatment of ARDS and neonatal RDS. Namely, in this case it would 
seem to be merely a case of attaining a high surfactant/inhibitor (S/I) ratio. Thus, 
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whether the lungs are filled with plasma proteins or not, intratracheal instillation of 
sufficiently high dosage of surfactant should restore lung function. In a recent study, 
surfactant at 200 mg/kg was not able to restore gas exchange in rats suffering from 
respiratory failure due to HCl aspiration (19). In another study, it was demonstrated that 
surfactant instillation at very high doses (280-350 mg/kg) was able to restore gas 
exchange in guinea pigs suffering from severe respiratory failure due to high permeability 
pulmonary edema after intravenous instillation of anti-lung serum (36). Recently, 
Kobayashi and colleagues investigated the capability of surfactant mixed with edema flttid 
at several ratios to restore lung function in immature rabbit fetuses, as measured by tidal 
volume at preset insufflation pressures (37). It was demonstrated that surfactant (25 
mg/ml) mixed with edema fluid at a protein to lipid ratio (P/L ratio) of2.2 was capable 
of restoring lung function, whereas surfactant mixed with edema fluid at P /L ratio of 
11.2, was not. Surface tension properties of these mixtures demonstrated high mirtimal 
surface tensions at P jL;;,3.4 and low surface tensions at P jL,; 1.8. Another way to 
accomplish a high S/l ratio would be to first lavage the lungs, followed by surfactant 
treatment (38,39). In a recent study we demonstrated that lung function could be 
restored in rats suffering from severe respiratory failure due to HCl aspiration after 
lavaging the lungs with a diluted surfactant suspension (39). From these results one can 
speculate that in the present study a larger amount of exogenous surfactant would 
perhaps be able to overcome the inhibition of both edema fluid and plasma. Also, in the 
case of edema fluid, perhaps anti-inflammatory drug therapy could be used to prevent 
attraction of neutrophils into the lungs. 
In conclusion: it has been demonstrated that both edema fluid and plasma 
interfere with the surfactant layer, probably by direct inhibition due to plasma-derived 
proteins. However, in the case of edema fluid some inflammatory agents could, in part, 
be responsible for the inhibition of surfactant function. The edema fluid and plasma were 
also capable to inhibit a therapeutical dosage of an exogenous surfactant preparation to 
restore gas exchange in surfactant depleted animals. Since inhibition of surfactant is 
dose-dependent it is proposed to attain a high S/l ratio by means of increasing the 
amount of surfactant, or decreasing the inhibitory effect via BAL (with saline or a diluted 
surfactant suspension) and giving surfactant at sufficiently high concentration. 
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SUMMARY 
Objective: The adult respiratory distress syndrome (ARDS) and neonatal respiratory 
distress syndrome (RDS) are characterized by high permeability pulmonary edema which 
contains plasma-derived proteins inhibiting pulmonary surfactant function. Currently, 
discussion continues as to what dose of surfactant is required for treatment of these 
syndromes. 
Design: The purpose of this study was to investigate the amount of exogenous surfactant 
needed to overcome the inhibitory components in human plasma. Male adult rats 
suffering from respiratory failure due to surfactant depletion after whole-lung lavage 
received human plasma (4 ml/kg body weight) mixed with surfactant at different 
concentrations, intratracheally. Rats receiving surfactant only at different concentrations 
served as controls. Blood gas analysis was performed. 
Measurements and results: lt was demonstrated that plasma (4 ml/kg" 280 mg plasma 
proteins/kg) mixed with surfactant at 300 mgjkg was able to increase and maintain Pa02 
at normal values. Plasma mixed with surfactant atlOO mg/kg, after initial restoration of 
blood gases, showed deterioration of Pa02 values. Plasma mixed with surfactant at a dose 
of 50 mg/kg did not improve Pa02, whereas surfactant at 50 mg/kg, without plasma, 
restored blood gases to pre-lavage values. 
Conclusion: It is concluded that approximately I mg surfactant phospholipids is required 
to overcome the inhibitory effect of approximately 1 mg plasma proteins. For clinical 
practice this means that an excess of surfactant should be given, or repeatedly be 
substituted ("titrated") at low concentrations, until blood gases improve. 
INTRODUCTION 
The adult respiratory distress syndrome (ARDS) and neonatal respiratory distress 
syndrome (RDS) are both characterized by respiratory failure and require therapy 
consisting of intubation and mechanical ventilation with high oxygen concentrations. RDS 
is characterized by primary surfactant deficiency due to immaturity of the lungs, while 
in ARDS high permeability pulmonary edema exists, containing plasma-derived proteins 
which inhibit pulmonary surfactant function [1-7]. Due to impaired surfactant function, 
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surface tension at the air-liquid interphase on the alveolar walls is increased, leading to 
increased suction force across the alveolar-capillary membrane [8]. This results in further 
intra-alveolar accumulation of protein-rich edema fluid. 
Several clinical trials have reported successful treatment with intratracheal 
surfactant instillation in prematures suffering from RDS [9-14]. In these studies, however, 
some infants did not respond to a single dose of surfactant and some infants had an only 
transient improvement of lung function [10,11]. One reason for this could be that 
surfactant function is inhibited by plasma-derived proteins present in intra-alveolar 
edema fluid. 
A few reports on ARDS patients treated with surfactant have been published. 
Although the results from these studies are not consistent, the best results were seen in 
those patients treated with higher surfactant concentrations [15-19]. 
Currently, discussion continues as to what dose of surfactant should be used in 
prematures with established RDS and what dose should be used for treatment of ARDS. 
To investigate this, a study was performed in an animal model of respiratory failure 
induced by bronchoalveolar lavage (BAL). This model has proven useful for a vatiety of 
experimental purposes, including e.g. testing of different surfactant preparations and 
demonstrating that exogenous surfactant restores blood gases to normal [20-22]. After 
respiratory failure was established, animals received plasma mixed with surfactant at 
different concentrations. Plasma was used to simulate protein-rich edema, an established 
characteristic of ARDS. Instead of lung mechanics, blood gas measurements were 
measured, since these have proven to be more sensitive to therapeutic interventions in 
this model [23]. 
MATERIALS AND METHODS 
Exogenous suifactant 
The surfactant used in these experiments was a freeze-dried natural surfactant isolated 
from bovine lungs in basically the same manner as previously described [24]. It consists 
of approximately 90% phospholipids, 1% hydrophobic proteins (SP-B and SP-C), the 
remainder being other lipids such as cholesterol, glyceride and free fatty acids. There is 
no SP-A in this surfactant preparation. This surfactant preparation has proven to be 
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highly effective in improving gas exchange and lung mechanics in various animal models 
of respiratory failure of differing etiologies [25-27] and in newborn babies suffering from 
respiratory failure due to congenital diaphragmatic hernia [28]. 
Animal study 
The protocol was approved by the Animal Care and Use Comntittee of the Erasmus 
University Rotterdam. 
The studies were performed in 45 male adult Sprague-Dawley rats (body weight 
300-350 g). After induction of anesthesia with nitrous oxide, oxygen and halothane 
(65/33/2%) the animals were tracheotomized and a catheter was inserted into the 
carotid artery. Anesthesia was maintained with pentobarbital sodium (60 mgjkg, i.p.) and 
muscle relaxation was attained with pancuronium bromide (0.5 mgjkg, i.m.). The rats 
were ventilated with a Servo Ventilator 900C (Siemens-Elema, Solna, Sweden) at the 
following ventilator settings: pressure-controlled ventilation, F,02 = 1.0, ventilation 
frequency=30jmin, peak airway pressure (PP"'J = 14 cmH,O, positive end-expiratory 
pressure (PEEP) = 2 cmH20 and inspiratory/ expiratory ratio= 1:2. 
After reaching steady state (Pa02 > 500 mmHg) respiratory failure was induced 
by BALas described by Lachmann et a! [20]. In brief: lungs were lavaged 6-7 times with 
warm saline (37-C; 30 mljkg) to produce a Pa02 <80 mmHg at P"',k=26 cmH20 and 
PEEP=6 cmH20. These ventilator settings were unchanged throughout the entire 
observation period. 
Approximately 5 min after Pa02 < 80 mmHg animals were randomly divided into 
seven groups: Groups I, TI, and Ill (n=6, n=7 and n=7, respectively) received undiluted 
citrated pooled human plasma ( 4 ml/kg) mixed with surfactant at concentrations of 50, 
100 and 300 mg phospholipids/kg body weight, respectively; Groups IV, V and VI (n=6, 
n=6 and n=7, respectively) received surfactant suspended in saline at concentrations of 
25, 50 and 100 mg phospholipids/kg body weight, respectively (total amount of surfactant 
suspension was 4 mljkg); Group VII (n=6) received undiluted citrated pooled human 
plasma ( 4 ml/kg). 
Blood samples for measurement of Pa02 and PaC02 were taken from the carotid 
artery before BAL and 5 min after the last lavage (directly followed by treatment) and 
at 5, 30, 60, 90, 120, 150 and 180 min post-treatment (ABL 330; Radiometer, Denmark). 
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The animals were then sacrificed with an overdose of intra-arterially administered 
pentobarbital sodium. 
Statistical analysis 
All data are expressed as mean ± standard deviation (SD). Statistical analysis of data 
was performed using repeated measurements Anovas, with time as the repeat variable. 
When differences between and/ or within groups occurred, these differences were further 
analyzed with a test that compensated for multiple comparison (Student-Newman-Keuls 
test). Statistical significance was accepted at p~0.05. 
RESULTS 
Figures 1A and 1B show Pa02 values for all groups. The intergroup differences both 
before and after lavage are not statistically different. After treatment, the Pa02 values 
of groups receiving surfactant only at 50 and 100 mg/kg (Groups V and VI, respectively) 
increase to pre-lavage values and remain high during the whole observation period and 
the differences between these groups are not significant; for this reason Pa02 values of 
these two groups are used for statistical comparison with other groups. Surfactant only 
at 25 mgjkg (Group IV), after initial improvement to pre-lavage values, did not stabilize 
Pa02 values over the whole observation period; the difference with Groups V /VI was 
significant after 60 min. Pa02 values of rats receiving plasma ( 4 mljkg) mixed with 
surfactant at 100 and 300 mg/kg (Groups II and lll, respectively) also increase to normal 
values. Immediately after treatment there is no significant difference in Pa02 values 
between Groups II and Ill and Groups V /VI. However, Pa02 values of Group II 
decrease significantly 60 min after treatment compared to Group lll. Pa02 values of 
Group lil remain at high levels througbout the observation period and are not 
significantly different from Groups V /VI. Pa02 values of rats receiving plasma mixed 
with surfactant at 50 mgjkg (Group !) did not increase significantly. Rats receiving 
plasma only (Group VII) died within 60 min. 
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Figure 1. Pa02 values (mmHg; mean ::!::: SD) before (•) and after BAL (=grey bar) in different treatment 
groups: Groups I, II, and III received plasma (4 ml/kg) mixed with surfactant at 50, 100 and 300 mg/kg, 
respectively (A); Groups IV, V and VI received surfactant only at 25, 50 and 100 mg/kg, respectively and 
Group VII received plasma only ( 4 mljkg) (B); t = 0 indicates the Pa02 values 5 min after BAL, immediately 
followed by treatment; t = one rat died; Pa02 = arterial oxygen tension. 
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Figure 2. PaC02 values (mmHg; mean ± SD) before (•) and after BAL (=grey bar) in different treatment 
groups: for explanation of groups, see Figure 1; PaC02 = arterial carbon dioxide tension. 
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Figures 2A and 2B show the PaC02 values for all groups. The intergroup differences 
both before and after lavage are not statistically different. PaC02 values of rats receiving 
surfactant only at 50 or 100 mgjkg do not differ significantly, and are used for 
comparison with other groups. PaC02 values of Groups I, II and VII differ significantly 
from Groups V /VI. There is no significant difference in PaC02 values between Group 
III and Groups V /VI. There are no significant differences in PaC02 values between 
Groups II and III. 
DISCUSSION 
It bas been established that in both ARDS and RDS the alveolar-capillary membrane 
is highly permeable to plasma proteins, leaking from the circulation into the alveolar 
space, resulting in edema formation [2,29,30]. BAL material of patients suffering from 
these syndromes demonstrates quantitative and qualitative changes in phospholipid 
composition of surfactant, and contains high protein concentrations [2,30-33]. Saline 
extracts of lung minces from infants who died from RDS and from adults with ARDS 
contained less phospholipids and had higher minimal surface tension than similar extracts 
from lungs of patients who died from other causes [15,34]. Several clinical studies have 
been performed treating infants suffering from RDS with intratracheal surfactant 
instillation [9-14]. The surfactant preparations used varied from natural surfactant (e.g. 
CI.SE, Curosurf, Surfactant TA and human surfactant) to synthetic surfactant 
preparations (ALEC, Exosurf). The doses used in these clinical trials varied from low (60 
mgjkg) to high (200 mgjkg). It has been reported that some infants did not respond to, 
or had an only transient improvement after a single treatment of low-dose surfactant 
[10, 11]. It has been suggested that in these patients surfactant was gradually inhibited by 
proteins present in the pulmonary edema fluid. This hypothesis could be confirmed in 
other clinical studies in which better clinical outcome was seen in infants treated with 
either a higher dose of surfactant [11] or by treatment with multiple doses [14]. Only a 
few patients with ARDS have been treated with surfactant. Although the results from 
these studies are not consistent, the best results were seen in patients treated with higher 
surfactant concentrations [15-19]. 
After treatment of RDS and ARDS with a low dose of surfactant the reason for 
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lack of response, or only transient improvement, is attributed to tbe alveolar space in 
tbese patients being filled with protein-rich edema fluid. Clinical and animal studies have 
established that tbese plasma-derived proteins inhibit surfactant [1-7,29,30,35-39]. Surface 
tension studies have shown that several plasma proteins inhibit surfactant in a dose-
dependent manner [7,36,37,40-45]. It is also established tbat some surfactant 
preparations, especially synthetic surfactants, are more sensitive to the inhibitory effect 
of plasma-derived proteins tban otber preparations [46-48]. However, in recent studies 
it was demonstrated that addition of surfactant-associated proteins increases resistance 
of syntbetic surfactants to inhibition of plasma proteins [49,50]. In physiological studies 
using excised lungs it was shown that intratracheal instillation of hemoglobin, albumin 
or membrane lipids decreased lung compliance, which could be reversed by intratracheal 
surfactant instillation [ 42]. 
The mechanism by which plasma derived proteins inhibit surfactant function is not 
clear. Balis and colleagues [51] have postulated two different types of surfactant 
inhibition. They demonstrated that inhibition of surfactant by serum could be reversed 
by centrifugating the surfactant-serum mixture: the sediment revealed normal surfactant 
function. Mixing surfactant with plasma allowed clot formation to occur: this "coagulative 
type'' of inhibition could not be reversed by centrifugation. Seeger and colleagues 
reported that fibrin monomers are potent inhibitors of surfactant: inhibition of surfactant 
could partially be reversed by adding plasmin to the fibrin-surfactant mixture [7]. Other 
investigators have hypotbesized that inhibition of surfactant by plasma derived proteins 
is due to competition for space at tbe air-liquid interphase. Holm and colleagues 
reported that at high surfactant concentrations the inhibitory effect of high 
concentrations of plasma protein or membrane lipids is abolished [42,43]. Other studies 
confirm the probable existence of a competition mechanism: after centrifugation of 
surfactant-inhibitor mixtures derived from BAL fluid of animals treated with surfactant 
or after centrifugation of surfactant-protein mixtures, the sediments containing surfactant 
revealed normal surface tension characteristics compared witb before centrifugation 
[2,35,38,43,51]. Also, when these BAL fluids or the surfactant-protein mixtures were 
investigated for surface tension properties, it could be demonstrated that after a certain 
number of cycles the minimal surface tension decreased from initially high levels to low 
levels [7,36,39,40]. These findings probably indicate that, if there is any chemical 
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interaction betv.reen proteins and surfactant, this interaction is not strong. 
If the mechanism of competition between surfactant and plasma proteins is 
correct, then this would be of great importance for treatment of ARDS and neonatal 
RDS. Namely, whether the lungs are filled with plasma-derived proteins or not, 
intratracheal instillation of sufficiently high doses of surfactant should restore lung 
function. Surfactant treatment of anintals with enormous amounts of pulmonary edema 
caused by prolonged exposure of 100% oxygen or hydrochloric acid (HCI) aspiration 
does not seem to have any positive influence on restoring gas exchange at the 
concentrations used [1,4]. Kobayashi and colleagues have demonstrated that surfactant 
treatment was only able to restore gas exchange in rabbits suffering from respiratory 
failure after HCI aspiration after lungs had been lavaged, this way removing proteins 
from the alveolar space [4]. This strongly suggests that a more favorable 
surfactant/inhibitor ratio was established after lung lavage followed by surfactant 
treatment. In another study, surfactant instillation at very high doses (280-350 mg/kg) 
was able to restore gas exchange in guinea pigs suffering from severe respiratory failure 
due to high permeability pulmonary edema after intravenous instillation of anti-lung 
serum [52]; thus a more favorable surfactant/inhibitor ratio was obtained by giving a 
large amount of surfactant. Recently, Kobayashi and colleagues investigated the 
capability of surfactant mixed with edema fluid at several ratios to restore lung function 
in immature rabbit fetuses, as measured by tidal volume at preset insufflation pressures 
[5]. It was demonstrated that surfactant (25 mg/ml) mixed with edema fluid at a protein 
to lipid ratio (P /L ratio) of 2.2 was capable of restoring lung function, whereas surfactant 
mixed with edema fluid at P /L ratio of 11.2, was not. Surface tension properties of these 
mixtures demonstrated high minimal surface tensions at P /L?:3.4 and low surface 
tensions at P /Ls 1.8. These results confirm the hypothesis of the competition mechanism 
between surfactant and proteins, although it cannot be ruled out that some direct 
interaction between surfactant and proteins occurs. 
The lung lavage model, used in the present study, has proven useful for a variety 
of experimental purposes, including e.g. testing of different surfactant preparations and 
demonstrating that exogenous surfactant restores blood gases to normal [20-22]. In this 
model, the concentration of the surfactant preparation (which is more or less comparable 
with all other natural surfactant preparations) needed to restore blood gases over a 3 
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hour observation period was 50 mg/kg (Fig. lB). To get the same results when surfactant 
was mixed with human plasma ( 4 ml/kg"' 280 mg plasma proteins/kg), six times as much 
surfactant (300 mg/kg) was necessary to restore and stabilize gas exchange (Fig. lA). 
This means that approximately 1 mg surfactant phospholipids is needed to overcome the 
inhibitory effect of 1 mg plasma proteins. In these experiments citrated plasma was used 
to obtain full inhibitory capacity, including fibrinogen. However, the inhibitory 
components in diseased lungs probably consist not only of products derived from blood 
but also consist of, for example, specific proteases, inflammatory mediators, bacteria, 
membranes, etc. Plasma-derived proteins, however, may be the most important 
compounds of high-permeability edema fluid and thus, from this point of view, it makes 
sense to "titrate" the amount of surfactant for replacement therapy by mixing it with full 
plasma. 
Our results favor the competition hypothesis: when mixed with plasma, surfactant 
at 50 mgfkg shows no improvement, at 100 mg/kg there is only transient improvement, 
and at 300 mg/kg there is sustained improvement of blood gas values. These results 
imply that for treatment of ARDS or established RDS a high concentration of surfactant 
is required to overcome the inhibitory effect of plasma-derived proteins. If after 
surfactant instillation there is no, or only transient, improvement of blood gas values in 
patients with either ARDS or RDS (fibrotic lungs excluded) this does not mean that 
surfactant treatment does not work. It only means that the concentration of the 
surfactant preparation used is too low in relation to the amount of surfactant inhibitors 
in the lungs. This raises the question of how to exclude the existence of fibrotic lungs. 
In our clinical practice we investigate this as follows: we increase the mean airway 
pressure in mechanically ventilated patients and observe blood gases. If blood gases 
improve this would mean that there are still recruitable lung parts which could be 
stabilized by exogenous surfactant treatment. On the other hand, if blood gases remain 
stable or even deteriorate after increasing mean airway pressure due to further mismatch 
of the ventilation/perfusion ratio, surfactant instillation may worsen the clinical situation 
by filling up the remaining areas participating in gas exchange, which is typical for 
fibrotic lungs. Thus, before giving surfactant, especially after a long period of artificial 
ventilation (2-3 weeks), one should always examine if there is still some lung tissue left 
which can be recruited by high ventilation pressures. As a consequence, in treatment of 
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ARDS or established RDS: 1) surfactant should be given as early as possible and 2) an 
excess of surfactant should be given, or repeatedly be substituted ("titrated") at low 
concentrations until blood gases improve. 
REFERENCES 
1. Ennema JJ, Kobayashi T, Robertson B, Curstedt T (1988) Inactivation of exogenous surfactant in 
experimental respiratory failure induced by hyperoxia. Acta Anaesthesiol Scand 32: 665-671 
2. Ikegami M, Jacobs H, Jobe A (1983) Surfactant function in respiratory distress syndrome. J Pediatr 
102: 443-447 
3. Johnson JWC, Permuu S, Sipple JH, Salem ES {1964) Effect of intra-alveolar fluid on pulmonary 
surface tension properties. J Appl Physiol 19: 769-m 
4. Kobayashi T, Ganzuka M, Tanigushi J, Nitta K, Murakami S (1990) Lung lavage and surfactant 
replacement for hydrochloric acid aspiration in rabbits. Acta Anaesthesia} Scand 34: 216-221 
5. Kobayashi T, Nina K, Ganzuka M, Inui S, Grossmann G, Robertson B (1991) Inactivation of 
exogenous surfactant by pulmonary edema fluid. Pediatr Res 29: 353-356 
6. Said SI, Avery ME, Davis RK, Banerjee CM, El-Cohary M (1965) Pulmonary surface activity in 
induced pulmonary edema. J Clin Invest 44: 458-464 
7. Seeger W, StOhr G, Wolf HRD, Neuhof H (1985) Alteration of surfactant function due to protein 
leakage: special interaction with fibrin monomer. J Appl Physiol 58: 326-338 
8. Guyton AC, Moffatt DS, Adair TH (1984) Role of alveolar surface tension in transepithelial 
movement of fluid. In: Robertson B, Van Golde LMG, Batenburg JJ (cds) Pulmonary surfactant. 
Elsevier Science Publishers, Amsterdam, pp 171-185 
9. Fujiwara T, Chida S, Watabe Y, Maeta H, Morita T, Abc T (1980) Artificial surfactant therapy in 
Hyaline-Membrane Disease. Lancet 1: 55-59 
10. Hallman M, Merritt TA, Jarvenpaa A-L, Boynton B, Mannino F, Gluck L, Moore T, Edwards D 
(1985) Exogenous human surfactant for treatment of severe respiratory distress syndrome: a 
randomized clinical trial. J Pediatrics 106: 963-969 
11. Konishi M, Fujiwara T, Naito T, Takeuchi Y, Ogawa Y, Inukai K, Fujimura M, Nakamura H, 
Hashimoto T (1988) Surfactant replacement therapy in neonatal respiratory distress syndrome: A 
multi-centre, randomized clinical trial: comparison of high- versus low-dose of Surfactant TA. Eur 
J Pediatr 147: 20-25 
U. Collaborative European Multicenter Study Group (1988) Surfactant replacement therapy for severe 
neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 82: 683-
691 
13. Ten Centre Study Group (1987) Ten centre trial of artificial surfactant (artificial lung expanding 
compound) in very premature babies. Br Med J 294: 991-996 
82 
14. Dunn MS, Shennan AT, Possmayer F (1990) Single~ versus multiplewdose surfactant replacement 
therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome. Pediatrics 86: 
564-571 
15. Lachmann B (1987) The role of pulmonary surfactant in the pathogenesis and therapy of ARDS. 
In: Vincent JL (ed) Update in intensive care and emergency medicine. Springer-Verlag, Berlin, pp 
123-134 
16. Nosaka S, Sakai T, Yonekura M, Yoshikawa K (1990) Surfactant for adults Vlith respiratory failure. 
Lancet 1: 947~948 
17. Richman PS, Spragg RG, Robertson B, Merritt TA,. Curstedt T (1989) The adult respiratory distress 
syndrome: first trials with surfactant replacement. Eur Respir J 2 (Suppl 3): 109s~111s 
18. Marraro G (1991) Respiratory emergencies and supplementary surfactant in the treatment of severe 
RDS in leukaemic adolescents. In: Cosmi EV, Di Rcnzo GC, Anceschi MM (eds) The surfactant 
system of the lung: prevention and treatment of neonatal and adult respiratory distress syndrome. 
Macmillan Press, pp 198w206 
19. Joka Th, Obertacke U (1989) Neue medikament6se Behandlung im ARDS: Effekt einer 
intrabronchialen xenogenen Surfactantapplikation. Z Herzw, Thoraxw,Gef3Bchir 3 (Suppl1): 21-24 
20. Lachmann B, Robertson B, Vogel J (1980) In vivo lung lavage as an experimental model of the 
respiratory distress syndrome. Acta Anaesthesia! Scand 24: 231-236 
21. Berggren P, Lachmann B, Curstedt T, Grossmann G, Robertson B (1986) Gas exchange and lung 
morphology after surfactant replacement in experimental adult respiratory distress syndrome induced 
by repeated lung lavage. Acta Anaesthesia! Scand 30: 321-328 
22. Robertson B, Lachmann B (1988) Experimental evaluation of surfactants for replacement therapy. 
Exp Lung Res 14: 279-310 
23. Lachmann B, Jonson B, Lindroth M, Robertson B (1982) Modes of artificial ventilation in severe 
respiratory distress syndrome. Lung function and morphology in rabbits after wash-out of alveolar 
surfactant. Crit Care Med 10: 724-732 
24. Metcalfe~ Enhorning G, Possmayer F (1980) Pulmonary surfactantwassociated proteins: their role 
in the expression of surface activity. J Appl Physiol 49: 34-41 
25. Van Daal GJ, So KL, Gammers D, Eijking EP, Fievez RB, Sprenger MJ, Van Dam DW, 
Lachmann B (1991) Intratracheal surfactant administration restores gas exchange in experimental 
adult respiratory distress syndrome associated with viral pneumonia. Anesth Analg 72: 589-595 
26. Eijking EP, Van Daal GJ, Tenbrinck R, Luijendijk A, Sluiters JF, Hannappel E, Lachmann B (1991) 
Effect of surfactant replacement on pneumocystis carinii pneumonia in rats. Intensive Care Med 17: 
475478 
27. Van Daal GJ, Bas JAH, Eijking EP, Gammers D, Hannappel E, Lachmann B (1992) Surfactant 
replacement therapy improves pulmonary mechanics in cndwstage influenza A pneumonia in mice. 
Am Rev Respir Dis 145: 859-863 
83 
28. Bos AP, Tibboel D, Hazebroek FWJ, Molenaar JC, Lachmann B, Gammers D (1991) Surfactant 
replacement therapy in high-risk congenital diaphragmatic hernia. Lancet 1: 1279 
29. Robertson B, Berry D, Curstedt T, Grossmann G, Ikegami M, Jacobs H, Jobe A, Jones (1985). 
Leakage of protein in the immature rabbit lung; effect of surfactant replacement. Respir Physiol61: 
265-276 
30. Hallman M, Spragg R, Harrell JH, Moser Kivi, Gluck L (1982) Evidence of lung function 
abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity 
phospholipase activity, and plasma myoinositol. J Clin Invest 70: 673-683 
31. Petty TL, Reiss OK, Paul GW, Silvers GW, Elkins ND (1977) Characteristics of pulmonary 
surfactant in adult respiratory distress syndrome associated with trauma and shock. Am Rev Respir 
Dis 115: 531-536 
32. Pison U, Seeger W, Buchhorn R, Joka T, Brand M, Obertacke U, NeuhofH, Schmit-Neuerburg KP 
(1989) Surfactant abnormalities in patients with respiratory failure after multiple- trauma. Am Rev 
Respir Dis 140: 1033-1039 
33. Von Wichert P, Kohl FV (1977) Decreased dipalmitoyllecithin content found in lung specimens from 
patients with so-called shock-lung. Intensive Care Med 3: 27-30 
34. Avery ME, Mead J (1959) Surface properties in relation to atelectasis and hyaline membrane 
disease. Am J Dis Child 97: 517-523 
35. Ikegami M, Jobe A, Glatz T (1981) Surface activity following natural surfactant treatment of 
premature lambs. J Appl Physiol 51: 306-312 
36. Ikegami M, Jobe A, Jacobs H, Lam R (1984) A protein from airways of premature lambs that 
inhibits surfactant function. J Appl Physio157: 1134-1142 
37. Ikcgami M, Jobe A, Berry D (1986) A protein that inhibits surfactant in respiratory distress 
syndrome. Bioi Neonate 50: 121-129 
38. Kobayashi T, Curstedt T, Grossmann G, Robertson B (1989) Inhibition of exogenous surfactant in 
ventilated immature newborn rabbits. Respir Physiol 76: 1-12 
39. Tierney DF, Johnson RP (1965) Altered surface tension of lung extracts and lung mechanics. J Appl 
Physiol 20: 1253-1260 
40. Fuchimukai T, Fujiwara T, Takahashi A, Enhorning G (1987) Artificial pulmonary surfactant 
inhibited by proteins. J Appl Physiol 62: 429-437 
41. Holm BA, Notter RH, Finkelstein JN (1985) Surface property changes from interactions of albumin 
with natural lung surfactant and extracted lung lipids. Chern Phys Lipids 38: 1J!,7-298 
42. Holm BA, Notter RH (1987) Effects of hemoglobin and cell membrane lipids on pulmonary 
surfactant activity. J Appl Physiol63: 1434-1442 
43. Holm BA, Enhorning G, Notter RH (1988) A biophysical mechanism by which plasma proteins 
inhibit lung surfactant activity. Chern Phys Lipids 49: 49-55 
44. Keough KMW, Parsons CS, Phang PT, Tweedale MG (1988) Interactions between plasma proteins 
84 
and pulmonary surfactant: surface balance studies. Can J Physiol Phannacol 66: 1166-1173 
45. Taylor Jr. FB, Abrams ME (1%6) Effect of surface active lipoprotein on clotting and fibrinolysis, 
and of fibrinogen on surface tension of surface active lipoprotein (with a hypothesis on the 
pathogenesis of pulmonary atelectasis and hyaline membrane in respiratory distress syndrome of the 
newborn). Am J Med 40: 346-350 
46. Holm BA, Venkitaraman AR, Enhorning G, Notter RH {1990) Biophysical inhibition of synthetic 
lung surfactants. Chern Phys Lipids 52: 243-250 
47. Ikegami M, Jobe A, Jacobs H, Jones S (1981) Sequential treatments of premature lambs with an 
artificial surfactant and natural surfactant. J Clin Invest 68: 491-496 
48. Ikegami M, Agata Y, Elkady T, Hallman M, Berry D, Jobe A (1987) Comparison of four 
surfactants: in vitro surface properties and responses of preterm lambs to treatment at birth. 
Pediatrics 79: 38-46 
49. Cockshutt AM, Weitz J, Possmayer F (1990) Pulmonary surfactant-associated protein A enhances 
the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. 
Biochemistry 29: 8424-8429 
50. Seeger W, Giinther A, Thede C (1992) Differential sensitivity to fibrinogen inhibition of SP-C- vs. 
SP-B-based surfactants. Am J Physiol (Lung Cell Mol Physiol) 5: L286-L291 
51. Balis JU, Shelley SA, McCue MJ, Rappaport ES (1971) Mechanisms of damage to the lung 
surfactant system. Ultrastructure and quantitation of normal and in vitro inactivated lung surfactant. 
Exp Mol Pathol14: 243-262 
52. Lachmann B, Hallman M, Bergmann KC (1987) Respiratory failure following anti-lung serum: study 
on mechanisms associated with surfactant system damage. Exp Lung Res 12: 163-180 
85 

CHAPTER 5 
PREVENTION OF RESPIRATORY FAILURE AFTER HYDROCHLORIC ACID 
ASPIRATION BY IN1RATRACHEAL SURFACTANT INSTILLATION IN RATS 
E.P. Eijking, D. Gommers, K.L. So, M.P.M. de Maat#, 
J. W. Mouton • and B. Lachmann 
Depts. of Anesthesiology, #Internal Medicine II and "Clinical Microbiology, 
Erasmus University, Rotterdam, The Netherlands 
In: Anesth Analg 1993; 76: 472-477 
87 
SUMMARY 
As the surfactant system is probably involved in the pathophysiology of respiratory failure 
caused by hydrochloric acid (HCI) aspiration, a study was designed to investigate the 
effects of different ventilation strategies and intratracheal surfactant instillation at 
different time intervals, on the course of pulmonary gas exchange after HCl aspiration 
in rats. In this study rats were anesthetized, tracheotomized and mechanically ventilated. 
Respiratory failure was induced by intratracheal instillation of 3 ml/kg 0.1 N HCI. 
Animals (n=49) were divided into 9 groups: Groups 1 and 2-9 were ventilated with peak 
airway pressure/PEEP of 14/2 and 26/6 cmH,O, respectively; Groups 3 and 4 received 
surfactant (200 mg/kg) intratracheally, 1 and 10 min after HCl aspiration; Groups 5 and 
6 received saline, 1 and 10 min after HCl aspiration; Groups 7 and 8 received surfactant, 
60 and 90 min after HCl aspiration; Group 9 received saline instead of HCI. Gas 
exchange deteriorated in Groups 1, 2, 5, 6, 7 and 8, whereas respiratory failure could be 
prevented in Groups 3 and 4. After deterioration of gas exchange, surfactant treatment 
prevented further decrease of Pa02 values in Group 7, whereas no effect on gas 
exchange was observed in Group 8; intratracheal instillation of saline had no effect on 
gas exchange (Group 9). These results suggest that surfactant should be given as early 
as possible after aspiration of gastric contents, to prevent development of respiratory 
failure. 
INTRODUCTION 
Massive aspiration of gastric contents is one of the most feared complications of general 
anesthesia and is an important cause of the adult respiratory distress syndrome (ARDS) 
(1, 2). ARDS caused by aspiration of gastric contents is characterized by deterioration 
of gas exchange requiring mechanical ventilation with high inspiratory oxygen 
concentration, high insufflation pressure and positive end-expiratory pressure (PEEP), 
and is associated with a mortality rate of over 90% (2). Hydrochloric acid (HCl) causes 
direct damage to the alveolar-capillary membrane, leading to influx of protein-rich 
edema fluid into the alveolar space (3-6). These plasma-derived proteins are known to 
be potent inhibitors of surfactant function (7-12). It has also been proposed that HCl 
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directly damages the surfactant system ( 4, 13). 
As the surfactant system is probably involved in the pathophysiology of respiratory 
failure caused by HCl aspiration, studies have been performed to investigate the effect 
of surfactant replacement therapy on lung function of animals suffering from respiratory 
failure due to HCl aspiration. Kobayashi and colleagues demonstrated that surfactant 
instillation could only partly restore gas exchange in rabbits suffering from respiratory 
failure due to HCl aspiration after lung edema was removed by broncboalveolar lavage; 
surfactant, when given without prior lung lavage, served only to prevent further 
deterioration of blood gases ( 6). Lamm and colleagues showed improved lung recoil 
without improvement in gas exchange in rabbits receiving surfactant 5 ntin after HCl 
aspiration (14 ). 
The aim of this study was to investigate the effects of different ventilation 
strategies and intratracheal surfactant instillation at different time intervals, on the 
course of pulmonary gas exchange after HCl aspiration in rats. 
MATERIALS AND METHODS 
Exogenous surfactant 
The surfactant used in these experiments is a freeze-dried natural surfactant isolated 
from bovine lungs in basically the same manner as previously described (15). It consists 
of approximately 90% phospholipids, 1% hydrophobic proteins (SP-B and SP-C), the 
remainder being other lipids such as cholesterol, glyceride and free fatty acids. There is 
no SP-A (the largest surfactant associated protein, MW: 26-38 kDa) in this surfactant 
preparation as a result of isolation procedures. Surfactant was suspended in saline at a 
concentration of 50 mg dry weight/mi. This surfactant preparation has proven to be 
highly effective in improving gas exchange and lung mechanics in various animal models 
of respiratory failure of differing etiologies (16-18). 
Animal study 
The study protocol was approved by the Animal Care Committee of Erasmus University 
Rotterdam, The Netherlands. 
The studies were performed in 49 male adult Sprague-Dawley rats (body weight: 
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300-350 g). After induction of anesthesia with nitrous oxide, oxygen and halothane 
(65/33/2%) the animals were tracheotomized and a catheter was inserted into the 
carotid artery. Anesthesia was maintained with pentobarbital sodium (60 mgjkg, i.p.) and 
muscle relaxation was attained with pancuronium bromide (05 mg/kg, i.m.). Lungs were 
ventilated with a Servo Ventilator 900 C (Siemens-Eiema, Solna, Sweden) at the 
following ventilator settings: pressure-controlled ventilation, F,02 = 1.0, ventilation 
frequency=30/min, peak airway pressure (P ""'J = 14 cmH20, PEEP =2 cmH20 and 
inspiratory I expiratory ratio= 1:2. After reaching steady state (Pa02> 500 mmHg), 43 rats 
received 1.5 ml/kg HCI intratracheally (0.1 N) while lying on their right side, followed 
by a bolus of air (30 ml/kg). This was immediately followed by instillation of 15 ml/kg 
HCI, while lying on their left side, again followed by a bolus of air. Six rats received 
saline (2 x 1.5 ml/kg) instead of HCI. 
Directly after instillation, P P"'k was increased to 26 cmH20 and PEEP to 6 cmH20 
in 38 rats receiving HCI and in the 6 rats receiving saline. P P"'k was kept at 14 cmH20 
and PEEP at 2 cmH,O in 5 rats receiving HCI. In all animals the same ventilator settings 
were maintained throughout the observation period. 
The animals were divided into 9 groups (Table 1): Group 1 (n=5) was ventilated 
at PP"'k=14 cmH20 and PEEP=2 cmH,O (HC114/2); Group 2 (n=6) was ventilated at 
Pp~k=26 cmH20 and PEEP=6 cmH20 (HC126/6); Group 3 (n=6) received surfactant 
intratracheally 1 min after HCl (Surf 1'); Group 4 (n=5) received surfactant 10 min after 
HCl (Surf 10'); Groups 5 and 6 (n=5 and n=5) received saline 1 and 10 min after HCI 
(Sal 1' and Sal 10', respectively); Group 7 (n=6) received surfactant 60 min after HCl 
(Surf 60') and Group 8 (n=5) received surfactant after 90 min (Surf 90'); Group 9 (n=6) 
received saline instead of HCl and served as control (NaCI). Animals from Groups 3, 4, 
7 and 8 were treated with surfactant at a dose of 200 mg dry weight/kg body weight. 
Blood samples for measurement of Pa02 and PaC02 (ABL 330; Radiometer, 
Copenhagen, Denmark) were taken from the carotid artery of each animal before 
intratracheal instillation and at 15, 30, 60, 90 and 120 min post-instillation. 
At the end of the experiments all animals were sacrificed with an overdose of 
intra-arterially administered pentobarbital sodium. Lungs of a few animals of Groups 2-6 
and 9 underwent bronchoalveolar lavage (BAL) with saline (37 • C; 30 ml/kg). 
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Table 1: Different treatment groups. 
Group n HCI P,..JPEEP Surf/Sal 
1 (HCI14/2) 5 + 14/2 
2 (HCI26/6) 6 + 26/6 
3 (Surl1') 6 + 26/6 Surfl' 
4 (Surf 10') 5 + 26/6 Surf 10' 
5 (Sail') 5 + 26/6 Sail' 
6 (Sal10') 5 + 26/6 SallO' 
7 (Surf 60') 6 + 26/6 Surl60' 
8 (Surf 90') 5 + 26/6 Surf 90' 
9 (NaCI) 6 - (NaCI) 26/6 
For explanation of abbreviations: see text 
Bronchoalveolar lavage fluid 
To compare all BAL samples with those from healthy controls, 6 additional male 
Sprague-Dawley rats (body weight 300-350 g) were lavaged once with saline (37'C; 30 
ml/kg). The BAL fluids of the different groups were prepared as follows: all samples 
were centrifugated for 15 min at 2000 g to remove cell material. Protein concentration 
was measured in all samples using a modified Lowry method (19), with bovine serum 
albumin as standard. Also, surface activity in BAL fluid was measured using a modified 
Wilhelmy balance (E. Biegler GmbH, Mauerbach, Austria). In this method, a tight-fitting 
teflon barrier reduces the surface area of a teflon trough from 100-20% at a cycle speed 
of 033/min. Saline is used as subphase and is kept at 37'C. The force on a platinum 
slide (lx1 em), dipped into the subphase, is measured by a force transducer and 
expressed as surface tension. Further, maximal surface tension is measured at 100% 
surface area and minimal surface tension at 80% surface compression and expressed as 
milli Newton/meter (mN/m). Surface tension characteristics of a BAL sample are 
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measured after application on the surface of the saline-filled trough. In this study 500 Ml 
of BAL fluid was applied to the surface of the trough; maximal and minimal surface 
tensions were measured after 3 cycles. 
Statistical analysis 
All data are expressed as mean ± standard deviation (SD). For the animal study 
statistical analysis of data was performed using repeated measurements Anovas (20), with 
time as the repeat variable. Three Anovas were performed initially: the effect of 
P I=JPEEP settings against controls; the effect of saline instillation against controls; and 
finally the effect of surfactant instillation against controls. When significant differences 
between groups occurred, the difference between these groups was further analyzed. For 
analysis of BAL parameters, standard Anova procedures were performed. Statistical 
significance was accepted at p50.05. 
RESULTS 
Animal study 
Figure 1 shows Pa02 values for each group. Before instillation of HCl or saline, Pa02 
values are high and there is no significant intergroup difference. There is a significant 
difference in Pa02 values between rats ventilated at 14/2 or at 26/6 cmH20 after HCI 
instillation (HCl14/2 and HC126/6, respectively); saline (NaCI), instead of HCl, at the 
applied ventilator settings had no influence on Pa02 values (Fig. 1A). There is no 
intergroup difference in Pa02 values between rats ventilated at 26/6 cmH20, rats treated 
with saline at 1 min (Sal 1') and rats treated with saline at 10 min (Sal 10') after HCI 
instillation; for this reason Pa02 values of these three groups are used (Control) for 
comparison with other treatment groups. The differences in Pa02 values between rats 
treated with surfactant 1 or 10 min after HCl instillation (Surf 1' and Surf 10', 
respectively) and Control are significant; there is no intergroup difference between Pa02 
values of Surf 1' and Surf 10' (Fig. lB). Although there is a significant difference in Pa02 
values prior to surfactant treatment between groups of rats treated at both 60 and 90 min 
after HCI instillation (Surf 60' and Surf 90', respectively) and Control, Pa02 values 
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increase significantly compared to pre-treatment values in Surf 60', whereas there is no 
increase in Pa02 values observed in Surf 90' (Fig. 1C). 
Figure 2 shows the PaC02 values for each group. Before instillation of HCl or 
saline there are no significant differences in PaC02 values between the groups. There 
is a significantly higber increase in PaC02 values in all animals ventilated at 14/2 crnH20 
compared to rats ventilated at 26/6 cmH20; in rats receiving saline instead of HC~ 
PaC02 values remained in physiological range (Fig. 2A). Again, there is no intergroup 
difference in PaC02 values between rats ventilated at 26/6 cmH20, rats treated with 
saline at 1 min and rats treated with saline at 10 min after HCl instillation and thus 
PaC02 values of these three groups are used (Control) for comparison with other 
treatment groups. Althougb PaC02 values of rats treated with surfactant at 1 or 10 min 
after HCl instillation appear to be lower compared to Control, these differences are not 
significant (Fig. 2B). There also is no significant difference in PaC02 values between rats 
receiving surfactant after 60 min and 90 min and Control (Fig. 2C). 
Bronchoalveolar lavage fluid 
Tahle 2 shows the recovery percentage, protein concentration and surface tension 
properties of BAL fluid samples. For statistical reasons the BAL parameters of rats 
receiving saline 1 and 10 min after HCl instillation were regarded to be comparable (as 
evidenced by a small SD), as were BAL parameters of rats receiving surfactant 1 and 10 
min after HCl instillation. 
The protein concentration in BAL fluid of animals receiving HCl is significantly 
higher than that of BAL fluid of controls and rats receiving saline instead of HCl; there 
is no significant difference in protein concentration between groups receiving HCL 
Surface tension measurements demonstrate decrease in surface activity in BAL fluid 
from rats after HCl aspiration, not receiving surfactant treatment. BAL fluid from rats 
receiving surfactant 1 and 10 min after HCl aspiration demonstrate favorable surface 
activity (for detailed statistical differences between groups, see Table 2). 
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Figure 1. Pa02 values (mean;!:;: SD) of the different groups: rats ventilated at Ppeak=14/PEEP=2 cmH::P 
or Ppeak=26/PEEP=6 cmH20 after HCI aspiration (HC114/2 and HC126/6, respectively) and rats receiving 
saline (NaCl) instead of HCl (A); rats receiving surfactant or saline, 1 or 10 min after HCI aspiration (Surf 
r, Surf 10', Sail' and SallO', respectively) (B); rats receiving surfactant 60 or 90 min after HCl aspiration 
(Surf 60' and Surf 90', respectively) and, again, rats ventilated at P peak=26/PEEP=6 cmH20 (HCl2fj/6) (C); 
t = one rat died; 1 = surfactant instillation; PaOz = arterial oxygen tension. 
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Figure 2. PaC02 values (mean ± SD) of the different groups; for explanation of abbreviations, see Figure 
1; PaC02 = arterial carbon dioxide tension. 
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Table 2: BAL parameters. 
Sample n Recovery Protein Surface tension 
[%] [mg/ml] [mN/m] 
maximal minimal 
Control 6 95.1 0.24"' 64.5 24.2@ 
± 5.23 ± 0.06 ± 5.83 ± 3.99 
Saline 5 93.8 0.41* 62.9 25.1§ 
± 5.45 ± 0.42 ± 3.11 ± 2.51 
HCI (26/6) 5 98.1 7.45 60.5 31.2 
:.+: 5.56 :.+: 1.33 ::': 3.24 :.+: 233 
HCI (Sal 1" + 10') 6 100.7 8.07 64.6 343 
± 5.62 ± 1.16 :t456 ± 4.42 
HCI (Surf 1" + 10') 7 95.5 6.98 46.8# 19.611 
± 433 :!::: 1.31 ::': 6.52 ± 4.11 
All data are mean ± SD; Control== BAL fluid of healthy contol rats; Saline= BAL fluid of rats receiving 
saline instead of HCl, intratracheally; (26/6) ==- rats ventilated at P pe:>~<=26 and PEEP=6 cmflzO; (Sal r + 
10') and (Surf 1' + 10')= rats receiving saline or surfactant, respectively, 1 or 10 min after HCl aspiration; 
"'=significant difference between Control/Saline and other groups; #=significant difference between HCI 
(Surf 1' + 10') and other groups; @""significant difference between Control and both HCI (2£)/6) and HCl 
(Sal r + 10'); §=significant difference between Saline and all HCl groups; 'IT =significant difference between 
HCl (Surf 1' + 10') and the two other HCl groups. 
DISCUSSION 
This study demonstrates that surfactant, when given within 10 min, prevents deterioration 
of gas exchange after massive aspiration of HCl (pH~ 1.0), but cannot prevent 
accumulation of plasma-derived proteins into the alveolar space. It is also shown that 
respiratory failure cannot be prevented by increasing insufflation pressure and PEEP to 
levels used in this study, although more animals survived during the whole observation 
period (HCl 14/2 versus HCl 26/6). Similar results have been reported by others; 
nan1ely, that lungs of rabbits receiving surfactant (100 mg/kg body weight) 5 min after 
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HCI aspiration (pH= 1.0, 2 ml/kg) showed improved lung recoil compared to lungs which 
did not receive surfactaot; however, this study did not demonstrate higher Pa02 values 
in rabbits treated with surfactaot, although it must be noted that low PEEP levels were 
used (14). 
The mechanism of respiratory failure in HCI aspiration cao be explained by a) 
damage to the alveolar-capillary membraoe (4), leading to increased permeability (5, 21, 
22) aod thus influx of protein-rich edema fluid into the alveolar space; b) direct damage 
to the surfactaot system (4, 13) aod c) secondary inhibition of remaining surfactaot 
activity caused by plasma-derived proteins present in the edema fluid (7-12). As a result 
of (functional) surfactaot deficiency, suction force across the alveolar-capillary membraoe 
increases, leading to further outpouring of edema fluid into the alveolar space: this way 
a vicious circle exists. Also, as a result of diminished surfactant function, surface tension 
on the alveolar wall increases, leading to increased retractive forces across the alveolar~ 
capillary membraoe, with subsequent formation of atelectasis and mismatch of the 
ventilation-perfusion ratio, leading to hypoxemia. 
Surfactaot is inhibited by plasma-derived proteins in a dose-dependent manner 
(7-12). Thus, with a high surfactaot/inhibitor (S/I) ratio there is no inhibition of 
surfactaot function, whereas with a low S/I ratio most surfactaot function is abolished. 
Although the exact mechaoism of inhibition remains unclear, it seems that competition 
between surfactaot and inhibitors at the air-liquid interphase of the alveolar wall plays 
ao importaot role (9, 12). When surfactant is given before deterioration of gas exchaoge 
(i.e. before the remaining surfactaot function is inhibited) the S/I ratio is increased, thus 
preventing the pathophysiological mechanisms that lead to respiratory failure. It is 
emphasized that the initial damage to lung tissue by HCl cannot be prevented, as HCl 
is neutralized within 30 seconds (21) aod, thus, lung structure is already damaged. This 
is confirmed in the present study, where protein concentration in BAL fluid of rats 
receiving surfactaot within 10 min is almost as high as protein concentration of rats 
receiving saline, or ventilated only. Comparable findings were also reported in the study 
mentioned earlier (14), namely increased wet/dry weight ratio in lungs of rabbits which 
received surfactaot 5 min after HCl aspiration as well as in lungs of rabbits not receiving 
surfactaot. However, surface tension properties of BAL fluid of rats receiving surfactaot 
demonstrated low minimal aod low maximal surface tensions compared to BAL fluid of 
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rats receiving saline. Thus, due to the lower surface tension of the "intrapulmonary fluid" 
the applied ventilator settings (26/6 cmH20) were sufficient for maintaining (normal) 
gas exchange. 
Earlier studies have demonstrated that intratracheal surfactant instillation fully 
restores lung function in allimals suffering from respiratory failure due to pneumonia (16-
18). Also, gas exchange in rats suffering from respiratory failure after bilateral whole 
lung lavage could be fully restored after surfactant treatment (23). In the present study 
surfactant treatment, 60 min after HCl instillation, showed slight improvement of gas 
exchange; surfactant treatment 90 min after HCl instillation did not prevent further 
deterioration of gas exchange during the observation period. A possible explanation 
could be that after HCl aspiration lung structure is more severely damaged compared 
with animals suffering from pneumonia, or after whole lung lavage. This would lead to 
increased permeability of the alveolar-capillary membrane and more severe intra-alveolar 
edema accumulation. After deterioration of gas exchange due to HCl aspiration, S/I 
ratio (before surfactant instillation) is low and lung structure is damaged. When 
surfactant is given in these conditions, little or no effect is seen on gas exchange. A 
possible explanation is that surfactant, at a concentration used in this study (200 mgjkg), 
is directly inhibited by high concentration of inhibitors. Another explanation could be 
that the edema fluid and atelectatic areas form a mechanical barrier, preventing 
surfactant from entering the alveolar spaces. However, there are studies in which gas 
exchange could be improved either by giving a large amount of surfactant (280-350 
mg/kg body weight) (24), or by lavaging the lungs with saline before surfactant 
instillation ( 6), as already mentioned in the introduction. With both methods an 
improved S /I ratio could be achieved. 
Similar results have also been reported in animals suffering from respiratory 
failure due to hyperoxic lung injury. Surfactant substitution (60 mgjkg body weight) can 
prevent development of respiratory insufficiency in rabbits exposed to 100% oxygen for 
64 hours: Pa02 values of surfactant-treated rabbits, during mechanical ventilation with 
100% oxygen, remained at high levels compared with saline-treated animals (25). Also, 
wet/dry ratio in animals receiving surfactant was high compared to lungs of healthy 
controls. However, in guinea pigs suffering already from respiratory failure due to 
prolonged exposure to 100% oxygen, surfactant treatment (200 mgjkg body weight) was 
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not able to restore gas exchange (7). 
In the present study a "point of no return" mechanism seems to be applicable to 
the situation: after deterioration of gas exchange, little or no beneficial effect can be seen 
after surfactant instillation at a concentration used in this study (200 mg/kg body weight), 
whereas gas exchange is preserved when surfactant is given within 10 min. Although it 
is difficult to extrapolate from this animal study to the clinical situation, our results 
suggest that when massive aspiration of gastric contents is suspected, surfactant should 
be given as soon as possible to prevent development of respiratory failure. An important 
consideration which favors direct treatment with surfactant is that ARDS, caused by 
aspiration of gastric contents, has a mortality rate of over 90% (2). 
In conclusion: increasing insufflation pressure and PEEP alone to levels used in 
this study has no beneficial effect on the course of hypoxemia after HCl aspiration in 
rats. Surfactant given within 10 min after HCl aspiration does prevent development of 
respiratory failure but does not prevent damage to lung structure, as evidenced by high 
protein concentrations in BAL fluid. Surfactant, at the dose used in this study, given after 
deterioration of gas exchange, can only prevent further decrease in Pa02 values. 
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CHAPTER 6 
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This topic was presented at the 6"' European Congress on Intensive Care Medicine in 
Barcelona in October 1992 An award was received for this presentation. 
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SUMMARY 
Background: The surfactant system seems to be involved in the pathophysiology of 
respiratory failure caused by hydrochloric acid (HCl) aspiration. This study investigated 
the effect of different treatment strategies using an exogenous surfactant preparation on 
lung function of rats suffering from respiratory failure after intratracheal HCl instillation. 
Methods: In rats anesthetized with halothane, nitrous oxide and oxygen, tracheotomy was 
performed and the lungs were mechanically ventilated. Respiratory failure was induced 
by intratracheal instillation of HCl (0.1 N, 3 ml/kg). After the Pa02 decreased to <200 
mmHg, the animals were randomly divided into 5 groups: Group I received no 
treatment; Group II received a natural surfactant preparation intratracheally (200 
mgjkg); Group III underwent bronchoalveolar lavage (BAL) with saline, followed by 
surfactant treatment (200 mgjkg); Groups IV and V underwent BAL with saline and a 
diluted surfactant suspension (3.3 mgjml in 30 mljkg), respectively. Groups IV and V 
received a second and a third BAL 60 and 120 min after the first lavage. Blood gas 
analysis and protein measurements in BAL fluids were performed. 
Results: Gas exchange improved in Groups Ill and V only. Protein concentrations were 
high in all BAL fluids. In the rats receiving BAL three times (Groups IV and V), a 
decrease in protein concentration was observed. 
Conclusions: From these results it is concluded that surfactant proteins (which are known 
to inhibit surfactant function) are washed out of the alveoli, resulting in improved 
efficacy of surfactant treatment. 
INTRODUCTION 
Massive aspiration of gastric contents is one of the most feared complications of general 
anesthesia and is an important cause of the adult respiratory distress syndrome (ARDS) 
(for review, see [1,2]). ARDS caused by aspiration of gastric contents is characterized by 
deterioration of gas exchange requiring mechanical ventilation with high inspiratory 
oxygen concentration, high inspiratory pressure and positive end-expiratory pressure 
(PEEP), and is associated with a mortality rate of over 90% (2). Hydrochloric acid (HCl) 
causes direct damage to the alveolar-capillary membrane, leading to influx of protein-rich 
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edema fluid into the alveolar space (3-6). These plasma-derived proteins are known to 
be potent inhibitors of pulmonary surfactant function (7-13). 
Several studies have been performed in which animals suffering from respiratory 
failure due to HCl aspiration were treated with surfactant. Kobayashi et al (6) 
demonstrated that surfactant instillation could only partly restore gas exchange in rabbits 
suffering from respiratory failure due to HCl aspiration after intra-alveolar lung edema 
was removed by bronchoalveolar lavage (BAL) with saline. Lamm et al (14) showed 
improved lung recoil in rabbits receiving surfactant 5 min after HCl aspiration, but no 
effect was seen on blood gases. Strohmaier et al (15), in a study on rabbits suffering from 
respiratory failure due to HCl aspiration, also were unable to improve oxygenation after 
surfactant treatment. In a recent study using this model we reponed that surfactant, when 
given as a bolus at 200 mg/kg body weigbt after development of respiratory failure, was 
only able to prevent further deterioration of lung function, but was unable to improve 
gas exchange (16). For this reason the present study was designed to investigate whether 
there is any possibility to improve blood gases to almost normal values using an 
exogenous surfactant preparation in rats suffering from respiratory failure due to HCI 
aspiration. Different surfactant substitution regimes are investigated; the removal of 
edema fluid from the alveolar space with a diluted surfactant suspension was of 
particular interest. 
The surfactant preparation used in this study has proven to be highly effective in 
improving gas exchange and lung mechanics in various animal models of respiratory 
failure of differing etiologies (17-19) and in newborns suffering from respiratory failure 
due to congenital diaphragmatic hernia (20). 
MATERIALS AND METHODS 
Exogenous swfactant 
The surfactant used in these experiments is a freeze-dried natural surfactant isolated 
from bovine lungs in basically the same manP.er as previously described (21). It consists 
of approximately 90% phospholipids, 1% hydrophobic surfactant-associated proteins (so 
called SP-B and SP-C), the remainder being other lipids such as cholesterol, glyceride 
and free fatty acids. There is no SP-A (the largest surfactant-associated protein, 
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molecular weight: 26-38 kDa) in this surfactant preparation. Surfactant was suspended 
in saline. 
Animal study 
This protocol was approved by the Animal Care and Use Committee of the Erasmus 
University Rotterdam, the Netherlands. 
The studies were performed in 44 male adult Sprague-Dawley rats (body weight: 
300-350 g). After induction of anesthesia with nitrous oxide, oxygen and halothane 
(65/33/2%) a tracheotomy was performed and a catheter was inserted into the carotid 
artery. Anesthesia was maintained with pentobarbital sodium (60 mgjkgjh, i.p.) and 
muscle relaxation was attained with pancuronium bromide (0.5 mg/kg/h, i.m.). The lungs 
were ventilated with a Servo Ventilator 900 C (Siemens-Elema, Solna, Sweden) at the 
following ventilator settings: pressure-controlled ventilation, F,02 = 1.0, ventilation 
frequency=30/min, peak airway pressure (P "''J = 14 cmH20, PEEP=2 cmH20 and 
inspiratory/ expiratory ratio= 1:2. After reaching steady state (Pa02 > 500 mmHg), 38 rats 
received 1.5 mljkg HCI intratracheally (0.1 N; pH= 1.0) while lying on their right side, 
followed by a bolus of air (30 ml/kg). This was immediately followed by instillation of 
1.5 ml/kg HCl, while lying on their left side, again followed by a bolus of air; 6 rats 
received saline (2x1.5 ml/kg) instead of HCI and served as controls. Directly after 
instillation, P- was increased to 26 cmH20 and PEEP to 6 cmH20 in all rats; these 
ventilator settings were maintained throughout the whole observation period. 
After Pa02 decreased to <200 mmHg (within 1-2 h) in rats receiving HC~ the 
animals were randomly divided into 5 groups: Group I (n=7) received no treatment; 
Group II (n=8) received surfactant intratracheally; in Group !II (n=7) the lungs were 
lavaged with saline followed by intratracheal surfactant instillation; in Groups IV and V 
(n = 8 per group) the lungs were lavaged with saline or a diluted surfactant suspension, 
respectively, at two time points: the first lavage was after Pa02 values decreased to <200 
mmHg, followed by a second lavage 60 min after the first. The amount of saline used in 
all bronchoalveolar lavages was always 30 mljkg body weight at 37- C; the amount of 
surfactant in the diluted surfactant suspension (Group V) was 33 mg phospholipids/ml 
(100 mg phospholipids/kg body weight). The amount of surfactant used for intratracheal 
instillation in Groups II and III was 200 mg phospholipids/kg body weight at a 
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concentration of 50 mg phospholipids/mi. 
Blood samples for measurement of Pa02 and PaC02 were taken from the carotid 
artery of each rat before intratracheal HCl (or saline) instillation, at regular intervals 
post-instillation and at 5, 30 and 60 min after treatment (ABL 330; Radiometer, 
Copenhagen, Denmark). In Groups IV and V blood gas analyses were also performed 
at 5, 30 and 60 min after the second lavage. 
Bronclwalveo/ar lavage fluid 
Bronchoalveolar lavage (BAL) was performed in the following groups for measurement 
of total protein concentration and surface tension properties. At the end of the 
experiments (i.e. 60 min after the second BAL) Groups IV and V were lavaged for the 
third time with saline (37 • C; 30 mljkg). BAL fluids of Group III and the 1", znd and 3"' 
BAL fluids from Groups IV and V were prepared as described below. To compare all 
BAL samples with BAL samples from healthy control animals, the rats of the control 
group were lavaged 2 h after saline instillation. The BAL fluids of the different groups 
were prepared as follows: all samples were centrifugated for 15 min at 2000 g to remove 
cell material. Protein concentration was measured in all samples using a modified Lowry 
method (22), with bovine serum albumin as standard. Also, surface activity in BAL fluid 
was measured with the Wilhelmy balance (E. Biegler GmbH, Mauerbach, Austria) by 
applying 500 J.Ll of BAL fluid to the surface of a saline-filled trough. Surface area was 
reduced and expanded at a cycle speed of 0.33 /min. Maximal and minimal surface 
tensions were measured after 3 cycles at 100% and 20% surface area, respectively. 
Statistical analysis 
All data are expressed as mean ± standard deviation (SD). For Pa02 and PaC02 data, 
a two-factor mixed-design AN OVA (group by repeated measures [time]) was used. For 
analysis of BAL parameters, a one-way between-subjects ANOVA (group) was used. 
When significant differences between and/ or within groups occurred, these differences 
were further analyzed (Student-Newman-Keuls test). Statistical significance was accepted 
at p;<;0.05. 
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RESULTS 
Animal study 
Figure 1 shows Pa02 values for each group. Before instillation of HCl, Pa02 values are 
high (536.3 :!: 29.9 mmHg) and there is no significant intergroup difference. HCl 
instillation decreased Pa02 values to approximately 140 mmHg ("Pre"). After treatment 
there is a statistically significant increase in Pa02 values in rats undergoing BAL followed 
by surfactant (Group Ill) and rats lavaged with the surfactant suspension (Group V). 
Pa02 values did not increase in the other groups. The Pa02 values of control rats 
receiving saline instead of HCI remained high after 2 h of ventilation (550.5 :!: 27.7 
mmHg). For other statistically significant differences, see Figure 1. 
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Figure 1. Pa02 values (mean ± SD) of different groups after HCI instillation; after Pa02 values decreased 
below 200 mmHg (=Pre) rats were divided into 5 groups: Group I received no treatment, Group IT received 
surfactant (200 mgfk:g), Group III was lavaged with saline followed by surfactant treatment (200 mg/kg); 
Groups IV and V were lavaged with saline or a diluted surfactant suspension (33 mg/ml), respectively; 
"'""statistically significant differences between Group III and pre~treatment, Group I and Group IV; 
#=statistically significant differences between Group V and pre-treatment, Groups I, II and IV; PaOz = 
arterial oxygen tension. 
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Table 1 shows the PaC02 values for each group. There are no significant differences in 
PaC02 values between all groups at any time. PaC02 values remained low in control rats 
which received saline instead of HCl (36.5 ± 3.50 mmHg). 
Table 2 shows the blood gases of rats lavaged with saline, and rats lavaged with 
the surfactant suspension (Groups IV and V, respectively) after the first and second 
lavage. After the second lavage there appears to be an increase in Pa02 values in both 
groups compared to Pa02 values after the first lavage, however, this increase is not 
significant. For statistically significant differences, see Table 2 
Table 1: PaC02 values (mmHg) of all groups. 
Group n control pee 5' 30' 60' 
I 7 30.7 58.1 53.ott 62.4 76.ott 
± 3.19 ± 15.8 ± 11.6 ± 23.1 ± 13.6 
ll 8 34.8 67.5 67.5 68.6 65.6t 
± 4.58 ± 20.3 ::!:: 13.9 ± 10.3 ± 8.81 
Ill 7 32.6 65.1 65.9 57.3 57.4 
± 4.78 ± 15.8 ± 23.4 ± 15.2 ± 18.7 
IV (1") 8 31.5 57.6 52.3 49.9 54.3tt 
± 3.61 ± 13.3 ± 8.10 ::!: 10.3 ± 4.12 
v (1") 8 33.1 65.1 63.8 57.3 57.1t 
± 3.25 ± 16.4 ± 10.8 ::!: 8.66 = 5.32 
All data are mean ± SD; Control = before HCl instillation; pre = after HCl instillation and before 
treatment; 5', 30' and 60' = min after treatment; IV (1"1) and V (1") = PaC02 values after the first BAL 
treatment; t = one animal died. 
109 
Table 2: Pa01 and PaC02 values (mmHg) after repeated BAL. 
1'1 BAL 2nd BAL 
Group n control pre 5' 30' 60' 5' 30' 60' 
IV (1"/2'') Pa02 8 539.1 128.3 90.3 95.1 SLOtt 99.8tt 131.4 129.5 
± 25.8 ± 30.9 ± 38.7 ± 43,1 ± 30.7 ± 32.5 ± 57.9 ± 68.1 
PaC02 31.5 57.6 52.3 49.9 54.3 41.8" 42.1 42.5 
± 3.61 ± 13.3 ± 8.10 ± 10.3 ± 4,12 ± 10,9 ± 7.98 ± 9.21 
v (1"/2"') Pa0 2 8 536.0 144.7 345.2# 332.2 340.0t 411.0 418.9 388.5t 
± 30.7 ± 28.8 ± 56.5 ± 77.4 ± 56.8 ± 45.3 ± 53.7 ± 87.6 
PaC02 33.1 65.1 63.8 57.3 57.1 55.6 50.9 53.7 
± 3.25 ± 16.4 ± 10.8 ± 8.66 ± 5.32 ± 7.26 ± 5.88 ± 6.93 
All data are mean ± SD; IV and V (1'1/2nd) "" Pa02 and PaC02 values after the first and second BAL treatment; Control "" before HCI instillation; pre = after HCI 
instillation and before BAL treatment; 5', 30' and 60' = min after first and second BAL treatment; "'p<0.05 between 1'1 and 2nd BAL; #p<0.05 between pre-BAL and 
5 min after BAL; t = one animal died. 
Bronchoalveolar lavage fluid 
Table 3 gives tbe recovery percentage, protein concentration and surface tension 
properties of BAL fluid samples. The control lavages are from rats which received saline 
instead of HCI. The protein concentrations in BAL samples of control animals are much 
lower compared to all other groups, whereas tbere are no differences between tbe other 
groups. Maximal and minimal surface tensions of tbe BAL samples of rats lavaged witb 
a diluted surfactant suspension are significantly lower compared to all otber groups. The 
minimal surface tensions of BAL samples of sick animals lavaged with saline are 
significantly higher compared to healtby controls. 
Table 3: BAL parameters of different groups. 
Sample n Recovery Protein Surface tension 
[%] [mg/ml] [mN/m] 
maximal minimal 
Ill 5 97.0 7.14 59.7# 32.1# 
:!:. 2.45 ± 1.26 ± 1.82 " 1.00 
IV (1") 5 100.0 7.95 60.1@ 32.2§ 
± 8.16 ± 1.29 ± 0.41 ± 0.42 
v (1'~ 6 97.5 7.50 54.911 16.6'11 
± 3.82 ± 0.97 ± 3.28 ± 2.19 
Control 6 94.2 0.40* 63.1 24.9 
::!:: 5.32 ± 0.39 ± 3.16 ± 255 
All data are mean ± SD; Control = BAL fluid of control rats receiving saline instead of HCl; IV (1'1) and 
V (1'~ = fluid from first BAL treatment; "'p<O.Ol between Control and other groups; #p<O.OS between 
maximal/minimal surface tension of III and other sample groups, except IV (1.1); @p<0.05 between IV (lj 
and V (lr>t); §p<O.OS between IV (1"') and other sample groups, except III; 1Tp<0.05 between V (lJt) and 
other groups. 
Table 4 gives the protein concentrations in the 1", 2"d and 3"' BAL samples from Groups 
IV and V. In both groups, tbere is a significant decrease in protein concentrations 
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between the 1" and the 3"' BAL samples. The difference in protein concentrations 
between Groups IV (3"' BAL) and V (3"' BAL) is statistically significant. There is no 
statistically significant difference in either maximal or minimal surface tensions between 
the 1", z•• and 3"' BAL samples of Group IV; the same is true for Group V (data not 
shown). The differences in surface tension between BAL samples of Groups IV and V, 
as shown in Table 3, also exist for the second and third BAL. 
Table 4: Protein concentrations (mgjml) in 1", 2"d and 3n:1 BAL. 
IV v 
7.95 ::!:: 1.29'" 750 = 0.97# 
6.11 = 0.96 5.56 = 0.84 
536 = 0.70 3.99 = 0.75@ 
All data are mean ± SD; "'p<O;Q5 between 1<~ BAL and 3n:1 BAL; #p<O.OS between 1'1 BAL and both 2"d 
and 3rd BAL; @p<O.OS between IV (3n:l) and V (3n:l). 
DISCUSSION 
Massive aspiration of HCI with low pH leads to damage of the alveolar-capillary 
membrane which in tum leads to increased permeability to, and intra-alveolar 
accumulation of, plasma proteins (3-6). These proteins have proven to be potent 
surfactant inhibitors (7-13). The resulting impaired surfactant function leads to 
accumulation of edema fluid in the alveolar space. Also, as a result of diminished 
surfactant function, surface tension on the alveolar wall increases, leading to increased 
retractive forces across the alveolar-capillary membrane, with subsequent formation of 
atelectasis and mismatch of the ventilation-perfusion ratio, leading to hypoxemia. The 
damage to the surfactant system and the fact that surfactant is no longer produced as a 
result of damage to the surfactant producing type II pneumocytes ( 4 ), makes treatment 
of this pathological entity with surfactant plausible. 
The results in the present study demonstrate that ventilation with 100% oxygen 
and increased inflation pressure and PEEP to the levels used in this study, were not able 
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to maintain high Pa02 levels in rats after HCI aspiration. Also, surfactant instillation 
without prior lavage did not restore lung function. The best way to treat these animals 
appears to be either to lavage the lungs with saline, directly followed by intratracheal 
instillation of a high dose of surfactant, or to lavage the lungs with a diluted surfactant 
suspension, as evidenced by an increase in Pa02• 
The decrease in Pa02 values after HCI aspiration could not be explained by a 
fluid challenge, as demonstrated by Pa02 values remaiuing high in rats receiving saline 
instead of HCI. 
It has been hypothesized that the mechauism of inhibition of surfactant by 
proteins is based on competition for space at the air-liquid interphase (9,12). Thus, the 
way to overcome the inhibition of surfactant by these proteins would be to get a 
relatively high surfactant concentration in relation to the amount of proteins. This 
favorable surfactant/inhibitor (S/I) ratio can be achieved in two ways. In the first place 
by treating the animals with a large dose of surfactant (without prior lavage), a high S/I 
ratio could be achieved. The results from the present study demonstrate no increase in 
Pa02 values after instillation of surfactant at a dose of 200 mg/kg in animals suffering 
from respiratory failure after HCI aspiration, although a further decrease in Pa02 values 
seemed to be prevented at this surfactant concentration. Also, in comparable studies on 
animals suffering from respiratory failure due to HCl aspiration, surfactant only was not 
able to restore gas exchange (6,15). A possible explanation is that surfactant, at the 
concentration used, is directly inhibited by high concentration of inhibitors. Another 
explanation could be that the edema fluid and the atelectatic areas form a mechauical 
barrier, preventing surfactant from entering the alveolar spaces. However, in another 
study, surfactant instillation at very high doses (280-350 mg/kg) was able to restore gas 
exchange in guinea pigs suffering from severe respiratory failure due to protein-rich lung 
edema after intravenous instillation of anti-lung serum (23). Thus, in the latter study a 
more favorable S/I ratio was obtained by giving a large amount of surfactant. Recently, 
Kobayashi and colleagues (24) investigated the ability of surfactant mixed with edema 
fluid at several ratios to restore lung function in immature rabbit fetuses, as measured 
by tidal volume at preset insufflation pressures. It was demonstrated that surfactant (25 
mgjml) mixed with edema fluid at a protein to lipid ratio (P /L ratio) of 2.2 was capable 
of restoring lung function, whereas surfactant mixed with edema fluid at P /L ratio of 
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1 1.2, was not. Surface tension properties of these mixtures demonstrated high minimal 
surface tensions at P jL;,3.4 and low surface tensions at P /L:>L8. 
In the second place a favorable S/l ratio could be achieved by removing the 
inhibitors from the alveolar space by means of BAL. In the present srndy Pa02 values 
increased after surfactant treatment (200 mgjkg) following lung lavage. Similar findings 
were also reported by Kobayashi and colleagues (6). In our study, although there was no 
statistically significant difference in Pa02 values with rats receiving surfactant after BAL, 
BAL with a diluted surfactant suspension (100 mg/kg) seemed to be more efficient in 
restoring gas exchange. BAL with saline alone (without any additional surfactant 
treatment) was not able to restore gas exchange. The difference between Pa02 values of 
rats lavaged with a diluted surfactant suspension and rats lavaged with saline (not 
followed by surfactant treatment) may be explained as follows: after removal of a large 
amount of proteins in both groups, a small amount of surfactant remains in the lungs of 
the rats lavaged with a diluted surfactant suspension. This appears sufficient to establish 
surface active material at the air-liquid interphase, allowing improved gas exchange 
across the alveolar-capillary membrane. As no surfactant concentration measurements 
were made in the recovered surfactant suspensions after BAL, no exact data is available 
on the amount of surfactant remaining in the lungs after BAL. If one tries to estimate 
the amount of surfactant remaining in the lungs, the following equations cao be made: 
the functional residual capacity (FRC) of the lungs is approximately 10 mljkg; BAL was 
performed with 30 ml/kg and almost 100% of the BAL fluid was recovered; the total 
amount of surfactant in the BAL fluid was 100 mg phospholipids/kg; this was diluted 
with 10 ml/kg of residual (edema) fluid in the lungs. Considering the mixture of these 
two concentrations (10 ml/kg= no surfactant; 30 mljkg= 100 mg surfactant), this means 
that approximately 25 mg phospholipids/kg remains in the lungs. Considering the amount 
of surfactant needed to treat respiratory failure due to HCl aspiration, half the amount 
· of surfactant is needed when BAL is performed with the diluted surfactant suspension, 
compared to treatment with surfactant after BAL with saline. 
Protein concentrations in BAL material from all rats suffering from respiratory 
failure due to HCl aspiration were significantly higher compared to protein 
concentrations in BAL material from healthy control animals. Also, surface tension 
measurements demonstrated high minimal surface tensions in BAL material from rats 
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suffering from respiratory failure after HCl aspiration, when compared to BAL material 
from healthy controls. These results indicate that the surfactant system is damaged in 
animals after HC! aspiration. In BAL material from rats which underwent multiple 
lavage, the protein concentration decreased significantly, both in rats lavaged with the 
diluted surfactant suspension and in those lavaged with saline (Table 4). In rats lavaged 
with the diluted surfactant suspension, the decrease in protein concentration was greater 
compared to those lavaged with saline. Perhaps this indicates repair of the alveolar-
capillary membrane, resulting in a decrease of protein influx into the alveoli. Pa02 values 
appeared to increase further after the second lavage with the diluted surfactant 
suspension, although this increase was not statistically significant (Table 2). Thus, 
although BAL with saline also removes the proteins from the alveolar spaces, surfactant 
substimtion is needed to restore lung function. These results suggest that surfactant 
inhibitors (e.g. plasma-derived proteins, specific pro teases and cellular breakdown 
products) can be removed by means of BAL, resulting in improved efficacy of surfactant 
in restoring lung function. 
In conclusion: intratracheal surfactant instillation without prior BAL does not 
improve pulmonary gas exchange in rats suffering from respiratory failure due to HCI 
aspiration; in these animals gas exchange could be improved after BAL with saline, 
followed directly by surfactant instillation, or by BAL with a diluted surfactant 
suspension. It is shown that (multiple) BAL removes edema fluid (containing plasma 
proteins) from the lungs. It is argued that surfactant treatment can only succeed when 
there is a favorable ratio of surfactant to proteins inhibiting surfactant function. 
It is difficult to extrapolate from this animal smdy to the clinical simation. 
However, if one decides to treat patients suffering from ARDS with surfactant, it should 
be considered that the amount of surfactant needed to overcome the inhibition by 
proteins is enormous. From this it could be speculated that it would probably be more 
effective to reduce the amount of intra-alveolar proteins by means of BAL and then treat 
with surfactant, or directly by means of BAL with a diluted surfactant suspension. 
However, the optimal way to perform this in patients has yet to be studied. 
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SUMMARY 
The effect of intratracheal surfactant instillation on pulmonary function in rats with 
pneumocystis carinii pneumonia (PCP) was investigated. In those animals which 
developed PCP with severe respiratory failure after s.c. adntinistration of cortisone 
acetate over 8-12 weeks, pulmonary function was improved by surfactant instillation. 
Pa02 values 30 min after surfactant instillation were significantly higher compared to pre-
treatment values and also compared to Pa02 values of rats 30 ntin after receiving saline 
(482.9 mmHg ± 44.7, 170.7 mmHg ± 39.3 and 67.2 mmHg ± 17.4, respectively). 
Histological examination showed that alveoli of rats with PCP which received no 
exogenous surfactant are filled with foamy edema, whereas after exogenous surfactant 
alveoli are stabilized and well~aerated. These results indicate that exogenous surfactant 
may help patients with severe PCP to overcome an acute stage of respiratory distress. 
INTRODUCTION 
Infectious diseases are of great concern in intensive care health service in 
inununocomprontized patients; especially infectious diseases of the lung. In these patients 
pneumocystis carinii is a major cause of pneumonia leading to severe respiratory distress 
[1,2]. It has been demonstrated in rats that pneumocystis carinii pneumonia (PCP) 
decreases the total amount of phospholipids in bronchoalveolar lavage (BAL) fluid 
whereas phospholipase activity in BAL fluid increases [3,4]. Furthermore, lung 
compliance also decreases in PCP [3]. These findings suggest that in the pathophysiology 
of respiratory failure in PCP the pulmonary surfactant system may be involved. 
It has been repeatedly demonstrated by several authors that intratracheal 
instillation of exogenous surfactant restores lung function in animals with respiratory 
failure due to surfactant depletion or intratracheal HCl adntinistration [5,6]. Also large 
numbers of neonates with respiratory distress syndrome (RDS) due to lack of surfactant 
have been succesfolly treated with exogenous surfactant [7,8,9,10]. 
We designed a study to investigate the effect of surfactant replacement therapy 
on pulmonary function in rats with PCP. If surfactant replacement would increase gas 
exchange, then one could conclude that a disturbed surfactant system is one of the 
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factors in the pathophysiology of respiratory failure in PCP. 
MATERIALS AND ME1HODS 
Surfactant 
The surfactant used in these experiments is a natural surfactant isolated from bovine 
lungs in basically the same manner as previously described [11]. It consists of 
approximately 83% phospholipids, 1% hydrophobic proteins (SP-B and SP-C), the 
remainder being other lipids such as cholesterol, glyceride and free fatty acids. There is 
no SP-A in this surfactant preparation. 
Animal model 
This protocol was approved by the Animal Care and Use Committee of the Erasmus 
University Rotterdam, The Netherlands. 
The smdies were performed in 28 male Wistar rats (initial body weight: 110-120 
g), placed in two groups. The first group (n=20) was treated with cortisone acetate, 
based on the model described by Frenkel and Chandler [12, 13]. These animals received 
12.5 mg cortisone acetate s.c. four times weekly over 8-12 weeks and 10 ~tg/ml 
doxycycline in drinking water to reduce a possible bacterial superinfection. The second 
group (n=8) received no treatment and served as controls. All animals were housed in 
standard plastic cages and received standard food ad libitum and were weighed at weekly 
intervals. 
After 8-12 weeks the cortisone acetate treated animals developed respiratory 
failure as judged by clinical symptoms (e.g. tachypnoea, cyanosis and fast decrease in 
body weight). Eleven animals died during the night hours on various days before 
treattnent with exogenous surfactant could be started. Nine rats which suffered clinically 
from respiratory failure were anesthetized with pentobarbital sodium (60 mg/kg, i.p.), 
tracheotomized and paralyzed with pancuronium bromide (0.5 mg/kg, i.m.). A catheter 
was inserted into the carotid artery for blood sampling. Animals were ventilated 
pressure-controlled with a Servo Ventilator 900 C (Siemens-Eiema, Solna, Sweden) at 
the following settings: Fi02 = 1.0, ventilation frequency =30/min, peak airwaypressure=22 
em HzO, PEEP=2 em HzO and I:E=1:2. 
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After a :±: 20 min stabilization period, 6 animals received bovine surfactant (200 
mg dry weight/kg body weight), suspended in 0.7 ml saline, intratracheally, whereas 3 
received the same amount of saline. Blood samples were taken from the carotid artery 
immediately before surfactant instillation and at 30 and 60 min post treatment. Blood 
gases were measured with the ABL 330 Acid-Base Laboratory (Radiometer, 
Copenhagen, Derunark). 
Histological examination 
At the end of the experiments the animals were sacrificed with an overdose of intra-
arterially administered pentobarbital. The lungs were removed, the left lobe was minced 
and a cytospin preparation was made. This preparation was stained with a modified 
Gomori stain [14], which allows visualization of the cysts (not the intra-cystic structures) 
and Giemsa stain, and examined to confirm presence of PCP. The right lobes were fixed 
in 10% formalin for light microscopy examination, dehydrated, embedded in paraffin and 
6 11-m sections of the right middle lobe were stained with hematoxylin and eosin, Grocott-
Gomori methenamine silver nitrate and periodic acid-Schiff stain. 
Statistical analysis 
Statistical evaluation of data was performed using the Wilcoxon signed rank test for 
paired observations or the Mann-Whitney-U test (two-tailed). All data are expressed as 
mean:±: SEM. Statistical significance was accepted at p<O.OS (two-tailed). 
RESULTS 
Blood gases 
During an 8-12 week period the animals developed respiratory insufficiency which could 
be reversed by surfactant instillation. Pa02 values at 30 and 60 min after surfactant 
instillation are significantly higher compared to pre-treatment values. There is no 
significant difference between Pa02 values after surfactant treatment and Pa02 values 
of healthy control animals, though the latter are somewhat higher. Intratracheal 
instillation of only saline, however, led to a decrease of Pa02 compared to pre-treatment 
Pa02 values. The difference at 30 and 60 min between rats receiving surfactant and rats 
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receiving saline is significant. Pre-treatment Pa02 values of both groups do not differ 
significantly (Fig. 1). Figure 2 shows one example of a dramatic increase of Pa02 of a 
rat with PCP treated with exogenous surfactant. This rat had the lowest Pa02 of the 
whole group. 
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Figure 1. Pa02 values of the different groups before treatment (~Before") and 30 min and 60 min after 
treatment (respectively: "30 min" and "60 min''). Grey bar= healthy controls; striped bar= saline group; open 
bar= exogenous surfactant group.("'= significantly different from pre-treatment;"'*= significantly different 
from surfactant treated rats [p<O.OS]). 
Histologic findings 
Histological examination of lungs of rats with PCP which received only saline and no 
exogenous surfactant showed alveoli filled with a characteristic foamy edema (Fig. 3). 
Surfactant treatment resulted in stabilized and aerated alveoli, thus allowing the 
emphysematous structure of the lungs to become apparent (Fig. 4). 
In all 9 lung homogenates a large amount of cysts was present which confirmed 
the presence of PCP in all animals. 
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Figure 2. Pa02 over time in a rat with PCP having the lowest Pa02 of the whole group before surfactant 
treatment: in this animal Pa02 was also measured 10 min after surfactant instillation. The arrow indicates 
the time of surfactant instillation. 
DISCUSSION 
The treatment of choice in patients suffering from respiratory failure due to PCP is 
administration of antimicrobial drugs combined with ventilatory support. The aim of the 
present study was to investigate the effect of an exogenous surfactant preparation on gas 
exchange under unchanged ventilator settings in an animal model of PCP. 
The primary functions of surfactant are stabilization of alveoli of different size, 
and reduction of work of breathing by reducing surface tension at the air-liquid 
interphase on the alveolar walls [15]. In this study two hypotheses were proven valid: 
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Figure 3. Typical histological findings in a rat with PCP which received saline instead of exogenous 
surfactant. Hematoxylin and eosin stain; the scale-line equals 100 IJ.ffi. 
Figure 4. Typical histological findings in rats with PCP after treatment with surfactant; note the 
emphysematous structure. Hematoxylin and eosin stain; the scale-line equals 100 p.m. 
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hypothesis 1: if surfactant is necessary to keep retractive forces as low as possible and to 
ensure optimal gas exchange, any disturbance in the surfactant system will result in 
abnormalities in lung distensibility and gas exchange; hypothesis 2: if the first hypothesis 
is correct, surfactant replacement will restore lung distensibility and gas exchange to 
normal. In other words, if surfactant replacement improves decreased lung compliance 
and impaired gas exchange in lung diseases of different etiologies, then the surfactant 
system is also involved in the pathogenesis of these lung diseases [16]. 
The results of this study demonstrate that surfactant instillation in rats with 
respiratory failure due to pneumoncystis carinii infection leads to restoration of 
pulmonary gas exchange, which could be demonstrated by improvement of blood gases 
and by histological examination. These results underline our hypothesis that the 
pulmonary surfactant system is at least partly responsible for the respiratory failure 
caused by PCP. The mechanism can be explained as follows: as a result of damage to the 
alveolar-capillary membrane caused by infection with pneumocystis carinii, large volumes 
of edema fluid accumulate into the alveolar space. This edema contains large amounts 
of plasma proteins and specific enzymes capable of disrupting the surfactant system 
[3,4,17,18,19]. As a result of this functional surfactant deficit, surface tension at the air-
liquid interphase on the alveolar wall increases, leading to increased retractive force 
across the alveolar-capillary membrane, with subsequent formation of atelectatic areas, 
functionally expressed as a decrease in functional residual capacity (FRC). This leads to 
a mismatch of the ventilation-perfusion ratio resulting in hypoxaemia. Also, due to 
increase of surface tension on the alveolar walls, suction force across the alveolar-
capillary membrane increases, facilitating a further outpouring of edema [20]. The 
mechanism by which surfactant replacement therapy leads to improvement of gas 
exchange can be explained by reversing these mechanisms. The fact that gas exchange 
improves only after administration of surfactant and not after saline indicates that the 
positive effect observed is caused by surfactant and not by the fluid itself. 
In all animals treated with exogenous surfactant it was also found that many 
alveolar septa were damaged, leading to an emphysematous lung structure. Similar 
observations were reported recently in patients with PCP [21 ]. These findings suggest that 
in PCP lungs proteolytic enzymes may be over-represented. These proteolytic enzymes 
are perhaps excreted by activated leukocytes attracted to the site of inflamation. Also in 
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the past it has been found that type I pneumocytes undergo degenerative changes in rats 
infected with pneumocystis carinii. This leads to damage to the ultrastructure of the 
alveolar wall, thus leading to increased permeability of the alveolar-capillary membrane 
[22]. Perhaps both mechanisms play a role in the damage of the alveolar septa. It could 
be speculated that proteinase inhibitors, given to the patient after manifestation of 
pneumocystis carinii infection, could prevent (further) morphological damage to the 
pulmonary structure. 
It is established that immunosuppressed rats, as is the case in humans, can 
develop pneumocystis carinii infection of the lungs, leading to respiratory distress. The 
current treatment of choice is parenteral administration of trimethoprim-
sulfamethoxazole or pentamidine-isothionate. Both drugs have about the same rate of 
success of around 75% (percentages vary depending on the study) but high incidences 
of systemic adverse reactions are reported (for review see: [23]). To prevent these 
adverse reactions it is necessary to lower the systemic concentration, which led to studies 
on aerosolized pentamidine. Results from these aerosol studies have shown that it is 
possible to get high concentrations in the lungs with low systemic concentrations [24,25]. 
For the future one could speculate to use surfactant as a carrier-substance for 
antimicrobial drugs, this way achieving high intra-alveolar drug concentration and low 
systemic concentration. 
In conclusion, it has been demonstrated that surfactant instillation can improve 
gas exchange in rats suffering from respiratory failure due to PCP. These results could 
be important in future for treatment regimens of patients suffering from acute respiratory 
failure due to PCP. 
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SUMMARY 
In this study the importance of a low-weight surfactant protein (11 kDa) is demonstrated 
by selectively blocking this protein with a monoclonal antibody. In adult rats respiratory 
failure was induced by repeated broncho-alveolar lavage to remove all pulmonary 
surfactant. It was shown that surfactant mixed with the antibody was not capable of 
restoring lung function when compared with surfactant alone or surfactant mixed with 
control serum. Using the pulsating bubble surfactometer, it could be demonstrated that 
surfactant mixed with this antibody had a significantly higher minimum surface tension 
when compared with surfactant alone, or surfactant mixed with an unrelated mouse-IgG. 
The inhibition of surfactant function by the monoclonal antibody suggests the importance 
of the 11 kDa protein for normal surfactant function. 
INTRODUCTION 
Pulmonary surfactant is mainly composed of specific phospholipids and proteins. 
Surfactant proteins have been divided into three groups: SP-A, SP~B and SP-C (for 
review, see [1,2]). Recently the presence of a collagenous protein, SP-D (MW 43 kDa, 
reduced), has been demonstrated in primary type II cell cultures. This protein has been 
proven to be immunologically and structurally different from SP-A and the low molecular 
weight surfactant proteins. The function of SP-D is still unknown [3]. 
SP-B and SP-C are low-weight hydrophobic proteins with overlapping molecular 
weights between 5 kDa and 18 kDa, depending on the animal species, the method of 
preparation and the state of reduction (for review, see [2]). Mixtures of phospholipids 
and low-weight hydrophobic proteins reduce surface tension and increase the 
effectiveness of exogenously administered phospholipids in fetal rabbits, as measured by 
an increased lung compliance [4,5,6]. On the other hand it has been demonstrated that 
monoclonal and polyclonal antibodies directed against surfactant can inhibit the function 
of surfactant in vitro, i.e. lowering surface tension and facilitating adsorption [7,8,9,10]. 
The role of hydrophobic surfactant proteins in surfactant function in adult animals 
remains unclear. In the present study a monoclonal anti-surfactant antibody was raised 
in rats. This monoclonal antibody recognizes an 11 kDa surfactant protein. The function 
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of this 11 kDa surfactant protein was investigated in vivo and in vitro, by selectively 
blocking the its function with the monoclonal antibody (Cl). 
MATERIALS AND METHODS 
Surfactant 
The surfactant used in these experiments is a natural surfactant isolated from bovine 
lungs in basically the same manner as previously described [11]. It consists of 
approximately 83% phospholipids, 1% hydrophobic proteins (SP-B and SP-C), the 
remainder being other lipids such as cholesterol, glyceride and free fatty acids. There is 
no SP-A in this surfactant preparation. 
Monoclonal antibody 
Monoclonal antibodies against bovine surfactant were raised in rats. Procedures used to 
raise, absorb and assay rat polyclonal antisera have been described in detail 
[9,12,13,14,15]. In brief: F344 rats received bovine surfactant emulsified in Freund's 
complete adjuvant (Difco) subcutaneously, followed by intravenous boosts. Antibody 
reactivity to surfactant was measured by ELISA [16] using antibody to mouse-Ig, 
conjugated to alkaline phosphatase (Cappel), and an automated ELISA reader 
(Oynatech). The animals showing high serum titers of antibody to bovine surfactant were 
boosted and their spleen cells fused to the nonsecreting rat myeloma line YB2/0 
(ATCC). After growth in HAT (hypoxanthine + aminopterin + thymidine) containing 
medium for two weeks, positive wells were selected, subcloned and expanded. Resulting 
hybridomas were grown in RPMI-1640 with 10% normal horse serum (Hyclone ). These 
hybridomas have been stable for over 100 passages in vitro. One of these hybridomas, 
Cl, secretes the monoclonal antibody used in the present study. Using isotype-specific 
antiserum, this antibody was identified as lgG. 
Western blotting 
Western blot analysis of the specific protein reactivity of Cl was performed under 
reducing conditions according to procedures described elsewhere [17,18], with several 
modifications. Bovine surfactant proteins were electrophoresed in parallel lanes using 
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SDS-PAGE. All gels were 15% acrylamide, 0.1% SDS and 4 M urea. We transferred 
surfactant containing slab gel proteins to lmmobilon• (Millipore Corp.), prepared 
according to package insen. All transfers were accomplished in standard transfer buffer 
[18], supplemented with 0.1% SDS. Filters were then cut into strips ("Spaghetti 
Westerns") and exposed to the antibody-containing culture supernatant (diluted 1:10), 
washed, and then exposed to rabbit anti-mouse IgG (1:20) (Miles Immunochemicals). 
Finally antibody-treated filter strips were incubated with lOS cpm of 125!-Staphylococcus 
protein A per strip and visualized by autoradiography. Protein sizing was accomplished 
by interpolating between the positions of known molecular weight markers run in 
adjacent lanes. These procedures revealed that Cl recognizes an 11 kDa protein (Fig. 
1). 
Measurement of surface activity 
The effect of the antibody on surface activity was studied in vitro using the pulsating 
bubble surfactometer, as described by Enhorning [19]. 
In brief: the surfactometer used in these in vitro experiments measures the 
pressure gradient across the air-liquid interphase of a bubble in a 37 ° C water-enclosed 
sample chamber. The bubble size is viewed through a microscopic optic. The bubble 
pulsates between a maximal (0.55 mm) and a minimal (0.45 mm) radius at a rate of 20 
cycles/min. The surface tension is calculated according to the law of Young and Laplace 
and expressed as milli Newton/meter (mN/m). In this study a bubble was formed to a 
maximal radius and 15 seconds later pulsation was started. A continuous tracing of 
pressure differences was made 1 min after bubble formation. 
There were three groups of samples for surface activity measurements. In the first 
group (n;5) the sample chamber of the surfactometer contained surfactant only. In the 
second group (n=5) surfactant was mixed with an unrelated mouse-IgG (vol:vol = 1:1). 
In the third group (n=5) surfactant was mixed with the undiluted culture supernatant of 
the Cl hybridoma, containing the monoclonal antibody. For the mixing procedure a 
Vonex mixer was used for 30 seconds, followed by incubation for 30 min at 37 ° C with 
shaking. The final surfactant concentration was 5 mg phospholipid/ml in all groups. The 
corresponding antibody concentration was approximately 200 ng/ml in both the second 
and the third groups. Of these groups surface tension was calculated at minimum radius 
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after 5 min of pulsation. 
C1 
11 
Animal model 
Figure 1. Western blot analysis of antigenic specificity of the Cl 
monoclonal antibody generated in rats. The procedures used are 
described in the text. The Cl antibody is directed to an 11 kDa 
surfactant protein, indicated by the arrow on the left. The 
markers indicating the positions of proteins with known 
molecular weight are shown on the right; these are: albumin (68 
kDa), ovalbumin (43 kDa), chymotrypsinogen (23 kDa) and 
RNase (18 kDa). 
The smdies were performed in 28 male adult Wistar rats (body weight: 240-260 g), 
divided into four groups. Respiratory failure was induced by lung lavage as described by 
Lachmann et al [20]. In brief: all rats were anesthetized with pentobarbital sodium (60 
mgjkg, i.p.), tracheotomized and paralyzed with pancuronium bromide (0.5 mg/kg, i.m.). 
A catheter was inserted into the carotid artery. Lungs were lavaged six times with 8 ml 
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warm saline (37 • C) to produce a Pa02 < 80 mmHg at the following ventilator settings: 
pressure-controlled ventilation, Fi02 = 1.0, ventilation frequency=30/min, peak airway 
pressure=26 cmH,O, PEEP=6 cmH,O and inspiratory/expiratory ratio = 1:2. These 
ventilator settings were maintained throughout the observation period; a Servo Ventilator 
900 C (Siemens-Elema, Solna, Sweden) was used. 
Treatment began approximately 5 min after the last lavage. Surfactant was 
intratracheally instilled in three of four groups at a concentration of approximately 150 
mg phospholipids/kg. Group I (n=6) received 2 ml surfactant only; group 2 (n=7) 
received 2 ml surfactant mixed with the monoclonal antibody (C1) (vol:vol = 1:1); group 
3 (n=6) received 2 ml surfactant mixed with the control preparatior. (RPMI-1640 + 10% 
horse serum in which YB2/0 cells alone had been cultured). Group 4 (n=9) received 2 
ml saline only, intratracheally. The antibody in group 2 was used as a culture supernatant 
at concentrations of 400-500 ng/ml in RPMl-1640 + 10% normal horse serum. For 
groups 2 and 3, surfactant plus culture supernatant or surfactant plus control preparation, 
were incubated together for 30 min at 37 • C with shaking, as for the measurement of 
surfactant tension described above. 
Blood samples were taken from the carotid artery of each rat just before and 5 
min after broncholavage (directly followed by treatment) and at 5, 30, 60, 120 and 180 
min post treatment. Pa02 and PaC02 were measured with the ABL 330 Acid-Base 
Laboratory (Radiometer, Copenhagen, Denmark). 
Histological examination 
At the end of the animal study the rats were sacrificed with an overdose of intra-arterial 
administered pentobarbital. The lungs were illi'lated to 20 em H20 with air, the trachea 
was clamped and the lungs removed and fiXed in 10% formalin for light microscopy 
examination. The tissues were dehydrated and embedded in paraffin, and 6 f.I.ID sections 
of the base of the right lung were stained with hematoxylin and eosin. 
Stastistical analysis 
Statistical evaluation of collected data was performed using the Mann-Whitney-Wilcoxon 
test. Statistical significance was accepted at p<0.05 (two-tailed). 
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RESULTS 
Measurement of surface activity 
After 5 min of pulsation, minimum surface tension was high in the surfactant plus C1 
sample (17.7 ± 0.63 mN/m), whereas the surfactant alone (4.3 ± 0.76 mNjm) and 
surfactant plus mouse-lgG (3.1 ± 0.67 mN/m) samples had significantly lower minimum 
surface tensions; the difference between these latter sample groups was not significant. 
Animal studies 
Figure 2 shows Pa02 values for each group. Before lavage Pa02 values are high in all 
groups, whereas after lavage all values are low; the intergroup differences both before 
and after lavage are not statistically significant. After treatment, the difference in Pa02 
values between tbe surfactant plus Cl group and surfactant alone group remains highly 
significant throughout the observation period, as does the difference between the 
surfactant plus C1 group and surfactant plus RPMI-1640 group. The Pa02 values of the 
surfactant only group are higher than those of the surfactant plus RPMI-1640 group, but 
the difference is not significant. Comparing Pa02 values of the surfactant plus C1 group 
with the saline group revealed almost identical values after 60 min post·treatment. 
Table 1 shows PaC02 values for all groups; the intergroup differences before and 
5 min after lavage are not significant. The PaC02 values of the group receiving surfactant 
plus C1 are significantly higher at 60 - 180 min compared to the group receiving 
surfactant alone. The difference in values between the groups receiving surfactant plus 
C1 or surfactant plus RPMI-1640 is significant at 60 and 120 min post treatment. As with 
Pa02, the difference in PaC02 values between the surfactant plus RPMI-1640 and 
surfactant alone groups is not significant at any time. Similarly, there is no significant 
difference between post lavage PaC02 values in the surfactant plus Cl group, compared 
to tbe saline alone group. 
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Figure 2. PaOz values in mmHg (mean ± SEM) of the four treatment groups: surfactant plus Cl (•); 
surfactant only (o); surfactant plus RPMI-1640 (T); saline only (v). The vertical grey bar indicates the 
moment of broncholavage; t = 0 indicates Pa02 values 5 min after lavage, immediately followed by treatment. 
Figure 3. Typical histologic fmdings in rats: (A) after treatment with surfactant plus RPMI-1640. 
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Figure 3. Typical histologic findings in rats: (B) after treatment with saline; (C) after treatment with 
surfactant plus Cl (arrows indicate the eosinophilic substance covering the alveolar walls). Hematoxylin and 
eosin stain. 
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Table 1: PaC02 values (mmHg) before and after lavage and after different therapeutic regimes. 
Surfactant Surf. + C1 Surf. + RPMI-1640 Saline 
(n=6) (n=7) (n=6) (n=9) 
Before lavage 37.6 34.7 39.0 39.4 
:!:: 1.84 :!:: 1.60 :!:: 2.10 ::!: 3.30 
5 min after lavage 57.1 59.7 56.2 513 
:!:: 5.76 :!:: 2.85 :!:: 4.81 ::!: 3.77 
5 min after treatment 443 50.1 46.1 51.5 
± 3.08 :!:: 2.30 :!:: 1.79 ::!: 320 
30 min 42.7 46.6 40.5 51.8 
:!:: 3.41 ± 2.41 ± 1.69 ::!: 3.62"' 
60 min 37.5 45.6 39.2 52.0 
:!:: 2.82 ± 1.93* ± 155 ::!: 3.79"' 
120 min 37.7 47.8 393 51.8 
::!: 1.97 ± 1.98"' :!:: 2.43 ::!: 3.98"' 
180 min 39.9 51.4 45.0 56.6 
:!:: 2.99 ± 3.35"' :!:: 3.71 ::!: 4.19* 
All data are mean ± SEM; "'statistically significant difference between surfactant and the other groups; for 
further significant differences see text. 
Light-microscopic findings 
The lungs of the animals receiving surfactant only or surfactant plus RPMI-1640 were 
well aerated (Fig. 3A). The lungs from animals receiving saline showed widespread 
atelectasis, alternating with areas of hypere>:pansion; the alveoli were filled with 
amorphous exudate and erythrocytes, indicating damage to the alveolar-capillary 
memrane (Fig. 3B). Lungs of rats which got surfactant plus Cl showed regions with 
atelectasis, alternating with aerated areas, which were partly overdistended. Especially 
these overdistended alveoli were covered with an eosinophilic substance. A typical light-
microscopic picture is shown in Figure 3C. 
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DISCUSSION 
It has been reported that in adult animal models (guinea pigs, rabbits, pigs and dogs) 
repeated bilateral whole-lung lavage with saline severely impairs lung function through 
loss of lung surfactant [20]. It is established that this lung lavage model is useful for a 
variety of experimental purposes, including e.g. testing of different surfactant 
preparations, and to demonstrate that exogenous surfactant restores blood gases to 
normal [21,22,23,24]. Since the purpose of this study was to investigate the influence of 
a monoclonal antibody on the function of exogenous surfactant containing the 
hydrophobic surfactant proteins (SP-B and SP-C), the lung lavage model was used to 
detect any inhibiting effect of this monoclonal antibody on the effectiveness of the 
exogenous surfactant preparation to restore blood gases. The monoclonal antibody used 
in this study, C1, recognizes an 11 kDa surfactant associated protein. Tanaka and 
colleagues have demonstrated that bovine surfactant contains SP-B with a molecular 
weight of 10 kDa in the reduced state [25]. SP-C has a much lower molecular weight 
after reduction (for review, See [2]). These results and the findings reported by others 
suggest that the llkDa protein is most likely a bovine SP-B monomer. 
This C1 monoclonal antibody inhibits pulmonary surfactant function, as 
demonstrated by low Pa02 and high surface tension in this study. A similar elevation of 
the minimum surface tension of porcine surfactant after mixing with a monoclonal 
antibody against porcine SP-B has also been reported by Kobayashi and colleagues. They 
also demonstrated that this mixture of porcine surfactant and monoclonal antibody, 
unlike porcine surfactant alone, is not able to improve lung compliance in immature 
rabbit fetuses [26]. The reason for this inhibition of surfactant function could be that the 
monoclonal antibody simply inhibits the function of SP-B. As already mentioned in the 
introduction, the hydrophobic proteins SP-B and SP-C play an essential role in the 
function of surfactant [ 4,5,6]. 
Another mechanism by which the antibody perhaps inhibits surfactant may lie in 
the formation of surfactant-antibody aggregates, with subsequent loss of surfactant 
function. Comparable results have been reported in an in vitro study using IgG 
subfragments where it was found that surfactant mixed with polyclonal rabbit anti-
surfactant antiserum inhibited the ability of surfactant to lower surface tension, as 
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measured by the pulsating bubble surfactometer. It was demonstrated that bivalent 
antibody (F[ ab'h) preparations inbibited surfactant activity, whereas monovalent antibody 
(F[ab']) fragments did not [9]. Thus, it was concluded that these polyclonal antibodies 
agglutinate surfactant. It is possible that this aggregation of surfactant with the C1 
monoclonal antibody alters the surface activity of surfactant and/ or that the aggregates 
themselves are responsible for further deterioration of pulmonary function. 
Another explanation for the failure of surfactant mixed with the monoclonal 
antibody to restore lung function can be that the antibody causes a configuration change 
of the 11 kDa protein, which affects the protein-phospholipid interaction. Also, it is 
possible that other physicochemical characteristics of surfactant, such as charge, are 
altered. These changes in characteristics of surfactant could affect the function of 
surfactant, i.e. surface tension lowering capacity. 
The reason for the initial increase of Pa02 after administration of surfactant plus 
the monoclonal antibody followed by a decrease of Pa02 (Fig. 2), could be explained as 
a functional surfactant deficit. In a recent study (unpublished observations), using the 
same lung lavage model, the effect of different doses of surfactant, ranging from 10-300 
mg/kg, to improve arterial oxygenation was investigated. In adult rats receiving only 10-
15 mg surfactant-phospholipids/kg surfactant intratracheally, a similar behavior as 
observed in the present study could. be demonstrated, namely, an initial rise of Pa02, 
rapidly followed by deterioration of lung function. Rats receiving the same dose of 
surfactant used in the present study (150 mg surfactant-phospholipids/kg) showed the 
same results as the rats receiving surfactant alone in this study, i.e restoration of blood 
gases to normal values and remaining constantly high for the observed period. From 
these findings one could conclude that about 90% of the exogenous surfactant was 
inhibited by the monoclonal antibody and perhaps, in part, by the horse serum. The 
amount of surfactant which was not inhibited by the monoclonal antibody was too low 
to stabilize the lungs at the applied ventilator settings for the observed period. 
As can be seen in Figure 2, the Pa02 values of rats receiving surfactant plus 
control serum (RPMI-1640 + 10% horse serum) are lower than Pa02 values of rats 
receiving surfactant alone, though this difference is not significant. An explanation for 
the lower Pa02 values in the group receiving surfactant plus control serum could lie in 
the fact that proteins in the control serum inhibited a part of the exogenous surfactant. 
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This inhibitory capacity of different serum proteins has already been demonstrated in in 
vitro stndies [27,28]. 
Histologically, lungs of rats receiving surfactant plus the monoclonal antibody 
showed an eosinophilic substance covering the alveolar walls. This finding could suggest 
that the C1 antibody aggregates surfactant by crosslinking 11 kDa surfactant proteins, 
supporting the suggestion that antibody inactivates surfactant by causing aggregation of 
surfactant-antibody complexes. On the other hand, it is possible that the histological 
findings reflect the presence of hyaline memranes due to fibrin deposition, caused by 
leakage of the alveolar-capillary membrane as a result of a functional surfactant deficit. 
No experiments were performed in this stndy to demonstrate the presence of fibrin in 
the material covering the alveolar walls; but in earlier histological stndies hyaline 
membranes were observed in animal lungs following lung lavage and ventilation for a 
period of 2-6 h [20,23]. The lungs of rats receiving saline showed widespread atelectasis 
and edema-filled alveoli. The reason for the difference between the lungs of rats 
receiving surfactant plus C1 and lungs of rats receiving saline alone could perhaps be 
explained by the initial protective effect of surfactant in the first group. Perhaps there 
was still some partial protective effect from surfactant remaining, preventing excessive 
intra-alveolar edema accumulation, although this effect was not enough to permanently 
increase Pa02• When compared to lungs of rats receiving surfactant plus RPMI-1640, 
lungs of rats receiving surfactant plus Cl showed regions with atelectasis and an 
eosinophilic substance covering the aerated alveoli. 
1n conclusion, we have demonstrated that a monoclonal anti-surfactant antibody 
(C1) to an 11 kDa apoprotein of bovine surfactant (SP-B) inhibits the function of 
exogenous bovine surfactant, both in vivo and in vitro. As already suggested in other 
stndies [4,5,6], these results confirm the importance of the hydrophobic surfactant 
proteins for optimal surfactant function in the adult lung. 
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APPEND IX A 
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Tables 1 and 2 contain the data of the clinical studies on exogenous surfactant therapy 
in neonates performed until the end of 1989. These tables are incorporated in a review 
article on surfactant function, which has been published recently (see Chapter 1). 
The major clinical trials performed from begin 1990 until end 1992 are 
summarized in Tables 3 and 4. These tables contain studies on prophylactic surfactant 
treatment and on rescue surfactant treatment in neonates, respectively. The references 
from Tables 3 and 4 are listed at the end of this Appendix. 
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Table 1: Prophylactic surfactant treatment 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
Surfactant TA Soil et al, 79 81 Birth weight 750-1250 g, Fi02 I; X·chest 
(supplemented bovine 1988 (72) intubated at 4-37 min improved; patients who 
homogenate) after birth weighed 750-999 g 
responded better 
Bovine lung lavage Enhorning et al, 39 33 < 30 wk gestation Incidence of death I; 
extract 1985 (11) incidence of IVH I; 
incidence of air leaks I 
Calf lung surfactant Shapiro et al, 16 16 25-29 wk gestation Severity of RDS 
extract (CLSE) 1985 (67) decreased transiently 
Wood et al, 25 35 (saline) 25-29 wk gestation Incidence of RDS I; 
1987 (80) 20 (air) X-chest shows 
decreased severity of 
RDS in treated group 
Kendig et al, 34 31 25-29 wk gestation Severity of RDS I i 
1988 (32) incidence of air leaks I 
Shennan et al, 39 (phase 1) 33 <30 wk gestation (See Enhorning, 1985); 
1988 (69) 29 (phase 2) 27 Both phases: incidence 
and severity of RDS I; 
PIE I; Fi02 I; 
a/A P01 I; incidence 
ofBPD I 
Phase 2: no decrease in 
IVH and mortality 
16 17 30-33 wk gestation No effect 
Jnfasurf (CLSE) Kwong et al, 14 13 24-28 wk gestation Severity of RDS at 
1985 (36) 48 h I;Fi02 I; 
ventilatory support I 
Table 1 (continued): 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
Kwong et al, 315 0 23-29 wk gestation Incidence of death 
1988 (37) 
Egan et al, 1437 0 <33 wk gestation Severity of RDS was 
1988 (9) (262 were treated higher in patients who 
too late) were treated too late; 
mortality I compared 
to earlier studies 
Shapiro et al, 78 (prophylaxis) 0 24-29 wk gestation; Both groups: identical 
1988 (68) 81 (rescue) RDS: Fi02> 0.4, mortality; no difference 
MAP;;.; 7cmH20, in incidence of 
X-chest showing RDS complications 
Bloom et al, 43 (Infasurl) 30 24-31 wk gestation Incidence of death I; 
1987' 13 (Human amniotic incidence of PIE I; 
fluid) Fi02 I 
Bloom et al, 30 (Infasurl) 30 24-31 wk gestation Mortality I; BPD I; 
1988 (3) 10 (Human amniotic PIE I; incidence of 
fluid) pneumothorax I; 
Fi02: CLSE< HAF; 
MAP: CLSE< HAF; 
a/A PO,: CLSE> HAF 
Human amniotic fluid Merritt et al, 31 29 24-29 wk gestation; Incidence of death I; 
1986 (51) L/S ratio :5: 2.0 incidence of BPD I; 
incidence of air leaks 
Merritt et al, 23 (prophylaxis) 0 24-29 wk gestation; < 6 h after treatment: 
1988b (53) 23 (rescue) 23 twin pairs: blood gas values better 
first half: prophylaxis in prophylaxis group; 
second half: rescue >6 h: MAP I and 
Fi02 I in rescue group 
Table 1 (continued): 
Type of surfactant 
Synthetic phospholipids 
(ALEC) 
Exosurf 
(synthetic surfactant) 
DPPC + HDL 
Source 
Morley et al, 
1981 (54) 
Wilkinson et al, 
1982* 
Milner et al, 
1984' 
Morley et al, 
1985* 
Ten Centre Study 
Group, 
1987 (55) 
Morley et al, 
1988 (56) 
Phibbs et al, 
1988 (61) 
Halliday et al, 
1984 (21) 
No. of patients 
22 
16 
10 
243 
159 
163 
29 (prophylaxis) 
45 (rescue) 
49 
No. of controls 
33 
16 
6 
220 
149 
164 
32 
40 
51 
Treatment criteria 
5.:34 wk gestation 
:s;32 wk gestation 
:s;34 wk gestation 
25-34 wk gestation 
25-29 wk gestation 
23-34 wk gestation 
:s;34 wk gestation; 
700-1350 g birth weight 
>650 g birth weight; 
RDS: Fi022: 0.4, 
MAP2:7cmHp, 
X-chest showing RDS 
25-33 wk gestation 
Outcome 
Incidence of death I 
No effect 
No effect 
Incidence of death 
before 30 wk 
Mortality I; incidence 
of IVH I; hours of 
ventilation I 
Before 30 wk gestation: 
incidence of death I; 
IVH I; dependence on 
0 2 therapy I 
No effect on survival; 
Fi02 I and PIP I 
during first 72 h 
Treated group shows 
higher survival; 
Fi02 I during first 48 h 
No effect 
a/A P02 = arterial-alveolar P02 ratio; ALEC = Artificial Lung Expanding Compound; BPD = bronchopulmonary dysplasia; HAF = Human amniotic fluid; HMD 
= hyaline membrane disease; IVH = intraventricular hemorrhage; MAP = mean airway pressure; PDA = patent ductus arteriosus; PIE = pulmonary interstitial 
emphysema; PIP = positive inspiratory pressure; t = increase; I = decrease; *cited from (52) 
Table 2: Rescue surfactant treatment 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
Surfactant TA Fujiwara et al, 10 0 RDS Pa02 I; PaC02 I; 
1980 (13) af A P02 I; 9 patients 
had PDA 
Fujiwara et al, 19 0 RDS Pa02/Fi02 I; Fi02 I; 
1981 (14) incidence of PDA I 
Fujiwara ct al, 20 10 RDS a/A PO, I; MAP I; 
1984* X-chest improved; 
Fujiwara et al, 37 5 RDS a/A P02 I; Fi02 I; 
1984 (15) X-chest improved; 
incidence of PDA I 
Fujiwara et al, 91 yes RDS Early improvement; 
1987 (16) IVH 1; BPD I; 
incidence of death I; 
pneumothorax I 
Raju et al, 17 13 HMD; birth weight 750- a/A POt 1; Fi01 I; 
1987 (62) 1750 g; age::: 6 h; incidence of PDA I; 
MAP> 8cmHp; BPD I; air leaks I 
a/A PO,< 0.24 
Gitlin et al, 18 23 Age< 8 h; a/A P02 I; MAP I; 
1987 (18) birth weight:>: 1000 g; time on ventilator I; 
Fi02:o: 0.4 no. of days with 
Fi02 :>: 0.4 I 
Fujiwara et al, % 0 Birth weight 520-2400 g; "Pure RDS": sustained 
1988 (17) MAP> 7cmH20; improvement 
Fi02> 0.4 "RDS + PDA": at ftrst 
improvement; secondly 
relapse; after treatment 
of PDA: recovery 
Table 2 (continued): 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
Horbar et al, 38 46 Birth weight 750-1750 g a/A P02 I; MAP I; 
1988b (28) incidence of IVH I 
Horbar el al, 78 81 Birth weight 750-1750 g Fi02 I; MAP I; 
1988a (27) a/A P02 I; incidence 
of ventilatory support 
> 48 h I 
Konishi et al, 206 0 23-39 wk gestation; Group I (good 
1988b (35) birth weight 600-3400 gj response): mortality 
MAP> 7cmH20; 10%; Fi02 I; MAP I; 
Fi02 > 0.4 a/A PO, I 
Group II (poor 
response): mortality 
22%; no increase in 
a/A P02 
Konishi et al, 23 (high dose) 0 Birth weight 1000- Both groups a/ A P02 1; 
1988a (34) 23 (low dose) 1500 g High dose: prolonged 
effect of treatment; 
lower incidence of IVH 
and BPD; lower no. of 
patients treated with 0 2 
for 30 days 
Charon et al, 29 23 Age< 8 h; (See Gitlin, 1987); in 
1989 (4) birth weight 750-1750 g the lasting response 
group the a/A P02 
improved > 48 h 
Bovine lung lavage Smyth et al, 3 0 Severe RDS Pa02 I; Fi02 I; 
extract 1981 (70) X-chest improved 
Table 2 (continued): 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
Smyth et al, 6 0 Severe RDS a/A PO, I (24 h effect) 
1983 (71) 
Shennan et al, 22 (1 dose) 20 30-36 wk gestation Prolonged improvement 
1988 (69) 17 (> 1 dose) of gas exchange in 
(phase 3) group receiving 
::-: 1 dose; no difference 
in mortality and 
morbidity between 
treatment groups and 
control group 
SF-RI 1 (bovine Gartner et al, 15 (high dose) 0 24-31 wk gestation; High dose: survival I; 
surfactant) 1988 (19) 19 (low dose) birth weight 430-1500 g; both groups: Fi02 I; 
Fi0 2> 0.5 MAP I; a/A PO, I 
CLSE Davis et al, 35 0 Fi02 .::>: 0.4 Improvement of gas 
1988 (7) exchange; improvement 
of lung mechanics only 
during spontaneous 
breathing 
Bovine or porcine Mortensson et al, 10 0 27-32 wk gestation; X-chest: improvement 
surfactant 1987 (57) birth weight 795-1680 g of aeration, distension 
of bronchioli, right-left 
shunt I 
Noack et al, 10 0 See Mortensson, 1987 a/A PO, I 
1987 (58) 
Porcine surfactant Svenningsen et al, 4 4 Birth weight 700-1400 g; Transcutaneous P02 I; 
1987 (74) Fi02> 0.6 X-chest improved 
McCord et al, 12 8 Fi02> 0.6 Incidence of IVH I and 
1988b (49) pneumothorax I 
Table 2 (continued): 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
McCord et al, 14 15 Birth weight< 2000 g; a/A P02 I; incidence 
1988a (48) Fi01> 0.6 of IVH I and 
pneumothorax I 
Porcine CK Kobayashi et al, 1 0 RDS Pa02/Fi02 1; 
1981* PaC02 I; X·chest 
improved 
Ohta et al, 1 0 RDS "Improvement" 
1981* 
Nohara ct al, 6 0 RDS Pa02 I in 4 patients; 
1983' X·chest improved 
Curosurf (porcine Berggren et al, 4 0 Se\'erc RDS Pa02 I; PaC02 I; 
surfactant) 1984* incidence of air leaks 
Robertson et al, 77 69 Birth weight 700·2000 g Incidence of death I; 
1988a (64) BPD I 
Robertson et al, 55 0 Birth weight 700·2000 g Incidence of death I; 
1988b (65) BPD I 
Speer et al, 14 20 Severe RDS Oxygenation 1; 
1988 (73) duration of PIP and 
Fi02> 0.4 I; 
mortality I; PDA I; 
pneumothorax I; no 
difference in BPD and 
IVH 
Human amniotic fluid Hallman et al, 3 0 RDS Pa02 I; Fi02 I; 
1982 (22) MAP I 
Table 2 (continued): 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
Hallman et al, 5 5 Mean birth weight Pa02 I; PaC02 I; 
1983 (23) 974±61g pH I; X-chest 
improved; severity of 
RDS I 
Merritt et al, 4 3 Severe RDS Pa02 I; PaC02 I; Fi02 
1983 (50) I; MAP I; 
X-chest impoved 
Hallman et al, 25 2S Age< 10 h; birth Incidence of death I; 
1985 (24) weight< 1500 g; BPD I; incidence of air 
L/S ratio~ 2.0 leaks I; no. of patients 
requiring Fi02> 0.3 at 
30 days I 
Heldt et al, 49 12 25-29 wk gestation; Maturity of ductus 
1988 (26) birth weight 450-1580 g arteriosus parallels 
maturity of the lung and 
is independent of 
surfactant therapy 
Lang et al, 10 14 25-32 wk gestation; Pa02 I; Fi02 I; 
1988 (45) mean treatment time: a/A PO, I; MAP I 
5.6 h 
ALEC Milner et al, 10 0 RDS No effect 
1983* 
Weintraub et al, 22 0 Fi02> 0.6; PaC02 I; PIP I; 
1985* PIP~ 20cmH20 8 patients died 
Wilkinson et al, 12 0 < 32 wk gestation No effect; L/S ratio t 
1985' in tracheal fluid 
Table 2 (continued): 
Type of surfactant 
Liposomal 
phospholipids 
Artificial surfactant 
Synthetic L-«-lecithin 
Dipalmitoyl L-a:-lccithin 
Source 
Wilkinson et al, 
1985 (79) 
Obladen et al, 
1988 (59) 
Friedman et al, 
1982 (12) 
Robillard et al, 
1964 (66) 
Chu et al, 
1967 (5) 
No. of patients 
16 (trial I) 
12 (trial II) 
10 
3 
11 
27 
No. of controls 
16 
12 
0 
0 
0 
21 
Treatment criteria 
< 32 wk gestation; 
L/S ratio immature 
<30 wk gestation; 
birth weight< 1500 g 
RDS 
RDS 
RDS 
Ouh;ome 
No significant difference 
in ventilation pressures 
or 0 2 therapy used, nor 
in mortality and 
morbidity< 2 years 
a/A P02 I; Fi02 1; 
lung compliance I; 
3 patients died 
X-chest improved; 
"clinical improvement" 
in 2 patients 
Cyanosis I; retraction 
score I 
No beneficial effect 
a/A P02 == arterial-alveolar P01 ratio; ALEC == Artificial Lung Expanding Compound; BPD = bronchopulmonary dysplasia; CLSE = Calf Lung Surfactant Extract; 
HAF = Human amniotic fluid; HMO = hyaline membrane disease; IVH = intraventricular hemorrhage; MAP = mean airway pressure; PDA = patent ductus 
arteriosus; PIE = pulmonary interstitial emphysema; PIP = positive inspiratory pressure; I = increase; I = decrease; "'cited from (52) 
Table 3: Prophylactic surfactant treatment 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
Survanta Hoekstra et a!, 210 220 23·29 wk gestation; Mortality I; incidence 
(==Surfactant TA) 1991 (1) birth weight 600·1250 g; of DPD I and PIE I; 
treated within 15 min incidence of RDS I; 
after birth improved oxygenation 
Ferrara ct al, 26 28 Birth weight 600· 750 g; Mortality I; increase of 
1991 (2) treated within 15 min normal survivors 
after birth compared to control 
group 
Alveofact Gartner et al, 34 35 25·30 wk gestation; Mortality I; incidence 
( ~sF-RI 1) 1990 (3) mechanical ventilation of BPD I; improved 
oxygenation; MAP I; 
time on mechanical 
ventilation I 
Bovine surfactant Dunn et al, 62 (prophylaxis) 60 < 30 wk gestation Improved oxygenation 
1991 (4) 31 (rescue) and lower incidence of 
air leaks and severe 
chronic lung disease in 
surfactant groups; 
prophylaxis group had 
higher incidence of mild 
chronic lung disease 
compared to rescue 
group 
Infasurf Kendig et al, 235 (prophylaxis) 0 < 30 wk gestation; Higher survival, and 
(~CLSE) 1991 (5) 244 (rescue) Rescue: Fi02 ~0.4 incidence of 
and/or MAP> pneumothorax I in 
7cmHp prophylaxis group, 
especially in infants 
delivered at 5.26 wk 
gestation 
Table 3 (continued): 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
Human amniotic fluid Merritt et al, 55 (pcophylaxis) 52 24-29 wk gestation Mortality I, PIE I and 
1991 (6) 50 (rescue) improved indexes of 
oxygenation in 
surfactant groups 
ALEC Morley et al, 102 108 23-34 wk gestation <29 wk gestation: 
1991 (7) compliance I from 
6-24 h after birth; 
> 29 wk gestation: 
compliance I 
Exosurf Bose et at, 192 193 Birth weight 700-1350 g Mortality I; survival 
1990 (8) without BPD I; PIE I 
Corbet et al, 224 222 Birth weight 700·1100 g; Mortality I; no 
1991 (9) mechanical ventilation difference in incidence 
of RDS; PIE I; MAP I; 
0 2 requirements I 
Phibbs et al, 36 (pcophylaxis) 38 Propylaxis: birth weight Fi02 I and MAP I 
1991 (10) 53 (rescue) 51 700-1350 g during first 72 h in 
Rescue: birth weight surfactant groups; no 
>650 g; RDS difference in IVH and 
PDA between surfactant 
groups and controls 
Stevenson et al, 106 109 Birth weight 500-699 g 0 2 requirements I; 
1992 (11) P(A-a)02 improved; 
MAP I; incidence of 
pneumothorax I; death 
from RDS I; overall 
mortality unchanged; 
incidence of pulmonary 
hemorrhage I 
Table 3 (continued): 
Type of surfactant 
Exosurf 
Source 
The OSIRIS 
Collaborative Group, 
1992 (12) 
No. of patients 
Part 1: 
1344 (early) 
1346 (delayed) 
Part II: 
3381 (2 doses) 
3376 (2-4 doses) 
No. of controls 
0 
Treatment criteria 
Part 1: 
Early: at risk; age< 2h 
Delayed: age> 2h; 
RDS; a/A P02<0.22 
Part II: at risk or RDS 
Outcome 
Part I: risk of death or 
dependence on extra 0 2 
at expected date of 
delivery were lower in 
early treated infants; 
incidence of 
pneumothorax I in 
early treated infants; 
Part II: no difference in 
outcome 
a/A P02 "" arterial-alveolar P01 ratio; ALEC = Artificial Lung Expanding Compound; BPD = bronchopulmonary dysplasia; IVH "' intraventricular hemorrhage; MAP 
= mean airway pressure; PDA = patent ductus arteriosus; PIE "" pulmonary interstitial emphysema; P{A-a)02 "' alveolar-arterial P02 gradient; PIP = positive 
inspiratory pressure; I "" increase; I "" decrease 
Table 4: Rescue surfactant treatment 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
Survanta Fujiwara et al, 54 46 Birth weight 750-1749 g Severity of RDS I; 
("Surfactant TA) 1990 (13) incidence of PIE 1, 
IVH I and 
pneumothorax I; 
number of infants 
surviving without IVH 
and BPD I; no effect 
on overall mortality 
Couser et al, 47 47 Birth weight 600·1250 g Dynamic compliance I; 
1990 (14) oxygenation improved; 
MAP I 
Horbar et al, 53 53 Birth weight 750·1750 g; a/A P02 I; Fi02 I; 
1990 (15) Fi02:;..0.4 MAP I; no effect on 
mortality; PIH I in 
surfactant treated group 
Bhat et al, 6 9 Age< 6h: 27-32 wk Oxygenation improved; 
1990 (16) gestation; birth weight MAP I; airway 
750-1750 g; Fi02>0.4 resistance I; improved 
dynamic compliance 
only at 24 h 
Reller ct al, 22 14 > 26 wk gestation; No effect on PDA 
1991 (17) birth weight < 1750 g; 
FiQ2:;._Q,4 
Liechty et al, 402 396 Birth weight 600-1750 g Mortality I; incidence 
1991 (18) of BPD I and PIE I; 
oxygenation improved 
Table 4 (continued): 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
Bovine surfactant Dunn et al, 24 (1 dose) 24 Age< 6 h; Improvement of 
1990 (19) 27 (> 1 dose) 30-36 wk gestation oxygenation in both 
surfactant groups; 
multiple doses: 
sustained improvement 
of oxygenation 
Infasurf Auten et al, 7 (pneumonia) 0 Respiratory failure in Improvement of 
(~CLSE) 1991 (20) 7 (MAS) full-term newborns due oxygenation; X·chest 
to pneumonia or MAS improvedj MAP I; no 
patient died 
Goldsmith et al, 7 0 Age< 9 h; gestational FRC I; specific 
1991 (21) age: 28.3 ± 2.6 wks; compliance 1; specific 
birth weight: 1080 ± airway conductance I; 
361 g oxygenation improved 
Davis ct al, 28 0 Respiratory failure due HFJV and ::.:1 dose of 
1992 (22) to RDS, pneumonia or surfactant improved 
MAS, which did not several respiratory 
respond to CMV and variables 
surfactant therapy 
Curosurf Speer et al, 19 (early) 0 Severe RDS; Fi02::.:0.6; Improvement of 
1990 (23) 7 (late) early: 2-15 h of age; oxygenation; no. of days 
late: > 15-48 h of age with Fi02>0.21 was 
increased in late-
treatment; incidence of 
severe BPD increased 
in late-treatment 
Table 4 (continued): 
Type of surfactant Source No. of patients No. of controls Treatment criteria Outcome 
Curosurf Collaborative European 164 69 Birth weight 700-2000 g; Mortality I; incidence 
Multicentre Study Fio1 ~0.6 of PIE I and 
Group, 1991 (24) pneumothorax I; 
a/A P02 1; no. of 
survivors without 
chronic lung disease I 
Speer et al, 176 (1 dose) 0 Birth weight 700-2000 g; a/A PO, I and MAP I 
1992 (25) 167 (>1 dose) Fi02 ~0.6 in both groups; 
Mortality and incidence 
of pneumothorax were 
lower in the multiple-
dose group at 28 days 
Human amniotic fluid Lang eta!, 28 31 24-32 wk gestation; Fi02 I; a/A P02 I; air 
1990 (26) birth weight :<>:1500 g leaks I; no effect on 
survival and incidence 
ofBPD 
Exosurf Long et al, 206 (1-2 doses) 213 Birth weight 700-1350 g; Mortality I; a/ A P02 1; 
1991 (27) a/A P02<0.22 incidence of PIE I and 
pneumothorax I; no 
effect on BPD 
Long et al, 614 623 Age< 24 h; birth weight Mortality I; incidence 
1991 (28) ~1250 g; a/A P02<0.22 of BPD I, air leaks I, 
IVH I, seizures I, 
PDA I, hypotension I, 
pulmonary 
hypertension I; 
incidence of pulmonary 
hemorrhage I 
Table 4 (continued): 
Type of surfactant 
Exosurf 
Source 
Bhutani et al, 
1992 (29) 
Goldman et al, 
1992 (30) 
Ha? ..a.n et al, 
1992 (31) 
No. of patients 
13 
20 
12 
No. of controls 
19 
10 
11 
Treatment criteria 
Birth weight > 1100 g 
Birth weight 500-1100 g 
Birth weight > 1000 g; 
Fi01<0.65 
Outcome 
Dynamic compliance I 
during ftrst 7 days; 
pulmonary resistance I 
during first 2 weeks 
No difference in lung 
compliance and 
pulmonary resistance at 
28 days of age 
No effect on energy 
expenditure 
a/A P02 =arterial-alveolar P02 ratio; BPD =bronchopulmonary dysplasia; CMV =conventional mechanical ventilation; FRC = functional residual capacity; HFJV 
= high-frequency jet ventilation; IVH = intraventricular hemorrhage; MAP = mean airway pressure; MAS = meconium aspiration syndrome; PDA = patent ductus 
arteriosus; PIE = pulmonary interstitial emphysema; PIH = pcrivcntricular-intraventricular hemorrhage; P1P = positive inspiratory pressure; I = increase; I = 
decrease 
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Table 2: Case reports 
Source 
B. Lachmann, 
1988 (72) 
P.S. Richman et al, 
1989 (91) 
Th. J aka et al, 
1989 (49) 
S. Nosaka et al, 
1990 (85) 
Surfactant 
Bovine surfactant 
Curosurf 
Bovine surfactant 
Surfactant TA 
Dosage 
300 mg/kg 
4 g (•50-100 mgjkg) 
50 mg/kg ( de1ided in 2 
dosages: day 9 and 13) 
240 rug/instillation 
Patients 
pt.l: Sepsis + pneumonia; 
Pa02 = 19 mmHg at 
pressure controlled 
ventilation, Fi02 = 1.0, 
PAP=48 cmH20, 
PEEP=12 cmHp and 
I:E~3:1 
pt.l: Aspiration 
pneumonitis 
pt.2: Sepsis 
pt.3: Pancreatitis 
All patients intubated 
<72 h 
pt.l: Trauma: 188=45 
points; Pa02 =60 mmHg at 
Fi02=0.8 and 
PEEP= 18 em H20; 
Compliance I 
pt.l: 1'1 episode: Burns; 
surf. on day 4 and 5; 
znd episode: Aspiration 
pneumonitis; almost daily 
surf. between day 13 and 
38 
pt.2: Post -operative 
pneumonitis; surf. on days 
1,2and3 
Outcome 
PaO, I (19•240 mmHg), 
PaCO, I (68·45 mmHg); 
X-chest improved 
pts.l +2: Transient ( < 1 h) 
Pa02 1 
pt.3: Persisting (72 h) 
Pa02 1 
Pa02 1, Fi02 l; 
Compliance 1; Protein and 
elastase concentration in 
BAL lj Extubated on 
day 29 
pt.l: 1'1 episode: Pa02 1 at 
Fio,~ 1.0 (57•159 
mmHg); X-chest 
improved; 
zw episode: Pa02 1 at 
Fi0,~0.9 (86·224 
mmHg); X-chest 
improved; 
pt.2: PaO, I with 144 
mmHg; X-chest improved 
Comments 
-Unknown ventilator 
settings 
-Exact surf. dosage/kg is 
unknown 
No adverse 
(immunological) reaction 
to surf. 
-Unknown ventilator 
sellings 
-Exact surf. dosage/kg is 
unknown 
-No antibodies to surf. 
detected 
Table 2 (continued): 
Source 
G. Marraro, 
1991 (78) 
J. Weg et al, 
1991 (112) 
H. Wiedemann ct al, 
1992 (114) 
Surfactant 
Curosurf 
Exosurf 
Exosurf 
Dosage 
pl.l: 60 mg/kg 
pl.2: 40 mg/kg 
Group 1: 6 mg DPPC/kg 
nebulized during 
12 h/day 
Group 2: 12 mg 
DPPC/kg nebulized 
during 24 h/day 
Group 3: saline nebulized 
dudng 12/24 h/day 
Groups 1-3: treatment 
during 5 days 
Group 1: 40.5 mg 
DPPC/ml, nebulized 
during 24 h 
Group 2: 81 mg 
DPPC/ml, nebulized 
during 24 h 
Group 3: saline nebulized 
during 24 h Groups 1-3: 
treatment during 5 days 
Patients 
pt.l: ALL + bone marrow 
transplant; Pa02:=60 
mmHg at FiOz"' 1.0 and 
PEEP"' 12 cmHp 
pt.2: AML + massive 
pulmonary hemorrhage 
Sepsis: 
Group 1: n= 18 
Group 2: n:= 17 
Group 3: n:::l7 
Sepsis: APACHE U .. l7 
Group 1: n:= 16 
Group 2: n=17 
Group 3: n=16 
Outcome 
pts. 1 + 2: Pa02 1 and 
PaC02 l during first 3 h; 
Compliance: no effect; 
X-chest improved 
Mortality in groups 1-3: 
39%, 35% and 47%; 
Groups 1 +2: 
Compliance I, Os/Ot I 
Mortality in groups 1-3: 
25%, 35% and 50%; 
Groups 1 + 2: P(A-a)02 
and Fi02 improved 
Comments 
-pts. 1+2: 
Thromboembolic 
pathology 
-Unknown ventilator 
settings 
-Unknown ventilator 
settings 
-Nebulized surf. 
-1 pneumothorax in surf. 
treated group 
-Unknown ventilator 
settings 
-Nebulized surf. 
-1 pt. with skin rash and 
2 pts. with increased 
airway pressure in surf. 
treated groups 
Table 2 (continued): 
Source 
K. Stubbig et al, 
1992 (108) 
K. Kurashima et al, 
1991 (58) 
Surfactant Dosage 
Alveofact 76 mg/kg 
Surfactant TA 10 mg (total amount) 
Patients 
pt.1: Trauma: lung 
contusion, multiple rib 
fractures and 
pneumothorax; double-
lumen tube: right lung: 
CMV, Fi0,"0.4, PEEP"S 
cmHp and I:E:::1:1; left 
lung: high frequency jet 
ventilation (500/min), 
Fi02=1.0; surf. on day 15 
Mild asthmatic at!ack: 
Group 1 (n=6): surf. 
Group 2 (n:=c5): saline 
Outcome 
Initial deterioration; 
single-lumen tube, 
Fi02 =0.8; after removal of 
crusts via bronchoscopy 
improvement of gas 
exchange, Fi02 1, PEEP I, 
I:£=3:1 .. 1:1; X-chest 
improved 
Group 1: wheezing I, 
PVC: 11.7% I, FEV1: 
27.3% I, MMF: 33.2% I, 
Pa02: 67 .. 76 mmHg 
Group 2: no effect 
Comments 
Deterioration after surf. 
probably due to plugs in 
airways preventing surf. 
from sufficiently entering 
the alveoli 
-Asthmatic attack 
-Spontaneous breathing 
-Nebulized surf. 
ALL = acute lymphatic leukemia; AML = acute myeloid leukemia; BAL = bronchoalveolar lavage; CMV = continuous mechanical ventilation; DPPC = 
dipalmitoylphosphatidylcholine; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; I:E = inspiratory-expiratory ratio; ISS = injury severity 
score; MMF = maximal midexpiratory flow; P(A-a)02 "" alveolar-arterial P02 gradient; PAP = peak airway pressure; PEEP = positive end-expiratory pressure; Os/Ot 
= shunt; surf. = surfactant 

SUMMARY AND CONCLUSIONS 
Although the pathophysiological mechanisms in ARDS and neonatal RDS differ 
considerably, the pulmonary surfactant system is involved in both syndromes. & 
extensively outlined in Chapter I, neonatal RDS is characterized by immaturity of the 
lung, resulting in relative or absolute surfactant deficiency. Due to high surface tensions 
at the air-liquid interface of the alveolar walls, together with damage caused by 
mechauical ventilation, high-permeability edema fluid accumulates in the alveolar spaces. 
ARDS can be caused by different etiologies, such as sepsis, pneumonia, aspiration of 
gastic contents, and many others (see Chapter 2). Due to activation of all kinds of 
humoral and cellular mechauisms interacting with each other, damage to the alveolar-
capillary membranes results, leading to intra-alveolar accumulation of plasma-derived 
proteins and specific mediators. From experimental studies it is known that plasma 
proteins inhibit the pulmonary surfactant system in a dose-dependent way. Exogenous 
surfactant is currently accepted as a valuable treatment for neonatal RDS; also, patients 
suffering from ARDS have been treated with surfactant. In both neonatal RDS and 
ARDS it is discussed that in patients not responding to a single dose of exogenous 
surfactant (so-called "non-responders"), the exogenous surfactant may be inhibited by 
proteins present in the alveolar space. 
In Chapter 3 it was demonstrated that intratracheal instillation of both pulmonary 
edema fluid and homologous plasma influenced lung function in healthy rats. It could 
also be shown that exogenous surfactant, which normally restores gas exchange in 
surfactant-depleted lungs, failed to do so when mixed with either edema fluid or plasma; 
these mixtures showed high ntinimal surface tensions compared to exogenous surfactant 
alone. In contrast to rats receiving plasma, bronchoalveolar lavage fluid of rats receiving 
edema fluid showed a high percentage of neutrophils, suggesting the presence of 
chemotactic factors in the edema fluid. It was concluded that both edema fluid and 
plasma have the same inhibitory capacity on surfactant function. 
To investigate the hypothesis that the inhibitory effect of plasma proteins on 
(exogenous) surfactant may be dose-dependent, we designed the study in Chapter 4 in 
which an exogenous surfactant preparation was mixed with heterologous (human) plasma. 
Exogenous surfactant concentrations ranged from 50, 100 to 300 mg/kg body weight; 
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plasma at 4 ml/kg body weight was mixed with these surfactant preparations. These 
mixmres were intratracheally administered in rats suffering from respiratory failure after 
whole-lung lavage. Mixtures with surfactant concentrations of 100 and 300 mgjkg were 
capable of restoring gas exchange to normal. However, at 100 mg/kg lung function 
deteriorated, while at 300 mgjkg gas exchange was stabilized during a 3-hour observation 
period. Also, this model proved to be practical for investigating the influence of plasma 
proteins on different exogenous surfactant preparations. 
1n respiratory failure caused by aspiration of gastric contents the surfactant system 
is involved, probably due to inhibition of surfactant function due to plasma proteins and 
specific mediators. 1n Chapter 5 a model was presented in which rats received 
hydrochloric acid (HCl), intratracheally. In these animals lung function deteriorated 
rapidly. Bronchoalveolar lavage (BAL) fluid contained high concentrations of proteins, 
and had high surface tensions. Since these findings suggested inhibition of surfactant 
function, a study was designed in which the influence of intratracheal instillation of 
exogenous surfactant at different time points post-HCl instillation on lung function was 
investigated. It was demonstrated that exogenous surfactant given before development 
of respiratory failure (i.e. within 10 min post-HCl instillation) could prevent deterioration 
of lung function. After development of respiratory failure, exogenous surfactant served 
only to prevent further deterioration of lung function. In clinical practice, aspiration of 
gastric contents is often detected after development of respiratory failure. For this 
reason, it would not always be possible to give exogenous surfactant as prophylaxis after 
aspiration of gastric contents. Therefore, a study was designed to investigate how to treat 
respiratory failure due to HCl aspiration with exogenous surfactant (Chapter 6). It was 
demonstrated that blood gases improved after protein-rich edema fluid was removed by 
means of BAL, directly followed by exogenous surfactant administration. Another way 
to improve lung function was to lavage lungs with a diluted surfactant suspension, 
thereby probably removing proteins from the alveolar space and simultaneously treating 
with exogenous surfactant. This lavage procedure could be repeated, resulting in 
progressive removal of proteins from the alveolar space and improvement of lung 
function. 
1n the acute phase of pneumonia, protein-rich edema fluid accumulates in the 
alveolar space. In the past we demonstrated that exogenous surfactant therapy could 
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restore lung function in rats and mice suffering from pneumonia due to Sendai virus and 
influenza A virus infection, respectively. In Chapter 7 we demonstrated that exogenous 
surfactant therapy could improve oxygenation in rats suffering from pneumonia caused 
by pneumocystis carirtii infection. Although it is difficult to extrapolate to the clinical 
situation, exogenous surfactant therapy could be of value in patients suffering from acute 
respiratory failure due to, or accompanied by, pneumonia. Also, it is hypothesized that 
exogenous surfactant could serve as a carrier for antibiotics, this way simultaneously 
restoring gas exchange and delivering drugs to the site of infection. 
Natural exogenous surfactant preparations used in clincal studies contain proteins 
foreign to the patient. As the alveolar-capillary membrane in patients receiving 
exogenous surfactant is highly permeable to macromolecules, it is likely that some of the 
exogenous surfactant is lost into the circulation. Therefore, it is reasonable to assume 
that antibodies may be developed against the surfactant-associated proteins. In the study 
presented in Chapter 8 exogenous surfactant was mixed with a monoclonal antibody 
directed to a 11 kDa surfactant-associated protein. This mixture was not able to restore 
gas exchange in rats suffering from respiratory failure after whole-lung lavage. Although 
surfactant-antisurfactant immune complexes have been detected in neonates with RDS, 
no effect on exogenous surfactant therapy has been reported. These findings also 
demonstrate the importance of the 11 kDa (probably SP-B) for normal surfactant 
function. 
The work presented in this thesis demonstrates that exogenous surfactant therapy 
can restore lung function in different animal models of acute respiratory failure. In rats 
suffering from respiratory failure due to pneumocystis carinii pneumonia a single dose 
of exogenous surfactant was sufficient to restore lung function, whereas after 
deterioration of lung function after HCI aspiration, exogenous surfactant was only 
capable to restore gas exchange after edema fluid was removed by BAL, or BAL with 
a diluted surfactant suspension. It is concluded that exogenous surfactant therapy can 
only succeed when given in sufficiently high concentrations: there should be a favorable 
surfactant-inhibitor ratio. For clinical practice this means that either exogenous surfactant 
has to be given until gas exchange improves ("titrate"), or that proteins have to be 
removed from the alveolar space by means of BAL. The way to perform this latter 
possibility has yet to be investigated. 
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SAMENVATTING EN CONCLUSIES 
Hoewel de pathofysiologische mechanismen in ARDS (adult respiratory distress 
syndrome) en neonatale RDS (respiratory distress syndrome) verschillen, is in beide 
syndromen het long surfactant systeem betrokken. Zoals uitgebreid ter sprake kwam in 
Hoofdstuk I, wordt neonatale RDS gekarakteriseerd door iromaturiteit van de long, 
hetgeen resulteert in een relatief of absoluut tekort aan surfactant. Als gevolg van de 
hoge oppervlakte spamting aan de lucht-vloeistof overgang en de schade veroorzaakt 
door kunstrnatige beademing, ontstaat er eiwitrijk oedeem in de alveoli. ARDS kan 
worden veroorzaakt door verschillende ziektebeelden, zoals sepsis, pneumonie, aspiratie 
van maaginhoud en vele anderen (zie Hoofdstuk 2). Activatie van allerlei humorale en 
cellulaire mechanismen, welke met elkaar interfereren, leidt tot beschadiging van de 
alveolo-capillaire membraan. Dit laatst leidt tot intraalveolaire ophoping van plasma 
eiwitten en specifieke mediatoren. Het is bekend dat deze plasma eiwitten bet surfactant 
systeem op een dosis-afhankelijke wijze inhiberen. Op dit moment is exogeen surfactant 
substitutie geaccepteerd als een waardevolle behandeling voor neonataal RDS; tevens 
is er een aantal ARDS-patienten behandeld met surfactant. Bij zowel neonataal RDS als 
ARDS zijn er patienten die niet reageren op een enkele dosis exogeen surfactant 
(zogenaamde "non-responders'}. In deze patienten is bet exogeen surfactant 
waarschijnlijk geinhibeerd door onder andere plasma eiwitten, welke zich in de alveoli 
bevinden. 
In Hoofdstuk 3 werd gedemonstreerd dat intratracheale toediening van zowellong 
oedeem vloeistof als homoloog plasma de longfunctie van gezonde ratten beYnvloedt. Het 
kon ook worden aangetoond dat exogeen surfactant, welk normaal gesproken de 
gasuitwisseling herstelt in surfactant-deficiente longen, hiertoe niet in staat was wanneer 
het gemengd was met oedeem of plasma. Surfactant gemengd met oedeem of plasma had 
hoge oppervlakte spamtingen vergeleken met surfactant aileen. In tegenstelling tot ratten 
die plasma hadden gekregen, bevatte bronchoalveolaire lavage (BAL) vloeistof van 
ratten die oedeem hadden gekregen een hoog percentage neutrofiele granulocyten. Deze 
laatste bevinding suggereerde de aanwezigheid van chemotactische factoren in oedeem 
vloeistof. Er werd geconcludeerd dat zowel oedeem als plasma surfactant gelijkwaardig 
inhiberen. 
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Om de hypothese te testen dat het inhibitoir vermogen van plasma eiwitten op 
( exogeen) surfactant dosis-afhankelijk is, werd de volgende studie uitgevoerd (Hoofdstuk 
4). Exogeen surfactant werd gemengd met heteroloog (humaan) plasma. De concentraties 
exogeen surfactant varieerden van 50, 100 tot 300 mg/kg lichaamsgewicht. Plasma ( 4 
ml/kg lichaamsgewicht) werd gemengd met exogeen surfactant in genoemde 
concentraties. De mengsels met surfactant concentraties van 100 en 300 mg/kg waren 
in Staat de gasuitwisseling volledig te herstellen. Echter, bij 100 mg/kg verslechterde de 
longfunctie zich na verloop van tijd, terwijl bij 300 mg/kg de gasuitwisseling zich 
gedurende een observatie-periode van 3 uur stabiliseerde. Tevens bleek dit een praktisch 
model om de invloed van plasma eiwitten op verscbillende exogene surfactant preparaten 
te testen. 
Bij respiratoir falen als gevolg van aspiratie van maaginhoud is het surfactant 
systeem betrokken, waarschijnlijk door inhibitie van de surfactant functie door plasma 
eiwitten en specifieke mediatoren. In Hoofdstuk 5 werd een model geintroduceerd 
waarbij ratten intratracheaal zoutzuur (HCI) toegediend kregen. Hierdoorverslechterde 
de longfunctie zich. BAL vloeistof van deze ratten bevatte hoge eiwitconcentraties en 
had hoge oppervlakte spanningen. Daar deze bevindingen de inhibitie van surfactant 
suggereerden, werd de volgende smdie ontworpen. De invloed van intratracheale 
toediening van exogeen surfactant op verscbillende tijdstippen na HCI aspiratie werd 
onderzocbt. Aangetoond werd dat wanneer exogeen surfactant v66r verslechtering van 
de longfunctie werd gegeven ( d.w.z. binnen 10 minuten na HCI aspiratie ), deze 
verslechtering voork6men kon worden. Als exogeen surfactant gegeven werd n3. 
verslechtering van de longfunctie verbeterde de gasuitwisseling zich niet. In de praktijk 
wordt aspiratie echter meestal opgemerkt nadat er al een verslechtering van de 
longfunctie is opgetreden. Hierdoor zal het niet altijd mogelijk zijn om exogeen 
surfactant profylactisch na aspiratie van maaginhoud te geven. Om deze red en werd een 
smdie opgezet om een optimale manier te vinden ratten met respiratoir falen na HCI 
aspiratie te behandelen met exogeen surfactant (Hoofdstuk 6). Er werd aangetoond dat 
de gasuitwisseling verbeterde nadat eiwitrijk oedeem verwijderd was d.m.v. BAL, direct 
gevolgd door exogeen surfactant substimtie. Tevens kon de longfunctie verbeterd worden 
door de Iangen te spoelen met een surfactant suspensie, waarschijnlijk door gelijktijdige 
verwijdering van plasma eiwitten en bebandeling met exogeen surfactant. Deze lavage-
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procedure kon herhaald worden, hetgeen resulteerde in een progressieve verwijdering 
van eiwitten uit de longen en verbetering van de longfunctie. 
In de acute fase van pneurnonie hoopt eiwitrijk oedeem zich op in de alveoli. In 
het verleden hebben we aangetoond dat exogeen surfactant substitutie de longfunctie kon 
verbeteren bij ratten en muizen met pneumonie a.g.v. infectie met, respectievelijk, Sendai 
virus en influenza A virus. In Hoofdstuk 7 toonden we aan dat exogeen surfactant 
substitutie de gasuitwisseling kon verbeteren bij ratten met pneumonie a.g.v. 
pneumocystis carinii infectie. Hoewel het moeilijk te extrapoleren is naar de klinische 
situatie, zou exogeen surfactant van waarde kunnen zijn in behandeling van patienten 
met respiratoir falen als gevolg van, of in combinatie met, een pneumonie. Tevens zou 
exogeen surfactant kunnen fungeren als drager voor antibiotica; op deze manier zou 
tegelijkertijd behandeling van respiratoir falen en lokale applicatie van antibiotica 
plaatsvinden. 
Natuurlijke exogene surfactant preparaten, die in klinische studies gebruikt 
worden, bevatten lichaams-vreemde eiwitten. Gezien de verhoogde penneabiliteit van 
de alveolo-capillaire membraan voor macromoleculen in zowel ARDS als neonatale 
RDS, is het waarschijnlijk dat kleine hoeveelheden exogeen surfactant in de 
bloedsomloop terecht komen. Om deze reden is het aannemelijk dat antilichamen 
gevormd worden tegen surfactant-eiwitten. In de studie in Hoofdstuk 8 werd exogeen 
surfactant gemengd met een monoklonaal antilichaam gericht tegen een 11 kDa 
surfactant-eiwit. Dit mengsel bleek niet in staat te zijn de longfunctie te herstellen bij 
ratten met respiratoir falen a.g.v. surfactant-deficientie. Hoewel surfactant-antisurfactant 
immuuncomplexen aangetoond zijn in neonaten met RDS, is er geen invloed beschreven 
op het resultaat van exogeen surfactant behandeling. De bevindingen van deze studie 
tonen tevens het belang van het 11 kDa surfactant-eiwit (waarschljnlijk SP-B) voor de 
functie exogeen surfactant. 
De studies in dit proefschrift tonen in verschillende diermodellen voor acuut 
respiratoir falen aan dat exogeen surfactant de longfunctie kan herstellen. Bij ratten 
lijdend aan respiratoir falen a.g.v. pneumocystis carinii pneumonie, was een enkele dosis 
exogeen surfactant in staat om de longfunctie te herstellen. N a verslechtering van de 
longfunctie a.g.v. HCI aspiratie, kon exogeen surfactant slechts de gasnitwisseling 
verheteren nadat eiwitrijk oedeem d.m.v. BAL verwijderd was, 6f door BAL met een 
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surfactant suspensie. De conclusie is dat exogeen surfactant bebandeling s!ecbts kan 
slagen wanneer vo!doende boog gedoseerd wordt: er dient altijd een gnnstige 
surfactant/ eiwit ratio te zijn. In de praktijk betekent dit dat 6f exogeen surfactant 
gegeven moet worden tot de gasuitwisseling verbetert ("titreren"), 6f dat eiwitten 
verwijderd moeten worden d.m.v. BAl., gevolgd door exogeen surfactant substimtie. Het 
zal nog uitgezocbt moeten worden op welke marrier deze Iaatste optie kan worden 
uitgevoerd. 
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